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Abstract 
Classical Swine Fever Virus (CSFV) is an extremely contagious, hemorrhagic and often 
fatal disease of pigs that causes serious socioeconomic impact on countries which experience 
outbreaks or are endemically infected. Current control measures utilized for CSFV are 
contingent upon the epidemiological status of the inflicted area and entail either prophylactic 
vaccination or non-vaccination, “stamping out”, protocol with the elimination of infected herds 
and culling of animals on neighboring farms. This latter practice results in less than satisfactory 
consequences, although once thought to be the answer to eradication of CSFV from a region, 
“stamping out” results in tremendous economic losses as well as the ethical objection to the 
potential killing of millions of healthy pigs. Marker vaccines also referred to as DIVA vaccines 
because they allow for differentiation between naturally infected and vaccinated animals 
(DIVA), could complement or replace the “stamping out” strategy. The use of a DIVA vaccine 
with an accompanying diagnostic test would make mass vaccination of susceptible pigs during 
and outbreak possible thereby preventing the rapid spread of the virus while allowing for 
identification of CSFV infected animal through serological surveillance. With the advent of 
reverse genetic technology, it is now possible to rationally design a CSFV vaccine that contains 
such markers. Recently, we reported the development of a live attenuated CSFV strain with two 
antigenic markers, named Flag T4v. During the vaccine assessment process, Flag T4v showed 
  
 
evidence of reverting back to the virulent phenotype of wild type CSFV. Analysis of the genome 
sequence from the recovered revertant virus revealed the presence of four non synonymous 
substitutions and a deletion of one of the antigenic epitopes compared to the parental Flag T4v 
genome. In order to improve the genetic stability of Flag T4v, the nucleotide codon sequence in 
these regions was modified as much as possible from its original sequence without 
compromising the wild type amino acid sequence by taking advantage of codon redundancy in 
an attempt to make viral reversion more difficult while maintaining both viral attenuation and 
reactivity of the antigenic markers. The newly developed virus, Flag T4Gv, was shown to be 
stably attenuated when assessed in a reversion to virulence test. In addition, Flag T4Gv was also 
shown to possess similar efficacy of Flag T4v in terms of protecting swine at early and late times 
post vaccination.    
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INTRODUCTION 
 
Classical swine fever (CSF) is an extremely infectious and generally lethal hemorrhagic 
disease of domestic and wild pigs. The causative agent, classical swine fever virus (CSFV), is a 
small enveloped virus with a single stranded RNA genome with positive polarity. It belongs to 
the genus pestivirus within the family Flaviviridae (Francki et al., 1991). The 12.5 Kb CSFV 
genome contains a single open reading frame that encodes a 3898-amino-acid polyprotein which 
is processed co- and post translationally into 11 to 12 proteins (NH2-Npro-C-Erns-E1-E2-p7-
NS2-NS3-NS4ANS4B-NS5A-NS5B-COOH) (Rice, 1996). Structural components of the CSFV 
virion include the capsid (C) protein and glycoproteins Erns, E1, and E2. E2 is the most 
immunogenic of the CSFV glycoproteins (Weiland et al., 1990), inducing neutralizing 
antibodies, which provide protection against lethal CSFV challenge.  
 
CSFV is endemic in many parts of the world, including Asia, Africa, South and Central 
America. Outbreaks have also been reported in the Caribbean nations of Cuba, Haiti and the 
Dominican Republic. In Europe disease outbreaks occur intermittently due to the endemic 
presence of the CSFV in the wild boar population. Regions currently believed to be free of CSF 
include Australia, New Zealand, Scandinavia, Iceland, Ireland, Canada and United States. The 
last reported case of CSFV in the United States was in 1976 with official CSFV free status 
recognized in 1978 after a 16-year effort by the farm industry and State and Federal 
governments.  
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Due to the inherent ability of CSFV outbreaks to cause extreme detrimental socio-
economic consequences the Office International des Epizooties (OIE) has classified CSFV as a 
notifiable list A pathogen. The OIE is ultimately responsible for setting outlines for 
internationally agreed upon standards relating to animal health and conditions under which a 
country can be considered free of CSF which consequently affects the ability of a country to 
engage in international trade of pigs and pig products. Due to the highly infectious nature of 
CSF, disease free countries have imposed trade barriers that prohibit importation of animals or 
animal products from countries that do not possess CSF free status with the ban continuing until 
the OIE recertifies that country as CSF free. 
 
Although the United States has been free of classical swine fever (CSF) since 1978, 
today’s ease of global mobility has increased the possibility of livestock diseases to travel the 
world which has raised concerns about how an outbreak of CSFV would affect the United States. 
Agriculture is the largest employer and industry in the United States, generating more than $1 
trillion annually (DHS, 2008).  A major component of this is livestock, which contributes over 
$100 billion annually to the gross domestic product. The introduction of CSFV at the farm level 
would cause severe economic disruption given that agriculture accounts for 13 percent of the 
U.S. gross domestic products and 18 percent of domestic employment (DHS, 2008). This 
economic disruption could potentially be exacerbated by long-lasting trade embargoes imposed 
on U.S. pork and pork products. 
 
Currently, there are two main strategies utilized in the prevention and control of CSFV, 
prophylactic vaccination or non-vaccination “stamping out” policy with control strategy 
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selection dependent upon the epidemiological status of the country. Prophylactic vaccination 
with traditional live attenuated vaccines (LAVs) is commonly employed in regions where CSF is 
endemic, such as, Asia, Africa, South and Central America. However, the humoral immune 
response induced by these vaccines does not differ from that elicited by infections caused by the 
wild type viruses as such vaccinated animals cannot be serologically differentiated from infected 
animals. As a result, once emergency vaccination is implemented in a region, that region is 
thereafter prohibited from international trade for a period of at least 2 years from the last reported 
case of CSFV (van Oirschot et al., 2003). The resulting ban on pork and pork products result in 
major economic losses for the affected region. The second strategy for CSF control is a non-
immunization “stamping out” policy which has a more favorable time frame in the return to CSF 
free status. Due to the economic benefits of rapid return to disease-free status, the European 
Union (EU) and some parts of Eastern Europe have opted for this latter approach. However, the 
large scale culling of animals resulting from this practice is very problematic in that many 
healthy animals eventually have to be destroyed for welfare reasons. Due to the huge economical 
losses caused by the “stamping out” policy as well as ethical objections to the mass 
extermination of millions of healthy animals, alternatives to the current policies are needed.       
 
One important option being considered which suitably satisfies this problem is the 
development of safe LAV “marker” or differentiating infected from vaccinated animal (DIVA) 
vaccines, which are intended to be used with a companion diagnostic test which makes 
differentiation of infected animals from vaccinated animals possible (van Oirschot et al., 2003). 
The use of this type of vaccine would limit loss of livestock impacting the overall economic 
ramifications but could also be potentially used for CSF eradication. Development of such a 
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vaccine is of the utmost importance to the US and nations of the European Union which do not 
currently have a CSFV control plan that includes emergency vaccination. As such, the purpose of 
this study is to develop a safe and effective marker or DIVA vaccine to fulfill this need in the 
event that CSFV was reintroduced either intentionally or unintentionally into the US. The 
solution presented here is the development of a rationally designed safe and effective LAV with 
DIVA capabilities using reverse genetic technology.  
 
 
Literature Review 
 
Genome  
 
  Pestiviruses are small spherical-enveloped viruses approximately 40-60 nm in diameter 
(Fig. 1). The envelope surrounds an electron-dense hexagonally-shaped nucleocapsid that is 
about 30nm in diameter (Wengler et al., 1995). The nucleocapsid contains a single-stranded 
RNA genome of positive polarity with an approximate length of 12.5kb.  The viral genomic 
RNA is neither capped nor polyadenylated and contains one large open reading frame (ORF) 
coding for a polyprotein of approximately 4000 amino acids flanked by a 5’ and 3’ untranslated 
region (UTR). The polyprotein is processed co- and post translationally by viral and host cell 
proteases producing either 11 or 12 mature proteins.  The order of the cleaved products is as 
follows: NH2-Npro-C-E0-E1-E2-p7-NS2-3(NS2, NS3)-NS4A-NS4B-NS5A-NS5B-COOH (Fig. 
2).    
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5’UTR 
 
The 5’ UTR is comprised of cis-acting elements that are believed to be involved in both 
viral replication and protein expression. The first of these elements is a stem loop called the Ia 
hairpin which is composed of approximately the first 30 nucleotides of the viral sequence. 
Experiments with a replicon of the closely related pestivirus, BVDV, determined that the Ia 
hairpin is involved in both translation initiation and replication of pestivirus RNA with the first 
four residues of the genome necessary for replication (Grassmann et al., 2005; Yu et al., 2000). 
Pestivirus RNAs lack 5’cap structure which normally promotes translation initiation (Brock et al. 
1992). Instead, pestiviral RNAs contain an internal ribosomal entry site (IRES) that is able to 
directly attract the small ribosomal subunit and position it at the translational start site (Poole et 
al., 1995). The CSFV IRES belongs to the hepatitis C virus/pestivirus (HP) group of IRES which 
are characterized by two complex stem-loop structures denoted as domains II and III. The 
initiation site is located downstream of domain III with a pseudoknot located between them. This 
pseudoknot is essential for IRES function as it is crucial for orienting the AUG start codon in the 
P-site of the ribosome (Moes et al., 2007). 
 
3’ UTR 
 
Similar to the 5’UTR, the 3’UTR of CSFV is also believed to contain important cis-
acting elements. The 3’UTR is able to fold into three stem loops designated SLI, SLII, and SLIII. 
SLI is located closest to the 3’ end of the viral sequence, while SLII is positioned between SLI 
and SLIII, with SLIII directly downstream of the stop codon. The SLI loop has been shown to be 
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indispensible for pestiviral replication by functional analysis by both changing the codon usage 
of SLI which maintained the conserved secondary structure and by changes to the SLI 
nucleotides sequence which disrupted the naïve stem loop (Yu et al., 1999). Viable mutants were 
only obtained where the SLI loop remained unaltered. Surprisingly, pestiviral RNA do not 
contain a Poly(A) tail common in most eukaryotic mRNAs which is known to influence RNA 
stability as well as function to support translation initiation (Hinnebusch et al., 2012). 
 
Npro 
  
The first protein encoded for by the CSFV genome is a nonstructural protein, termed 
Npro, which possesses autoprotease activity that enables the protein to cleave itself at its C-
terminus from the downstream nucleocapsid protein (Tratschin et al., 1998).  Interestingly, while 
the other two members in the Flaviviridae family (flaviviruses and hepatitis C virus) have similar 
overall genome organization as the pestiviruses, neither contains an analogous counterpart to 
Npro.   
Protein crystallization experiments by two separate groups revealed that the Npro 
structure forms a novel fold characterized as a “clamshell” fold. (Gottipati et al., 2013; Zogg et 
al., 2013).  Npro is composed of mostly β-sheets and can be divided into two distinct domains, 
the catalytic protease domain and the zinc-binding domain. The protease domain contains coils 
and a single β-sheet formed by strands β1, β2, and β8 (Gottipati et al., 2013). The first two β-
strands of the sheet are formed by the first 100 amino acid residues in the sequence while the last 
6 residues at the C-terminus (163–168) construct the final β-strand which folds back into the 
protease active site, positioning the C-terminus, Cys168, for cleavage and remains within the 
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substrate-binding pocket after cleavage. This explains why Npro cleaves only at its C-terminal 
end and is proteolytically inactive thereafter, as the active site is no longer accessible to cleave 
any other substrate molecules. The zinc-binding domain of Npro is produced by amino acid 
residues 101 through 156 and forms an anti-parallel β-sheet consisting of five β-strands, β3, β4, 
β5, β6, and β7 (Zogg et al., 2013). 
 
Site-directed mutagenesis studies resulted in detection of three essential residues for 
catalytic activity in Npro; Glu22, His49, and Cys69 (Rumenapf, et al. 1998; Rawlings et al., 
2012). However, detailed analysis of this protease domain revealed that these residues do not 
form a catalytic triad commonly found in many viral proteases. To this end, the position of 
Glu22 was found to be too far from the active site to be involved in protease activity, instead, 
Glu22 was found to form a salt bridge with Arg100 which imparts stability to the overall 
structure of Npro which explains the deleterious effect that Glu22 mutations have on catalytic 
activity of Npro (Rumenapf, et al., 1998). In contrast, the spatial arrangement of Cys69 and 
His49 was determined to be sufficient to form a catalytic dyad responsible for protease activity 
of Npro. Cys69 was determined to be the nucleophilic residue in the active site of Npro, 
consequently, Npro is considered to be a cysteine protease. However, because Npro does not 
share sequence homology with any other known proteases, it has been assigned to its own family 
of cysteine proteases designated C53 (Rawlings et al., 2012).  
 
Interestingly, it has been shown that the expression of Npro is not required for viral 
replication of CSFV in vitro (Tratshin et al., 1998).  Additionally, the deletion of Npro from the 
genome of CSFV produces attenuation indicating that Npro may be a virulence factor of CSFV 
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(Mayer et al., 2004). To this end, Npro has been shown to be able to block the host cellular type I 
interferon responses to virus infection such as destruction of viral RNA, inhibition of cellular 
transcription and translation, and ultimately apoptosis. The central players of the signaling 
cascade that culminates in the induction of type I IFN are interferon regulatory factor 3 (IRF3) 
and IRF7. It has been demonstrated that Npro hinders the early innate immune response by 
binding IRF3 and targeting it for proteasomal degradation in the host cell (Bauhofer et al., 2007). 
Concurrently, Npro has also been shown to be able to modulate the IRF7 turnover, limiting the 
IFN-α induction in plasmacytoid dendritic cells (pDC) providing the virus with another strategy 
to elude the host innate defenses (Fiebach et al., 2011). Importantly, Npro relies on an intact Zn-
binding domain for the interaction with both IRF3 and IRF7 (Szymanski M. R., et al., 2009; 
Fiebach et al., 2011) 
 
Core 
 
The core (capsid) protein is a small, highly basic protein composed of 86 to 89 amino 
acids. The mature core protein of CSFV requires processing at the N and C termini in order to be 
released from the polyprotein. Processing occurs by three enzymatic cleavage events before 
incorporation into infectious virions. As described previously, the amino terminus of core is 
generated by autoprotease activity of Npro (Stark et al., 1993). The subsequent cleavage event is 
directed by a signal sequence in the carboxy terminus of core that targets the nascent protein to 
the endoplasmic reticulum (ER) membrane. Host cellular endoplasmic reticulum-associated 
signal peptidase (SPases) cleaves between Ala267/Asp268 in the ER lumen liberating Core protein 
from downstream Erns (Rumenapf et al., 1993). The final processing event is performed by host 
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signal peptide peptidase (SPPases) within the membrane spanning anchor of Core with the final 
C terminus determined to be alanine 255 in CSFV (Heimann et al., 2006). The liberated mature 
Core protein does not contain pronounced secondary structure and is primarily disordered 
(Murray et al., 2008). Disordered, unfolded regions of viral capsid proteins are often involved in 
nucleic acid binding, as such, it has been shown that pestivirus Core protein binds to RNA, 
although with low affinity and little discernible specificity (Murray et al., 2008). It is likely that 
this relatively low binding affinity allows the RNA genome to be released and accessed for 
translation upon entry into a new host cell. Core proteins of all Flaviviridae exhibit RNA 
chaperone activity which was determined to be mediated by disordered, highly charged protein 
segments of Core (Ivanyi-Nagy et al., 2008). This RNA chaperone activity likely results in the 
condensation of the viral RNA genome and subsequent packaging into virions.  Through 
mechanisms that are not well understood, the core protein and RNA genome together form the 
nucleocapsid and become enveloped by an ER-derived lipid membrane containing viral 
glycoproteins Erns, E1, and E2 (Thiel et al., 1991).  
 
Experimental evidence based on the results of various deletion and truncations 
demonstrated that CSFV Core protein is indispensable for infectious virion formation (Reidel et 
al., 2010). However, more recently it was found that single amino acid substitutions within the 
NS3 helicase domain are able to compensate for functionally compromised Core proteins even 
when nearly 90% of the core gene is deleted (Reidel et al., 2012).  
 
In an effort to elucidate the biological function of CSFV Core, Gladue et al. utilized a 
yeast two-hybrid (YTH) approach to identify swine proteins that interact with Core protein of 
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CSFV strain Brescia. Screening revealed several host proteins that specifically bound to Core. 
The most notable of these proteins included the cellular proteins SUMO-1 (small ubiquitin-like 
modifier), UBC9 (E2 SUMO conjugating protein), IQGAP1 (IQ motif containing GTPase 
activating protein1), and OS9 (osteosarcoma amplified 9 protein) (Gladue, et al., 2010; Gladue, 
et al., 2011; Gladue, et al., 2014). In general, the data obtained by characterizing each of these 
viral – host protein interactions suggests that the Core protein plays an important role in virus 
virulence.  
 
The first two host cell proteins examined after YTH assay findings were, SUMO-1 and 
UBC9, both of which are involved with the cellular SUMOylation pathway. It has been 
demonstrated, that the conjugation of SUMO can induce protein activation, affect protein 
stability, and cause changes in protein intracellular localization (Kerscher, et al., 2007). 
SUMOylation has also been shown to play a role in the regulation of gene expression and 
maintenance of genomic stability (Seeler, et al., 2003). Several viruses, including human 
cytomegalovirus, Epstein–Barr virus, dengue virus, Moloney murine leukemia virus, and 
vaccinia virus, induce modifications to the host SUMOylation pathway in order to evade the host 
immune response (Sadanari et al., 2005; Huh et al., 2008; Shirai et al., 2008; Chiu et al., 2007; 
Yueh et al., 2006; Palacios et al., 2005). The specific role of SUMOylation in CSFV was 
determined by initially mapping putative SUMOylation binding sites to two distinct regions in 
CSFV Core protein. (Gladue, et al. 2010).  Disruption of protein - protein interaction by 
substitution of specific residues within these regions was found to attenuate the virus in vivo. 
Similarly, interactions of viral proteins with the SUMOylation pathway in other viruses has also 
been observed to effect viral infectivity by either preventing or inducing SUMO conjugation of 
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target proteins, as shown for Ebola Virus Zaire VP35, Adenovirus CELO Gam1, Human 
Herpesvirus 6 IE2, and Human Cytomegalovirus IE2 (Chang et al., 2009; Chiocca et al., 2007; 
Tomoiu et al., 2006 Ahn et al., 2001). Although the function of SUMOylation within CSFV 
Core is still not clear, findings suggests that the interaction of Core with the cellular 
SUMOylation pathway plays a significant role in the CSFV growth cycle as well as viral 
propagation in vivo (Gladue et al., 2010). 
 
Subsequently, interaction of cellular protein, IQGAP1 with CSFV core was further 
examined to determine its significance. IQGAP1 protein has been shown to play an important 
role as a regulator of the actin cytoskeleton (Fukata et al., 2002; Watanabe et al., 2004). Notably, 
it has been reported that interaction of IQGAP1 with the Moloney murine leukemia virus 
(MMLV) matrix (M) protein plays an important role in the intracellular trafficking of MMLV, 
which is essential for virus replication (Leung et al., 2006). In this same study the critical 
residues within MMLV M protein that interact with IQGAP1 were mapped by mutagenesis 
experiments. Based upon these findings, four regions within CSFV Core, designated I – IV, were 
identified that potentially bind IQGAP1. (Gladue et al., 2011). Amino acid residues in these 
putative binding sites were replaced with alanines. Resulting mutations in areas I and III 
completely disrupted the Core–IQGAP1 protein–protein interaction while substitutions in areas 
II and IV only partially affected protein binding. CSFV mutants harboring substitutions in these 
four areas were assessed in animals to determine importance of the Core–IQGAP1 protein 
interaction on virulence. Interestingly, substitutions in regions I and III of the Core, resulted in 
complete attenuation in swine. These results suggest that the ability of CSFV Core protein to 
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bind cellular IQGAP1 protein during infection plays a critical role in virus virulence within the 
swine host. 
 
Lastly, osteosarcoma amplified 9 protein (OS9) a protein involved in the endoplasmic 
reticulum-associated degradation (ERAD) pathway, was identified by YTH system to interact 
with CSFV Core (Gladue et al., 2014a). OS9 has previously been shown to be involved in the 
degradation of misfolded glycoproteins (Huttner et al., 2012), which could be significant 
considering CSFV Erns, E1 and E2 are heavily glycosylated structural proteins. Therefore, it is 
possible that binding of OS9 by the Core protein could prevent degradation of viral 
glycoproteins. Utilizing alanine scanning mutagenesis, the OS9 binding site within the CSFV 
Core protein was mapped to the C-terminus of unprocessed Core, before its cleavage by signal 
peptide peptidase. A recombinant CSFV mutant lacking OS9 binding site in Core protein 
presented a significant decreased ability to replicate in primary swine macrophage cell cultures, 
the natural cell target of CSFV. However, no differences were observed in mutant infected swine 
when compared to animals infected with parental CSFV. As a result, it was concluded that the 
OS9-Core interaction affects the efficiency of virus replication by an unclear mechanism. It is 
also possible that this interaction is a redundant virus function, as there was no observable 
decrease in virus virulence in swine. It appears that either the structural glycoproteins of CSFV 
are not recognized as misfolded proteins, or that the virus has multiple ways of preventing its 
glycoproteins from being degraded. Although the role for OS9 binding to the Core protein is not 
clear, it is clear that the OS9 binding site resides in the unprocessed Core protein. The role of 
unprocessed Core protein has not been previously reported in pestiviruses, however, it is possible 
that Core protein may function differently in both an unprocessed form and after cleavage of the 
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C-terminus. Overall, the YTH system and resulting identification of Core host proteins partners 
has provided interesting insight into the pathogenesis of CSFV by elucidating what appears to be 
multiple roles for Core in the CSFV replication cycle. 
 
 
Erns  Envelope Glycoprotein 
 
Directly following the core protein is the first of three CSFV envelope glycoproteins, 
Erns. This protein is specific to pestiviruses, with no corresponding homologue observed in any 
other genus within the Flaviviridae family (Lindenbach et al., 2001).  Erns is a 44 – 48 kDa 
protein with a length of 227 amino acids. It contains 8–9 conserved cysteines that form intra- and 
intermolecular disulfide bonds. Erns is highly glycosylated with more than 50% carbohydrates in 
its mature form (Branza-Nichita et al., 2004). Erns is most commonly found as disulfide-linked 
homodimers (Thiel et al., 1991) with its most carboxy-terminal cysteine, C171, forming a 
disulfide bond between the Erns monomers (Tews et al., 2009). Of the three structural 
glycoproteins, only the structure for Erns has been determined (Krey et al., 2012). The crystal 
structure of Erns revealed that it contains five α helices and seven β strands with both a concave 
and convex face and is stabilized by four intramolecular disulfide bonds. Sequence analysis of 
different pestiviruses determined that the majority of N-glycosylation sites are localized to the 
convex face which is reasonable considering glycosylation on the concave face would likely 
interfere with Erns dimerization as well as enzymatic activity. Erns lacks a transmembrane 
domain nonetheless it is able to anchor itself to the membrane by a long amphipathic helix at its 
C-terminus (Fetzer, et al., 2005). In addition, a considerable amount of Erns is virion bound and 
is secreted from infected cells into the extracellular environment (Rumenapf, et al., 1993). 
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Several functions have been assigned to Erns. First, comparative sequence analysis and 
subsequent biochemical analysis established that Erns possesses RNase activity (Schneider et al., 
1993). It is probable that this RNase activity of Erns antagonizes host immune response by 
possibly mediating degradation of extracellular RNA components that might otherwise interact 
with host cell intracellular pattern recognition receptors (PRRs) thus circumventing the host 
immune response to viral infection (Schneider et al., 1993). In addition, two mutations in Erns at 
residues H297 and H346 have been identified that eliminate Erns RNase activity, resulting in 
attenuation of the parental CSFV strain (Meyers et al., 1999). Erns has also been proposed to 
mediate initial attachment to cells by binding to glycosaminoglycans (GAG) on the host cell 
surface, although it is probable that this particular binding is not sufficient for entry into the cell 
as observed for many other viruses which require additional, more specific cell surface 
interaction to facilitate penetration of the host cell (Hulst et al., 2000). Furthermore, as a viral 
surface protein, Erns is also able to elicit virus neutralizing antibodies (Weiland et al., 1992) and 
as such can block pestivirus infection in tissue culture (Hulst et al., 1997) as well as provide 
protection in infected animals against lethal CSFV challenge (Hulst et al., 1993). While the Erns 
is not necessary for attachment to the host cell as observed with non-Erns pseudotyped virus 
carrying E1 and E2 glycoproteins (Wang, et al., 2004),  Erns is however not indispensable as it is 
required for viral propagation (Widjojoatmodjo, et al., 2000). 
 
As mentioned previously, Erns is heavily glycosylated with N-linked glycans accounting 
for nearly half of its molecular weight. N-linked glycosylation is important not only for correct 
protein folding and assembly but also for receptor binding, mediation of membrane fusion and 
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penetration into host cells, directing virus morphogenesis at the budding site, and acting as 
antigens to which neutralizing antibodies are directed (Shi et al., 2004). The importance of 
glycosylation varies between proteins; some proteins are completely dependent on glycosylation, 
whereas others display no dependence at all. In addition, it is often found that some 
glycosylation sites are more important than others when individually evaluated (Helenius et al., 
2001). For CSFV Erns, seven potential sites for the attachment of N-linked oligosaccharides 
were identified. In order to determine the importance of these individual glycosylation sites on 
CSFV viral infectivity and virulence in swine, seven CSFV glycosylation deletion mutants were 
constructed (Fernandez-Sainz, et al. 2008). It was found that only one of the seven Erns mutants, 
with Asn - Ala substitution at Erns amino acid residue 269, had an impaired growth rate with a 
5- to 10-fold decrease in the final virus yield. When these seven deletion mutant viruses were 
assessed in animals, only the mutant virus containing mutation of N269A resulted in an 
attenuated phenotype with decreased virus replication and shedding in comparison to parental 
CSFV strain. In addition, these animals were completely protected from lethal CSFV challenge 
as earlier as 3 days post-inoculation. Interestingly, the rest of the single glycosylation site mutant 
viruses were virulent in swine, demonstrating that glycosylation at position 269 is important for 
in vitro and in vivo infectivity.  
 
For many enveloped viruses, the pattern of glycosylation on glycoproteins has been 
demonstrated to affect the number of accessible epitopes recognized by the host immune system 
as antigen (Fournillier et al., 2001). Therefore, to further examine the role of Erns glycosylation 
on the induction of humoral immune response and protection against lethal challenge, animals 
were immunized with either purified glycosylated or nonglycosylated CSFV Erns subunit protein 
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expressed in baculovirus (Gavrilov, et al., 2011). Pigs vaccinated with glycosylated Erns were 
found to be protected against CSFV surviving lethal challenge without presenting clinical signs 
of disease. Conversely, animals inoculated with nonglycosylated Erns protein and challenged 
with virulent CSFV developed symptoms indistinguishable from those observed in mock 
vaccinated control animals. Despite the observed protection in glycosylated Erns immunized 
animals, levels of Erns antibodies and virus neutralizing antibodies were either low or 
undetectable depending on the number of times these animals were immunized with glycosylated 
Erns before challenge. Consequently, glycosylation of glycoproteins can also play a role in 
masking viral neutralizing epitopes (Back et al., 1993), as a result, the removal of glycan 
moieties has been shown to enhance sensitivity of neutralizing antibodies and increase 
immunogenicity of viral epitopes (Reitter et al., 1998; Wei et al., 2003; Ansari et al., 2006). 
Therefore, in order to determine whether the removal of individual glycosylation sites in Erns 
would alter the antibody response against CSFV, animals were immunized with mutated 
glycosylated forms of Erns subunit protein (Gavrilov, et al., 2011). All animals survived lethal 
challenge and were protected against clinical disease with the exception of two groups of pigs 
immunized with Erns N3 and Erns N7. Contrary to what has been observed for other viruses, 
such as Porcine reproductive and respiratory syndrome virus (PRRSV), simian 
immunodeficiency virus (SIV) and hepatitis C virus (HCV) (Ansari et al., 2006; Reitter et al., 
1998; Helle et al., 2010), removal of single glycosylation sites from Erns did not result in 
enhancement of the antibody response in vaccinated pigs. From these results it is clear that 
immunogenicity of Erns is dependent upon glycosylation pattern for the proper conformation 
necessary for eliciting a protective immune response against CSFV, although, the exact 
mechanism mediating that protection remains unknown.  
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E1 envelope glycoprotein 
 
E1 is the only pestivirus envelope glycoprotein for which no structure or function has 
been determined. E1 is a 25–33kDa protein with a transmembrane anchor. Liberation of E1 from 
the polypeptide has been shown to occur in ER by mutation and inhibitor studies and that the 
cleavage between Erns and E1 is mediated by host cellular SPase despite not having a 
transmembrane anchor which is a common earmark in SPase cleavage sites (Bintintan et al., 
2010). Likewise, cellular SPase is also responsible for processing E1at its carboxy terminus 
(Rumenapf et al.,1993). E1 contains several cysteine residues, most of which are well conserved 
throughout pestiviruses (Fernandez-Sainz et al., 2014).  It is probable that these cysteine form 
intramolecular disulfide bonds which stabilize the protein structure. Importantly, E1 and E2 form 
a heterodimer via a disulfide bridge located on the virion surface (Weiland et al., 1990). Since 
the pestivirus E1 glycoprotein is approximately half the size of glycoprotein E2, recent models 
predict that E1is very thin and long in order to span the distance between the viral envelope 
surface and host cell membrane after E2 interacts with the host cell receptor (El Omari et al., 
2013).  
 
While little is known about the functionality of E1, it has been determined that infected 
animals do not develop neutralizing antibodies against E1. Correspondingly, it has proven 
problematic to raise antibodies against E1 protein even when heterologously expressed with 
either Erns or E2, both of which individually generate neutralizing antibodies against CSFV. As 
a result of the lack of available antibodies against E1, detection of E1 is very difficult; therefore, 
E1 is typically analyzed in conjunction with one of the other two envelope glycoproteins. 
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Accordingly, it has been determined that E1-E2 heterodimers are necessary to mediate 
attachment and virus entry into susceptible cells (Ronecker et al., 2008; Wang et al., 2004). 
Furthermore, in a study designed to reveal the mechanism responsible for viral fusion, no 
apparent fusion peptides were revealed in the crystallized E2 structure, as a result it has been 
proposed that E1 might contain the obscure fusion peptide, with a stretch of hydrophobic amino 
acids between residues 57–85 identified as a possible candidate (El Omari et al., 2013). Lastly, 
unlike Erns and E2 which are both able to provide protection against lethal CSFV challenge, E1 
alone was found to not be sufficient to elicit a protective immune response indicating that E1 by 
itself is not immunogenic (Konig et al., 1995).  
 
In efforts to identify virulence and host range determinants of CSFV, Risatti et al. used 
transposon linker insertion mutagenesis (TLIM) to mutate an infectious clone of the pathogenic 
strain Brescia, BIC (Risatti et al., 2005b). A resulting viral mutant, RB-C22v, with a 57 
nucleotide insertion in carboxyl terminus of E1 glycoprotein at genomic position 2429 was found 
to be highly attenuated in pigs. RB-C22v infected animals exhibited decreased replication in 
tonsils, limited generalization of infection, and significant reduction of viral shedding. Notably, 
these animals survived lethal challenge of CSFV presenting no signs of clinical disease. These 
results indicate that this mutation in E1 glycoprotein attenuates the virus and consequently has 
been identified as a virulent factor of CSFV. 
 
As mentioned previously, E2 glycoprotein forms heterodimers with E1 glycoprotein via 
disulfide bridges between cysteine residues. The interaction between these envelope proteins 
plays an important role in virus assembly, virion maturity, and viral infectivity. The E1 envelope 
  
19 
 
protein of CSFV contains six cysteine residues, however, until recently the contribution of E1 
cysteines in formation of disulfide bridges with E2 had not been determined. Furthermore, the 
biological significance of the formation of E1-E2 heterodimers during infection and the role of 
E1 cysteine residues in CSFV replication or infection of swine was also not known. In order to 
begin to understand the role of these residues in the formation of heterodimers and virulence in 
vivo, a panel of single and double recombinant mutant viruses was constructed by substituting 
cysteine residues with serine in E1 glycoprotein CSFV (Fernandez-Sainz et al., 2011). 
Interestingly, individual substitutions of cysteine residues did not have any impact on the 
formation of E1-E2 heterodimers or virulence in swine. Surprising 11 out of 15 double mutant 
constructs did not produce viable virus. However, of the remaining double mutant viruses, one 
exhibited an attenuated phenotype in animals while the other 3 retained the virulent phenotype of 
parental virus in pigs. In addition, the attenuated mutant displayed a partial disruption of E1-E2 
heterodimer formation in infected cells as well as decreased growth rate in primary swine 
macrophages. Despite its diminished growth in vitro, this mutant virus provided protection in 
swine challenged with virulent CSFV at 3 and 28 days post infection. The attenuated virus 
contains mutations at amino acid position 24 and 94 in E1 glycoprotein suggesting that these 
residues are critical in the proper formation of E1-E2 heterodimers and virulence in swine.  
 
Lastly, as with Erns, the role of post translational glycosylation on the immunogenicity 
and protective efficacy in pigs was evaluated for E1 both in the context of recombinant viruses as 
well as purified glycosylated forms of E1 glycoprotein expressed in baculovirus (Fernandez-
Sainz et al., 2009; Gavrilov, et al., 2011). Three putative N-linked glycosylation sites were 
identified in E1 (N500, N513 and N594). To determine the role of these glycosylation sites on 
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viral infectivity and virulence in swine a panel of E1 mutants were constructed in which each of 
the potential N-linked glycosylation sites was mutated either individually from Asn – Ala or in 
various combinations (Fernandez-Sainz et al., 2009). Substitutions at all three putative sites 
proved deleterious on virus yield, while all single and double mutants produced viable progeny. 
When assessed in animals, only one of the single site mutants (N594A) and one of the double 
mutants (N500A/N513A) were found to be attenuated. In addition, these two recombinant 
viruses efficiently protected animals from virulent challenge at 3 and 28 days post-infection. It 
was concluded from these findings, that residue N594 in El envelope protein is critical for virus 
viability in the context of two or more glycosylation site modifications and E1mutant viruses 
N594A and N500A/N513A lack determinants necessary for CSFV virulence in swine. More 
recently, purified glycosylated and unglycosylated E1 glycoproteins expressed in baculvirus 
were developed and assessed in swine (Gavrilov, et al., 2011). No detectable neutralizing 
antibodies were raised against either form of E1 subunit protein in immunized animals.  In 
addition, neither form of E1 glycoprotein was able to provide protection against lethal CSFV 
challenge in swine. These findings indicate that envelope protein E1 is not immunogenic and as a 
result does not play a major role in immunity against CSFV.  
 
 
E2 envelope glycoprotein 
 
E2, the major envelope glycoprotein of the virus, has a molecular weight of 53–55kDa.  
The cleavage between E2 and its adjacent proteins, E1 and p7, is processed by host cellular ER 
associated SPase (Elbers et al.,1996; Rumenapf et al., 1993). The C-terminus of E2 contains a 
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hydrophobic sequence that acts as transmembrane anchor. The mature E2 envelope protein is 
373 amino acids long and contains 15 conserved cysteines which form intra-and inter molecular 
disulfide bridges (El Omari et al., 2013; Li et al., 2013). As described previously, E2 associates 
with E1 to form disulfide-linked heterodimers which are retained on the viral surface by their 
transmembrane anchors.  In addition, E2 glycoprotein is also able to form E2-E2 disulfide-linked 
homodimers (Weiland et al., 1990). During virus assembly, E2 homodimers are formed early, 
whereas E1-E2 heterodimers are formed later after the release of E1 from the endoplasmic 
reticulum chaperone enzyme calnexin (Branza-Nichita et al., 2001).  
 
The CSFV E2 glycoprotein exists as an elongated protein with four antigenic domains 
arranged in a linear fashion in the order of B/C/D/A (Wensvoort et al., 1989). All four domains 
are located in the N-terminal half of E2 ectodomain and form two individual antigenic units. The 
unit closest to the amino terminal portion of the E2 seqeunce is comprised of domains B/C while 
the other unit is composed of domains D/A (Wensvoort et al., 1989). The B/C domains are 
linked by a putative disulfide bond, whereas D/A domains are presumably bound by two putative 
disulfide bonds (van Rijn et al., 1994). Domains B/C and D/A each form a globular head 
connected by a pan-handle shaped link. Domain A has been subdivided further into A1, A2 and 
A3 subdomains. A1 and A2 are conserved among classical swine fever virus strains, and 
domains A1, B and C are involved in neutralization (Wensvoort, et al., 1989). In contrast, 
subdomain A3 and domain D, are neither neutralizing nor conserved (van Rijn et al., 1993).  
 
Functionally, E2 has been suggested to be responsible for receptor-binding and identified 
as the main target for neutralizing antibodies (Weiland et al., 1990).  The E2 envelope protein 
has also been observed to play a major role in species tropism of pestiviruses (Liang et al., 2003; 
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Reimann et al. 2004). Importantly, both CSFV and BVDV use the same unknown host cell 
receptor as demonstrated by effective inhibition with either virus on porcine and bovine cells 
(Hulst et al., 1997). In addition, the availability of a large panel of monoclonal antibodies against 
E2 have made characterization of E2 possible by mapping binding sites and antigenic regions in 
order to gain information on the structure (Wensvoort G., 1986; van Rijn et al., 1993; van Rijn et 
al., 1994). Glycoprotein E2 is the most immunogenic of all CSFV glycoproteins (Konig et al., 
1995; Weiland et al., 1990). Moreover, it is well established that E2 alone is sufficient to elicit a 
protective immune response in animals against CSFV (Rumenapf, et al., 1991; van Zijl, et al., 
1991; Hulst et al., 1993; Hammond, et al., 2000). Consequently, due to these E2 glycoprotein 
specific properties, E2 has often been utilized in the development of potential CSFV vaccine 
candidates (van Gennip et al., 2000; Reimann, et al., 2004; Koenig et al., 2007).  
Unlike E1 glycoprotein, the envelope glycoprotein E2 has been extensively studied and 
characterized. Accordingly, multiple regions within E2 have been identified as virulent factors of 
CSFV (Risatti, et al., 2005a; Risatti et al., 2006). The role of E2 in virulence was first 
established in a study designed to identify genetic determinants of CSFV virulence and host 
range, in which a series of chimeric viruses were constructed where regions of CSFV genome 
were systematically replaced with the homologous regions of attenuated CSFV strain CS in the 
genetic backbone of highly virulent CSFV Brescia strain (Risatti, et al., 2005a). The resulting 
chimeric viruses were evaluated in swine for viral virulence. Interestingly, only chimeras 
harboring the CS E2 gene were attenuated suggesting that a significant virulence determinant 
absent in CS E2 was responsible for attenuation. Furthermore the exact area in CS E2 producing 
the attenuation was mapped between amino acid residues 886 and 1059 (Risatti, et al., 2005a, 
and 2007). These results demonstrate that CS E2 alone is sufficient for attenuating Brescia, 
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indicating that CSFV E2 glycoprotein is a major determinant of virulence in swine. In a 
subsequent study, progressive mutations were introduced into an area of E2 between residues 
829 and 837 (Risatti, et al., 2006) that contains a distinct CSFV specific epitope recognized by 
monoclonal antibody (mAb) designated WH303, a reagent which fails to react with BVDV or 
BDV E2 and is routinely used for CSF diagnostics (Lin et al., 2000). Amino acids in mAb 
WH303 epitope, TAVSPTTLR, of CSFV Brescia were progressively replaced with the 
corresponding amino acid residues of BVDV, TSFNMDTLR, producing 4 chimeric viruses. The 
resulting viruses were designated T1v – T4v and were evaluated in animals. T1v – T3v induced 
lethal disease, while T4v induced mild and transient disease in pigs. Notably, animals infected 
with T4v were protected when challenged with virulent Brescia virus at 3and 21 days post-
vaccination. These results demonstrate residues, TAVSPT, in mAb WH303 eptiope of E2 play a 
significant role in CSFV virulence.  
 
The majority of viral integral membrane proteins are post translationally modified by 
addition of N linked carbohydrate chains, although some have only O-linked carbohydrate chains 
while others have both (Doms, et al., 1993). Accordingly, five putative N-linked sites and one 
putative O-linked glycosylation have been predicted by algorithm analysis for the E2 
glycoprotein (Moormann, et al., 1990). Notably, a sixth N-linked putative glycosylation site has 
been reported for several CSFV strains including CSFV Brescia strain. Importantly, predicted E2 
glycosylation sites are highly conserved among CSFV isolates. However, not all predicted sites 
in a protein sequence are used for carbohydrates, since many of them are either inefficiently 
glycosylated or remain unglycosylated (Shakin-Eshleman, et al., 1992; Gavel, et al., 1990). As 
such, Risatti et al. investigated the role of E2 glycosylation in the highly virulent CSFV Brescia 
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strain in swine (Risatti et al., 2007). Seven putative glycosylation sites in E2 were modified by 
site-directed mutagenesis of a CSFV Brescia infectious clone (BIC) creating a panel of 15 
mutant viruses used to investigate whether the removal of putative glycosylation sites in the E2 
glycoprotein would affect viral virulence and pathogenesis in pigs. Interestingly, no viable virus 
was produced when all putative glycosylation sites were removed; however, viable progeny were 
generated upon reversion at mutation N185A back to wild type Asp. Furthermore, this reversion 
mutant virus was found to be attenuated in swine. In addition, analysis of single E2 glycosylation 
site mutant viruses in pigs revealed that removal of glycosylation at amino acid N116A (N1v 
virus) was responsible for BICv attenuation. N1v efficiently protected swine from challenge with 
virulent BICv at 3 and 28 days post-infection, suggesting that glycosylation at amino acids N116 
and N185 are critical for E2 activity as well as viral virulence. In addition, the importance of 
glycosylation in the immunogenicity of E2 was assessed using purified glycosylated, or 
nonglycosylated versions of E2 expressed in baculovirus. (Gavrilov, et al., 2011). Pigs 
vaccinated with glycosylated E2 protein induced virus neutralizing antibodies and were protected 
against lethal challenge with CSFV. Conversely, animals inoculated with nonglycosylated E2 
subunit protein did not elicit detectable neutralizing antibodies and when challenged with 
virulent CSFV developed symptoms indistinguishable from those observed in mock vaccinated 
control animals (Gavrilov, et al., 2011). Subsequently, naïve animals were immunized with 
single site glycosylation mutated E2 subunit proteins to assess whether individual glycosylation 
sites present in E2 were critical in the induction of the neutralizing antibody response. 
Neutralizing antibodies were detected in sera from all pigs immunized with single site 
glycosylation mutant E2 proteins. While, most of the animals infected with E2 single 
glycosylation mutant viruses presented diminished levels of neutralizing antibodies in 
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comparison to those animals vaccinated with glycosylated E2 subunit protein, two groups of 
animals infected with single mutations at either amino acid residue 260 or 297 elicited 
neutralizing antibody levels indistinguishable from levels raised in animals immunized with the 
glycosylated E2 subunit protein. In addition, all animals infected with single site glycosylation 
mutated forms of E2 protein were protected against lethal CSFV challenge, except for animals 
infected with E2 glycosylation mutant protein in which the glycan moiety at position 121 was 
removed. Overall, these results demonstrate that glycosylation pattern plays a major role in the 
immunogenicity of CSFV E2 glycoprotein 
 
As mentioned previously, E2 glycoprotein is involved in cellular attachment and entry 
into susceptible host cells. Entry of enveloped animal viruses requires fusion between the viral 
membrane and a cellular membrane. Using proteomic computational analysis, a putative fusion 
peptide (FP) between amino acid residues 818 to 828 was identified in CSFV E2. (Garry et al., 
2003). This sequence, CPIGWTGVIEC, was found to be highly conserved among pestiviruses, 
as is true of fusion peptides from other enveloped RNA viruses. Fernandez-Sainz et al. (2014) 
evaluated the role of this putative fusion by generating a series of 8 recombinant cDNA 
constructs by mutating amino acids in the E2 FP region either individually or combinatorially in 
the genetic background of full-length BIC. Six of these constructs produced viable viruses while 
a double mutant, 818S/C828S, and triple mutant, P819S/I820S/W822S amino acid substitutions 
were deleterious for CSFV replication. Amino acid substitutions of the remaining 6 FP mutant 
viruses were not found to significantly affect either virus growth in vitro or virulence in animals. 
Notably, the lethal amino acid substitutions of the double and triple mutants did not appear to 
impact the secondary structure of the FP at all. In contrast, the triple mutation was shown to 
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impair the ability of a synthetic peptide harboring these amino acid substitutions to penetrate 
target membranes. In addition, it was demonstrated that the synthetic peptide harboring the WT 
FP sequence was more efficient at pertubing the lipid bilayer than synthetic peptides containing 
the double or triple amino acid substitutions. Overall, this preliminary characterization suggests 
that the E2 putative FP is involved in membrane fusion activity and plays a critical role in virus 
replication. 
 
Lastly, until recently there was no information regarding host binding partners for the E2 
glycoproteins which could help expand the current understanding of the functions of the E2 
protein. To this end, Gladue et al. utilized the yeast two-hybrid system and identified 57 host 
proteins that bind the E2 glycoprotein of CSFV (Gladue et al., 2013). In an effort to map binding 
sites on E2 with these cellular proteins an alanine scanning approach was utilized thereby 
generating a panel of 76 CSFV E2 mutant proteins. However, after testing of all 76 E2 mutants 
against all the host proteins, identification of specific binding sites was unsuccessful as all of the 
host proteins were capable of binding all of the E2 alanine mutants. These results, suggest that 
the host proteins do not bind to linear amino acid stretches within of E2 rather it is likely that 
most of these proteins bind to multiple non-linearly arranged residues that are not disrupted by 
the polyalanine mutations in linear amino acid stretches. While no specific binding sites in E2 
were identified, the possible roles for viral E2 interaction with these host proteins were 
speculated based upon analysis with the PANTHER classification system (Protein ANalysis 
THrough Evolutionary Relationships). Fifteen different biological processes were found for 
these host proteins which include metabolic, cellular, developmental, immune system, cell 
communication, cell adhesion, system processses, response to stimuli, cellular compartment 
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organization, cell cycle, transport, generation of precursor metabolites and energy, apoptosis, 
localization, and reproduction processes.  
 
 
Non structural protein p7 
 
 
Immediately downstream of E2 is the gene coding for protein p7, a small hydrophobic 
polypeptide with a molecular weight of 6 to 7 kDa. This protein is not detected in virions of 
pestiviruses and is therefore classified as a non structrural protein (NSP) (Elbers et al., 1996). 
Similar to many CSFV proteins described previously, p7 is released from the polypeptide by 
cellular SPase (Elbers et al., 1996). Notably, in pestivirus-infected cells, p7 has been detected as 
both an individual protein as well as part of fusion protein E2-p7 (Elbers et al., 1996). The 
existence of fusion protein E2-p7 is unusual since cleavage by SPase is extremely efficient. No 
precursor-product relationship was found between E2-p7 and E2, which suggests E2-p7 fusion 
protein must be functionally important (Harada, et al., 2000). Furthermore, the cleavage of 
precursor E2p7NS2 into mature p7 and E2-p7 has been found to be conserved among 
pestiviruses as well as hepatitis C virus (HCV). Therefore, it has been proposed that E2-p7 
fusion protein may play an important role in the viral life cycle (Harada et al., 2000). However, 
upon further investigation it was found that the E2-p7 fusion protein is dispensable for both viral 
RNA replication and generation of infectious virions. Consequently, the function of E2-p7 fusion 
protein is presently unknown. Conversely, it has been demonstrated that p7 is required for 
generation of infectious virions in pestiviruses (Harada et al. 2000; Gladue et al., 2012). Given 
that p7 contains two hydrophobic stretches of amino acids interrupted by a short charged 
segment which is predicted to form two transmembrane helices connected by a charged cytosolic 
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loop, it has been suggested that CSFV p7 may be a member of the viroporin family (Harada, et 
al., 2000). Viroporins are small polypeptides that are capable of modulating membrane 
permeability and may play a crucial role in the release of virions. Recently, the p7 protein of 
CSFV was confirmed to function as a viroporin with pore forming activity by analysis in a 
liposome model membrane system mimicking the lipid composition of the ER membrane 
(Gladue et al., 2012). Importantly, the pore forming activity was mapped to the carboxyl half of 
the p7 protein. In the same study, constructs containing in-frame partial deletions of p7 in the 
context of full length cDNA CSFV infectious clone were unable to generate infectious particles 
suggesting that p7 is essential for in vitro viral replication. In addition by an alanine mutagenesis 
screening approach, p7 mutant viruses were produced and tested in swine to determine the effect 
that alterations of different regions of p7 have on virulence. Some of the constructs where unable 
to produce infectious progeny while other constructs produced viruses that were either partially 
or completely attenuated in animals, indicating that p7 plays a significant role in virulence. More 
recently, Largo et al. (2014) mapped the minimal p7 sequence required for pore formation to 
amino acids 33–67 which encompasses the basic cytosolic loop as well as the c-terminal 
transmembrane in CSFV (Largo et al., 2014). While the c-terminal transmembrane was 
sufficient for pore formation, the n-terminal loop was shown to be necessary for regulating the 
process. Other target membranes were also examined in this study and it was found that the c-
terminal hydrophobic domain was capable of inserting into membranes of the secretory pathway 
such as the ER and Golgi but not the plasma membrane. 
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NS2 
 
NS2 of pestiviruses consists of about 450 amino acids. The N-terminal half of the protein 
is highly hydrophobic and may form up to seven transmembrane regions followed by a cytosolic 
domain. The cytosolic domain contains a putative Zn2+-binding site, consisting of four cysteine 
residues, which is an integral part of an autoprotease subdomain responsible for cleaving NS2-3 
in cis between NS2 and NS3 (de Moerlooze et al.,1990; Lackner et al., 2004). After cis-
cleavage, the C-terminus of NS2 stays in the active site of the protease, thereby preventing 
further NS2 cleavages in trans (Lackner et al., 2006). In addition, it has been found that 
proteolytic activity of NS2 depends on interaction with a cellular chaperone Jiv (J-domain 
protein interacting with viral protein) (Lackner et al., 2006). Notably, cleavage of NS2-3 is 
limited by the availabity of cellular Jiv as the complex formation between Jiv and NS2 is tightly 
regulated with one molecule of Jiv responsible for the release of one NS3 protein.  
 
Recently, several amino acid residues were identified in the N-terminal region of NS2 
that are critical in regulation of the CSFV life cycle (Li et al., 2015).  In this study, residues at 
position 60 and 78 in the NS2 protein were found to be independently essential for RNA 
replication and virus production. While a substitution at amino acid residue 100 in NS2 resulted 
in significantly reduced viral titers suggesting that NS2 may also play a role in regulation of 
CSFV secretion from infected cells.   
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NS2-3 
  
Interestingly in pestiviruses, the unprocessed NS2-3 precursor forms a stable protein in 
infected cells (Collett et al., 1991). As a result, NS2-3, NS2 and NS3 proteins are all present 
within infected cells at varying concentrations. It was once thought that the difference observed 
between pestivirus noncytopathogenic (noncp) and cytopathogenic (cp) biotypes were dependent 
upon the processing of NS2-3 (Thiel, et al., 1996).  Essentially, processing of NS2-3 to NS2 and 
NS3 was suggested to result in the accumulation of NS3 which was responsible for the 
cytopathic effect observed in tissue culture infected with cp pestivirus strains. Conversely, this 
NS2-3 processing was presumed to be absent in the noncp biotypes (Kummerer, et al., 2000). 
However, it has been demonstrated that NS3 is indispensible for pestiviral RNA replication 
regardless of the specific biotype and cannot be functionally replaced by NS2-3 (Lackner et al., 
2004).  Nevertheless, the significance of uncleaved NS2-3 in infected cells was ultimately 
revealed as being required for production of virus particles. This role has been illustrated in both 
BVDV and CSFV where the genomes were modified in such a way as to prevent expression of 
NS2-3 while allowing normal expression of all the other viral proteins, including NS2 and NS3 
(Agapov et al., 2004 ; Moulin et al., 2007). In both instances, the absence of uncleaved NS2-3 
correlated with a defect in the production of infectious virus progeny, despite evidence of 
efficient viral RNA replication. Importantly as mentioned earlier, cleavage of NS2-3 is 
temporally modulated by the cellular cofactor Jiv which associates with NS2 (Lackner et al., 
2006). This NS2-mediated cleavage acts as a switch between RNA replication and infectious 
particle formation. Once the Jiv supply in the infected cell is consumed cleavage of NS2-3 ceases 
resulting in decreased viral RNA replication due to NS2-3’s inability to replace NS3 in the 
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replication complex (Lackner et al., 2006). Uncleaved NS2-3 accumulates in the cell and 
associates co-translationally with NS4A and subsequently enters the virion assembly process.  
 
 
 
NS3 
 
 
The NS3 protein is the most highly conserved non-structural protein among pestiviruses 
and predicted to be hydrophilic with a net positive charge (Xu et al., 1997). It has been 
established that NS3 plays a key role in formation of the replication-transcription complex and 
subsequent RNA replication (Zhang et al., 2003).  NS3 is a multifunctional protein containing 
protease, helicase and NTPase activity. In the N-terminal portion of NS3 resides a chymotrypsin-
like serine protease. This chymotrypsin-like serine protease acts in both cis-cleavage (NS3-4A) 
and trans-cleavage (NS4A-4B-5A-5B) (Rice et al., 1996). The other functional domains of NS3 
are found in the C-terminal region encompassing the helicase and NTPase domains (Warrener et 
al., 1995).  Notably, the NS3 serine protease requires the stable association with its cofactor 
NS4A in order to reach full activity (Xu et al., 1997). Consequently, the NS3/4A protease is 
responsible for cis-cleavage generating the C-terminus of NS3 as well as all downstream 
cleavages which occur in trans, releasing NS4B, NS5A, and NS5B from the polyprotein 
(Wiskerchen et al., 1991). Similarly, uncleaved NS2–3 was also shown to possess serine 
protease activity, though with reduced activity, and as a result could not functionally substitute 
for NS3 in viral RNA replication (Lackner et al., 2004). Once cleaved by NS2, the liberated NS3 
protein interacts with NS4A as well as with the downstream nonstructural proteins of the 
replication complex at the membrane of the endoplasmic reticulum where negative-sense RNA 
templates and progeny viral genomes are produced (Xu et al., 1997). For these processes, the 
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helicase and NTPase activities of NS3 were also found to be essential (Gu et al., 2000). Using 
mutational analysis, Gu et al. (2000) demonstrated that the NS3 NTPase/helicase activities of the 
BVDV were essential for the synthesis of minus-strand RNA. In addition, they also found that 
NTPase activity is absolutely required for helicase activity. While the functional mechanism of 
helicase activity remains unclear it has been proposed that NTPase/helicase could allow initiation 
of minus-strand template synthesis by unwinding the secondary structures present in the 3’ UTR 
thereby allowing initiation by the RNA-dependent RNA polymerase (RdRp). 
 
Lastly, a new and unexpected role has recently been described for the C-terminal region 
of NS3 of CSFV. In an experiment investigating properties of the pestivirus core protein C, a 
pestivirus mutant virus lacking almost the entire C gene sequence was unexpectantly found to be 
viable as a result of a random mutation in the helicase domain of NS3 (Riedel et al., 2010).  
Further investigation demonstrated that single amino acid substitutions in the helicase domain of 
NS3 could sufficiently compensate for the loss of core protein (Riedel et al., 2012).  
Correspondingly, this role of the NS3 helicase domain has also been observed in virion 
morphogenesis in other members of the Flaviviridae family, such as yellow fever virus and HCV 
(Patkar et al. 2008; Ma et al., 2008). Riedel et al. (2012) propose that the ability of NS3 to 
functionally replace the core protein may suggest that NS3 had a packing function in an ancestral 
prototype virus in the absence of a capsid gene which was later acquired during the evolutionary 
process in order to infect a novel host (Riedel et al., 2012).    
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NS4A 
 
NS4A is a non-structural protein with a predicted weight of 10 kDa. It contains a 
hydrophobic, membrane spanning N-terminal region and a C-terminal cytosolic domain (Liang 
et al., 2009). NS4A has a length of 64 amino acid residues and is quite acidic. It is also highly 
conserved among pestiviruses. Early studies demonstrated that the BVDV NS3 serine proteinase 
expressed alone was not sufficient for cleavage at the 5A/5B site (Wiskerchen et al., 1991). It 
was later determined that NS4A forms a complex with NS3 serine proteinase domain acting as a 
cofactor for NS3 and together are essential for cleavage at the 4B/5A and 5A/5B sites (Xu et al., 
1997). In addition to this protease cofactor function, trans-complementation experiments 
revealed another critical role for NS4A in virion morphogenesis (Agapov et al., 2004; Moulin et 
al., 2007). Consequently, it was ascertained for both BVDV and CSFV that uncleaved NS2-3 
requires expression of NS4A for optimal production of infectious virions (Agapov et al., 2004; 
Moulin et al., 2007). Furthermore, Moulin et al. (2007) demonstrated that CSFV infectious 
particle rescue was dependent upon a combination of uncleaved NS2-3 and processed NS4A 
rather than the NS2-3-4A polyprotein precursor. Notably, the role of NS4A with NS2-3 in 
infectious particle formation is independent of NS4A function in conjunction with NS3 in RNA 
viral replication.  
 
NS4B 
 
NS4B is 347 residues long with a molecular mass of approximately 35kDa (Xu et al. 
1997). It is a hydrophobic protein that is indispensable in pestiviral RNA replication (Collett et 
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al., 1991; Grassmann et al., 2001). NS4B is an integral membrane protein associated with the 
endoplasmic reticulum that possesses four putative transmembrane domains flanked by 
cytoplasmic N- and C-terminal regions (Weiskircher et al., 2009). The N-terminal region 
contains a conserved amphipathic helix that can become a transmembrane domain upon NS4B 
cleavage (Elazar et al., 2004) while the C-terminal region contains two predicted helical domains 
(Jones et al., 2009). A recent study mapped amino acids in the N-terminal region of NS4B that 
are essential in the formation of a functional replication complex (Gouttenoire et al., 2009). In 
HCV and BVDV replication studies, it has been demonstrate that NS4B colocalizes with 
replicase proteins NS3, NS5A and NS5B which suggests that NS4B may be a component of the 
BVDV replication complex (Piccininni et al., 2002; Weiskircher et al., 2009). In addition, it has 
been shown that NS4B may also play an important role in virus assembly and release (Jones et 
al., 2009). Finally, it has been reported for multiple flaviviruses that NS4B is able to strongly 
block the IFN-induced signal-transduction cascade by interfering with STAT1 function thereby 
evading the host immune system (Muñoz-Jordan, J. L. et al., 2003 and Tasaka, et al., 2007).     
 
Amino acid sequence analysis of pestivirus NS4B proteins revealed sequences with 
similarity to nucleotide-binding motifs (NBM), termed Walker A and B, which were initially 
observed in HCV although the location of these motifs within the protein differ among genus 
(Gladue et al., 2011; Einav et al. 2004). In pestiviruses, the motifs’ sequences are located 
towards the C-terminal portion of NS4B, consisting of amino acid residues 209-216 and 335-342 
of the protein, for Walker A and B respectively. This structural motif has been shown to bind and 
hydrolyze ATP, and GTP (Einav et al., 2004; Thompson et al., 2009). Substitutions of critical 
residues within these motifs have been reported to drastically reduce the ATPase and GTPase 
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activities of bacterial expressed NS4B proteins (Gladue et al., 2011). Similar mutations 
introduced into the genetic background of a full-length cDNA copy of CSFV strain Brescia 
rendered no infectious progeny or viruses with diminished replication capabilities, indicating that 
this NTPase activity is essential for the CSFV replication cycle (Gladue et al., 2011). 
 
In addition to the Walker A and B motifs, a putative Toll/interleukin-1 receptor (TIR)-
like domain has been predicted to reside in NS4B protein.  This domain is unique to both CSFV 
and BVDV and is not found in other pestiviruses or flaviviruses. TIR domains participate in 
signal transduction of Toll-like receptors (TLRs). In general, TLRs are a large family of proteins 
that play a crucial role in recognition of various microbial components, activate the innate 
immune system, and induce of cytokines needed for the adaptive immune response (Akira et al., 
2004). Importantly, the TIR domain contains 3 conserved motifs, termed box 1, 2 and 3. It has 
been shown that alanine substitution in box 1 and 2 of a TIR domain in a human interleukin 
receptor can inhibit its signaling, while signaling was unaffected by alanine substitutions in box3 
of the TIR domain. Based on these observations, Fernandez-Sainz et al. (2010) selectively 
generated mutations in boxes 1 and 2 in order to elucidate the function of this TIR domain in 
CSFV NS4B. Mutations, V2566A, G2567A, and I2568A in the box 2 domain produced a virus 
(NS4B VGIv) with an attenuated phenotype in pigs. Infection with recombinant NS4B VGI was 
characterized by localized replication in the tonsils with limited viral dissemination during 
infection. Furthermore, animals inoculated with NS4B VGIv were completely protected against 
lethal CSFV challenge as early as 3 days post infection. Analysis of cellular gene expression of 
infected primary swine macrophage revealed cultures infected with NS4B VGIv showed 
increased activation of several genes, compared to those in cultures infected with the parental 
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virus. Notably, most of the genes exhibiting increased transcriptional activation with NS4B 
VGIv infection are similarly induced by activated TLR-7 (Lee et al., 2003). Furthermore, TLR-7 
functional involvement was indirectly confirmed by the observation that transfection of 
macrophages with wild-type NS4B reduces the responsiveness of TLR-7 to a well characterized 
activator, imiquimod R837 (I-R837) while transfection with NS4B gene harboring box 2 domain 
mutations was less efficient at mediating this reduction. Ferandez-Sainz et al. (2010) speculated 
that these findings suggest that NS4B of wild-type CSFV blocks TLR-7 transcriptional activation 
during infection in animals.  
 
 
 
NS5A 
 
 
NS5A protein is a large, hydrophilic phosphoprotein with an approximate molecular mass 
of 58 kDa and is comprised of 497 amino acids. It encompasses three domains interconnected by 
two low-complexity sequences (LCSs). At the N-terminus of NS5A is an amphipathic α-helix 
which serves to anchor the NS5A protein to intracellular membranes (Brass et al., 2002).  It was 
demonstrated that the first 27 to 33 amino acids of NS5A of hepaciviruses and pestiviruses are 
necessary and sufficient for both targeting and anchoring the NS5A protein to the membrane 
(Brass et al., 2007). In addition, a conserved zinc-binding motif was also found in domain I of 
the NS5A protein of hepaciviruses and pestiviruses (Tellinghuisen et al., 2004; Tellinghuisen et 
al., 2006). Sequence analysis, identified four conserved CSFV cysteine residues, C2717-C2740-
C2742-C2767, involved in zinc binding (Sheng et al., 2010). Furthermore, mutation at any of 
these cysteine residues results in an NS5A protein unable to bind zinc a function shown to be 
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indispensable for RNA replication (Sheng et al., 2010). In addition, HCV and related viruses 
seem to be phosphorylated by the similar cellular kinase(s) which suggests that phosphorylation 
of the NS5A/NS5 proteins or their association with cellular kinases may play an important role 
in the flavivirus life cycle. While NS5A function is still not entirely clear, it is believed to be a 
component of the replication complex (Brass et al., 2002). NMR structure analyses suggests that 
the N terminus amphipathic helix may constitute a unique platform essential for the formation of 
the replication complex (Sapay et al., 2006). Finally, NS5A has recently been shown to regulate 
viral RNA synthesis and viral replication by either binding to the 3’UTR of the viral RNA 
genome or by modulation of NS5B RdRp activity by direct protein–protein interactions (Sheng 
et al., 2012). 
 
 
 
NS5B 
 
 
 
The last protein in the carboxyl end of the pestiviral polyprotein is NS5B which has a 
weight of about 77 kDa and contains 718aa. The CSFV NS5B protein has been demonstrated to 
contain RNA-dependent RNA polymerase (RdRp) activity and is able to bind to the 3′UTR in 
order to initiate genome replication (Steffen et al., 1999). RdRp is a required for replication of 
the positive-strand RNA genome. NS5B transcribes the genome into negative-sense strands, 
which serve as templates to produce more positive-sense RNAs for packaging into progeny viral 
capsids (Gong et al., 1996). The overall structure resembles a right hand with fingers, palm, and 
thumb domains and has 5 motifs designated A, B, C, D and E (O'Reilly et al., 1998). Motifs A, 
B, C and D are located at the catalytic portion of the palm domain (Hansen et al., 1997). 
Importantly, motif C forms a β-strand-turn-β-strand structure which contains the highly 
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conserved GDD motif found in all RdRps (Kamer & Argos, 1984). The GDD sequence is 
postulated to be involved in the catalytic-activity and metal-ion regulation of the RdRps 
(Jablonski et al., 1991). It has been demonstrated that NS5B directly binds to NS3/4A (Ishido et 
al., 1998), NS5A (Yamashita et al., 1998), and indirectly to NS4B by help of NS5A (Lin et al., 
1997), as such NS5B is not only the central enzyme for the viral replication but may also be a 
core protein for assembly of the replication complex. Moreover, NS5B has recently been 
implicated to play a role in infectious virion assembly (Ansari et al., 2004).   
 
 
Viral Life Cycle 
 
The proposed replication strategy for pestiviruses and other members of the Flaviviridae 
family is far from being completely understood and is largely based upon studies done with 
flaviviruses. Consequently, the virus is believed to enter a susceptible host cell via a multistep 
process which involves cellular receptors specific for viral envelope glycoproteins (Lindenbach 
et al., 2001). It is presumed that the viral Erns glycoprotein initially interacts with a currently 
unknown host cell surface receptor which mediates attachment of the virion to the cell surface 
(Gollins et al., 1985). Thereafter, the viral E2 glycoprotein is thought to interact with a separate 
and more specific cellular surface molecule facilitating penetration into the cell (Hulst et al., 
1997). It is speculated that the virion is then taken up into a prelysosomal endocytic compartment 
where the compartment’s acidic environment induces fusion between the viral envelope and the 
endosomal membrane thereby releasing the viral nucleocapsid into the cytosol of the host cell 
(Lindenbach et al., 2001). Next, uncoating of the nucleocapsid by a process that is not yet fully 
understood releases the viral genome into the host cytoplasm where the viral genome due to its 
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positive polarity is immediately translated into a single polyprotein. Processing of the 
polyprotein into discrete proteins occurs co- and post-translationally by viral proteases and host 
cell proteases residing in the lumen of the endoplasmic reticulum (ER). Once the polyprotein 
processing is completed, the formation of RNA replicase from the nonstructural proteins leads to 
replication of the viral genome which takes place on the intracellular membranes (Xiao et al., 
2004). Viral assembly proceeds on the surface of the ER, where the structural proteins and the 
newly synthesized RNA bud into the lumen of the ER.  As the immature viral particles pass 
through the secretory pathway, maturation of virions occur and the envelope proteins become 
glycosylated (Westaway, E. G., 1987). Finally, the nascent virions pinch off from the trans-Golgi 
network as exocytic vesicles which fuse with the plasma membrane releasing mature virions 
from the host cell (Mukhopadhyay et al., 2005).   
 
Translation and Protein Processing 
 
After the viral genome is released into the cytoplasm of the host cell the 5’UTR of the 
genome directs the RNA to ribosomes which are in close proximity with the ER (Leyseen et al., 
2000). The 5’UTR contains a complex RNA structure known as an internal ribosomal entry site 
(IRES) which promotes the binding of the ribosome to the start codon thereby initiating 
translation of the viral RNA. Translation produces a single long precursor polyprotein which is 
processed into individual proteins co- and post-translationally.  
 
 The polyprotein processing begins with cleavage of Npro from the downstream capsid 
protein and is expected to occur co-translationally (Tratshin et al., 1998). The Npro, as stated 
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before, possesses autoproteolytic activity allowing it to cleave itself from capsid protein creating 
its own C- terminus and the N- terminus of capsid protein (Stark et al., 1993). Next, processing 
of the structural proteins (C, E0, E1, and E2) proceeds in three separate cleavage events, all of 
which are presumed to be catalyzed by host cell signalases residing in the lumen of the ER 
(Rumenapf et al., 1993). These events lead to the formation of two intermediate products, E012 
and E01, which are not present in the mature virion. The first step in this process is the 
translocation of an internal signal peptide, downstream of the capsid protein, across the ER 
membrane. Immediately, upon translocation of this signal peptide through the ER membrane, 
host signalase cleaves the capsid protein from the nascent E012 polyprotein (Rumenapf et al., 
1993). The transfer of E012 continues until the process is interrupted by a hydrophobic stretch of 
amino acids at the end of the E1 protein. This stretch of amino acids acts as a stop transfer signal 
and anchors the E1 protein to the membrane. Soon after, a second stretch of hydrophobic amino 
acids is encountered in the E012 polyprotein that acts as a signal sequence to begin the transfer 
of E2 through the ER membrane (Rumenapf et al., 1993). Translocation of E2 proceeds until 
interrupted by a set of stop/start transfer signals at the end of the E2 protein which acts as a 
second anchor tethering E2 to the membrane. The first intermediate precursor, E012, is formed 
upon the translocation of E2 at which point signalase rapidly cleaves E012 from the downstream 
translation product, p7. Processing of the E012 precursor continues with the cleavage of E2 
resulting in the formation of the second intermediate precursor, E01 (Rumenapf et al., 1993). For 
reasons that remain unclear the cleavage between E1 and E2 occurs in a slightly delayed manner 
compared to the prior cellular signalase cleavage events. Finally, processing of the E01 precursor 
ensues soon after E2 is released thereby forming the two final glycoproteins, E0 (Erns) and E1. 
E0 which does not appear to possess a membrane anchor presumably remains associated with the 
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budding virus through noncovalent associations with the other glycoproteins (Rumenapf et al., 
1993). 
 
The next proteins in the polyprotein to be processed are the nonstructural proteins p7 and 
NS2-3, both of which are largely composed of hydrophobic amino acids. It is believed that these 
proteins like the structural proteins are translocated across the ER membrane and processed into 
individual proteins by cleavages mediated by host signalase (Harada et al., 2000). Release of the 
remaining nonstructural proteins located downstream of NS2-3 is mediated by a serine protease 
within NS2-3 (Harada et al., 2000). This serine protease located near the 5’ end of the NS3 
protein is essential for generation of its own C-terminus and for processing of the downstream 
cleavage sites (Tautz et al., 1997). Once NS4A is cleaved from the downstream product it acts as 
a cofactor to the NS3 serine protease for the remaining cleavages of NS4B, NS5A and NS5B 
(Xu et al., 1997). Cleavage between NS2-3 and NS4A and cleavage between NS4B and NS5A 
occur very rapidly. Conversely, the cleavage between NS4A and NS4B and cleavage between 
NS5A and NS5B are both delayed in comparison. The delay at these cleavage sites is thought to 
be dependent upon the composition of the amino acids surrounding the cleavage sites (Xu et al., 
1997).     
 
RNA Replication 
 
Viral replication of the genome is able to proceed only after processing of the polyprotein 
into individual proteins is complete because the nonstructural proteins NS4B, NS5A and NS5B 
are all required to form the viral RNA replicase. It is believed that NS5B encodes for RNA 
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dependent polymerase while the hydrophilic protein products of NS4B and NS5A are 
components of viral RNA replicase. Once the replication complex is assembled from the 
nonstructural proteins, it is able to recognize and bind to the 3’UTR of the viral genomic RNA 
and RNA synthesis is initiated (Xiao et al., 2004). RNA replication occurs in smooth membrane 
vesicles that appear as vesicle packets (VPs) (Lindenbach et al., 2001). These VPS are associated 
with the perinuclear membrane (Lindenbach et al., 2001). RNA replication begins with the 
synthesis of a negative-stranded RNA which serves as a template for the replication of additional 
positive-stranded genomic RNA (Lindenbach et al., 2001). RNA synthesis is asymmetric leading 
to 10 to 100 fold excess of positive strands over negative strands (Lindenbach et al., 2001). As 
described previously, the positive stranded progeny associate with nascent viral proteins for viral 
assembly and bud into the lumen of the ER, pass through the secretory pathway and are released 
as a mature virion into the extracellular space via exocytosis.       
  
Clinical Signs of CSFV 
 
CSFV causes a disease in swine with varying degrees of severity classified into three 
general forms: acute, chronic, and late onset. The course of disease depends predominantly upon 
the virulence of the viral strain and the age of the host animal but may also be affected by breed 
and immune status of the animal. Field isolates and laboratory strains of CSFV display a wide 
range of virulence and are distinguished as highly virulent, moderately virulent, low virulence 
and/or avirulent according to the severity of symptoms produced in swine. Highly virulent strains 
typically induce an acute phenotype of disease in infected animals with a 100% mortality rate, 
while moderate and low virulent strains generally induce a prolonged chronic form of disease 
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with mortality rates reaching as high as 90% (van Oirschot, J. T., 1986). Notably, it has been 
observed that the same virus isolate with moderate virulence can cause different forms of disease 
depending on the age of the infected animal, with younger animals commonly developing a more 
severe course of infection than older animals (Moennig et al., 2003). Not only do these 
differences in the degree of severity of infection make diagnosis of CSF difficult for 
veterinarians but in addition the symptoms of CSF are quite similar to those of many common 
farm infections such as salmonellosis, pasteurellosis, erysipelas, streptococcosis, and 
leptosspirosis which is further complicated by the emergence of new diseases such as porcine 
reproductive and respiratory syndrome (PRRS), porcine dermatitis and nephropathy syndrome 
which also have similar symptoms (Done et al., 2000).     
 
The initial symptoms observed in both the acute and the chronic forms of CSF are 
depression, lethargy, anorexia, rhinitis, and conjunctivitis. Infected animals typically huddle 
together which is a visual indicator of the presence of fever (pyrexia) which is a consistent 
clinical finding in all CSF infections (Moennig et al., 2003). These initial symptoms are 
generally followed by vomiting, diarrhea, labored breathing (dyspnoea) and coughing. Invariably 
animals that contract the acute form of the disease develop central nervous system disorders 
which are evident by the development of a staggering gait, weakness of the hind quarter and 
incoordination (ataxia) which eventually progresses to the point where the animal is unable to 
stand at all. In the terminal stage of disease, the infected animal typically becomes completely 
unresponsive and may lie on the ground continually moving its limbs, an action commonly 
referred to as peddling. Death usually occurs within 5 to 9 days after infection (van Oirschot, J. 
T., 1986).   
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The chronic form of CSF infection differs from the acute form in that neurological 
symptoms are not observed and there is a longer duration of infection with death occurring 
between 3-4 weeks. Over this course of time, animals begin wasting, losing both body mass and 
strength and commonly develop cyanosis of the skin in its extremities, beginning in the ears and 
proceeding to the snout, tail and eventually to the legs and ventral region. (van Oirschot, J. T., 
1986). In addition, chronically infected animals normally become severely immunosuppressed 
and develop secondary infections such as bronchopneumonia. Occasionally animals that contract 
the chronic form of disease recover from the disease developing antibodies which protect it from 
future CSF infection.    
 
The last form of CSF infection is referred to as late onset and is a congenital disease in 
piglets. CSFV has a tropism for the reproductive tissues and is readily able to cross the placenta 
in pregnant sows. Infection during early pregnancy typically results in abortion however 
infection in later stages (50-70 days) of pregnancy can lead to the birth of persistently viremic 
piglets. At birth the piglets appear clinically normal but as they mature they exhibit poor growth 
(runting), wasting, and congenital tremors. Passive immunity provided by maternal antibodies 
generally protects piglets against mortality during the first 5 weeks of life, but not against the 
replication and shedding of virus (van Oirschot, J. T., 1986). The survival period of infected 
piglets is usually a few months.   
 
Upon post mortem examination, animals infected with CSFV generally present a 
widespread petechiae of the skin, mucous membranes, lymph nodes, laranyx, bladder, kidney, 
and ileum (van Oirschot, J. T., 1986). The most noticeably affected organs are the lymph nodes, 
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spleen, and kidneys. The lymph nodes commonly appear enlarged, edematous and hemorrhagic 
while the spleen may exhibit multifocal infarctions which appear as variably sized dark blebs 
found on periphery and apex of the spleen. Lesions of the kidney also range in size from 
petechiae to ecchymotic hemorrhages. In addition, hemorrhagic lesions may be found on the 
liver, lungs and heart. A generalized depletion of lymphoid tissues is often observed in final 
stages of disease along with the presence of a non-purulent encephalitis particularly in animals 
that had contracted the acute form of the disease (van Oirschot, J. T., 1986).   
 
Importantly, analysis of blood samples drawn from infected pigs reveals yet another 
prominent manifestation of CSF infection which is the development of a severe leukopenia (low 
white blood cell count) and marked thrombocytopenia (decreased platelet count). The 
development of these conditions are invariably the causal factor for characteristic symptoms 
observed, with the leukopenia probably being the underlying cause for the immunosuppression 
seen during chronic courses of infection while the thrombocytopenia can account for the 
generalized hemorrhagic nature of the disease. Another interesting finding upon analysis of 
clinical samples taken from infected animals is the extent of viral dissemination throughout the 
entire body with virus being able to be isolated from all of the major organs as well as blood. 
       
Pathogenesis 
 
Under natural conditions, CSFV enters the host through oral, nasal, conjunctival and 
genital mucous membranes (Leiss, 1987). The virus initially infects epithelial cells of the 
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tonsillar crypts (Van Oirschot et al., 1989). The virus then travels via the lymphatic vessels to the 
lymph nodes draining the tonsils. The virus subsequently replicates in the regional lymph nodes 
and eventually enters the blood producing a primary viremia. Monocytes are early target cells for 
the virus. Accordingly, the virus carried by these cells through the peripheral bloodstream 
allowing the virus access to its primary targets readily infecting the spleen, bone marrow, 
visceral lymph nodes, and lymphoid structures lining the small intestines (Paton et al., 2003). 
The virus multiplies in these tissues of the reticuloendothelial system reaching very high titers, 
upon which the virus is released into bloodstream again associating monocytes producing a 
secondary viremia (van Oirschot, J. T., 1986). As a result of the monocytes ability to migrate 
into virtually every organ of the body, the secondary viremia disseminates the virus to the 
remaining parenchymateous organs.   
 
The time in which virus spread is completed mainly depends on the virulence of the 
virus. Highly virulent virus can be detected in most organs by 5-6 days PI. Importantly, CSFV 
has an affinity for reticular endothelial and epithelial cells. Resultantly, widespread hemorrhages 
are observed in acute CSF due to degeneration and necrosis of endothelial cells, as well as 
thrombocytopenia and disturbances in fibrinogen synthesis (Pauly et al., 1998; Gómez-
Villamandos et al., 2001). Consequently, acute CSFV is almost always fatal.   
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Viral Transmission and Route of CSFV Infection 
 
Domestic and wild pigs are the only natural reservoir for CSFV.  The primary route of 
viral transmission is by direct contact between infected and susceptible pigs. Infected pigs 
excrete virus in oral, nasal, and lacrimal secretions as well as urine and feces (van Oirschot, J. T., 
1986).  The virus gains entry into a susceptible animal by ingestion and/or inhalation of any of 
these bodily fluids, as well as contact with the conjuctiva, genital mucous membranes or skin 
abrasions. The virus may also be spread by indirect means via contaminated transport vehicle or 
by persons such as veterinarians, farmers, and other animal personnel and their equipment. In 
addition, it has been suggested that rodents, pets, and birds could also serve as possible 
mechanical vectors. Transmission of CSFV via these vectors is believed to occur by the vector 
becoming contaminated through contact with excretions of infected pigs and thereby providing 
transportation for the virus particles to other susceptible pigs. Further sources of infection 
include the feeding of improperly sterilized swill, artificial insemination with semen from 
infected swine, and contact with wild boar that may be infected. This is especially true in Europe 
where CSFV is known to be endemic in the wild boar population (Edwards et al., 2000).    
 
Epidemiology 
 
The Office of International des Epizooties (OIE: world organization for animal health) 
classifies CSFV as a notifiable disease. All notifiable pathogens are defined by the OIE as 
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transmissible diseases that have the potential for very serious and rapid spread, irrespective of 
national borders, that are of serious socio-economic and/or public health consequence and are of 
major importance in the international trade of animals and animal products (OIE, 2016). 
Moreover, the OIE considers CSF the most economically damaging swine disease worldwide.   
 
The first recognized outbreak of CSF was documented in Ohio in 1833, however it 
remains speculative as to whether this U.S. city was indeed the initial source of the disease or 
whether Europe was the actual origination of the disease. This latter belief is supported by 
reports of an epizootic resembling CSF in France as early as 1822 as well as the reappearance of 
the epizootic in Germany in 1833 (van Oirschot, J. T., 1986). Regardless of the origin, it is 
known that by the early 1860s CSFV was widespread throughout both Europe and America 
(Edwards et al., 2000).   
 
At the present time CSF is endemic in much of Asia, Eastern Europe, Central and South 
America, the southern states of Mexico (Fig. 3). Outbreaks have also been reported in the 
Caribbean nations of Cuba, Haiti and the Dominican Republic. The situation in Africa is largely 
unknown however CSF has been reported in Africa’s island nation of Madagascar. Regions 
currently believed to be free of CSF include Australia, New Zealand, United States, Canada, and 
Western Europe.  
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CSF was eradicated from the United States in 1978 after a 16-year effort by the farm 
industry and State and Federal governments. Of particular concern to the United States as a CSF 
free nation is the presence of CSFV in both Mexico and the Caribbean. The close proximity of 
these countries to the U.S. makes them a potential reservoir of infection and imminent threat for 
the reintroduction of CSFV into the United States.  
 
Pathways for CSFV entry into US 
 
 
Intentional Release of CSFV 
 
 There are many pathways in which CSFV could be reintroduced into the United States 
which may occur either by intentional or unintentional release. Intentional release may occur by 
the weaponization of viral diseases by foreign terrorist cells targeting livestock. There is 
substantial evidence that terrorists have considered culturing biological weapons for this purpose. 
For example in early 2002, United States Navy SEALs stormed a cluster of caves in eastern 
Afghanistan, known to be an Al Qaeda storehouse expecting to find guns and explosives. 
Instead, they found hundreds of documents all planning a terrorist attack on the United States 
food supply. There were agriculture articles from American science journals which were 
translated into Arabic. A comprehensive list of the most devastating livestock pathogens such as 
FMDV, CSF and rinderpest was also found. Most alarmingly, was the discovery of training 
documents, detailing how to deploy these pathogens on farms. Furthermore, in 2002 CIA agents 
found a dossier containing information on Plum Island Animal Disease Center which studies 
  
50 
 
foreign animal diseases such as FMD, CSFV, and ASFV, in a raid of Sultan Bashiruddin 
Mahmood’s residence in Afghanistan. Mahmood was a nuclear physicist from Pakistan and a 
known associate of Osama bin Laden. Lastly, in 2008 Aafia Siddiqui, aka Lady Al Queda, a 
Pakistan neuroscientist and MIT graduate, as well as a relative of 9/11 mastermind Khalid 
Sheikh Muhammad was arrested in Afghanistan. At the time of her apprehension among the 
items found in her possession were hand-written notes about a "mass-casualty attack" and a list 
of targets which included Wall Street, Brooklyn Bridge, Statue of Liberty, Empire State Building 
and the Plum Island Animal Disease Center. 
 
 
Unintentional Release of CSFV 
 
The risk of introduction of CSFV through unintentional acts would mostly likely involve 
indirect exposure of a host through a formite, with a formite constituting nearly any object that 
could potentially become contaminated with CSFV such as contaminated meat, boots, or 
clothing just to name a few. There are several different avenues in which a contaminated formite 
might enter the U.S. For instance, today’s ease of international travel has introduced a new 
means for diseases to be disseminated globally. The current volume and speed of travel has 
increased in industrialized nations at a rate of more than 1000-fold in the last century (Wilson, 
2003). Consequently, reintroduction of CSFV could result from travelers entering the U.S. from 
endemic countries with contaminated items. To serve as an illustration of the volume of travelers 
entering the US, in 2015 there were over 75 million international travelers that visited the 
country. Many of these visitors came from regions endemically infected with CSFV, 9.7 million 
were from Asia, 1.2 million from the Middle East, 5.5 million from South America, 1.3million 
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from the Caribbean and 17 million from Mexico (http://travel.trade.gov/view/m-2014-I-
001/index.html). Of particular concern of these figures is the volume of travelers coming from 
Mexico where CSFV is believed to be endemic in the pig population of backyard farmers.  
 
Exceedingly, the immense number of annual international visitors is compounded by the 
number of immigrants present in the country. In 2014, there were 42.4 million total immigrants 
with 11.7 million originating from Mexico (migrationpolicy.org). Furthermore in 2014, it was 
estimated that there was 11.4 million illegal nationals residing in the US. The significance of 
these statistics involving foreign born residents is that it is presumable that some portion of this 
population will receive mail and packages from their family and friends remaining in their native 
countries. In addition, cultural preferences would likely result in this population receiving food 
products from countries where they were born. Resultantly, there is a possibility that some of 
these items may have potentially been exposed to CSF virus which serves as another way for 
virus to enter the US. If any of these items coming into US were infected with CSFV then an 
outbreak could occur assuming that the item came into contact with a susceptible animal.  
 
Lastly, CSFV exposure could also occur through direct contact of contagious animals 
arriving from outside the US with domestic livestock. Notably, the United States imported 5.8 
million live hog in 2011. The majority of these pigs, specifically 79 percent, were from Canada. 
While, Denmark supplied 10% of these pigs to the U.S. (http://www.agmrc.org/commodities-
products/livestock/pork/pork-international-markets-profile). Although the risk of animals 
entering the US from CSFV free countries and infecting domestic livestock is minimal, the US 
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agricultural and customs officials must remain vigilant as the status of these countries could 
change at any time.  
 
CSFV Control Strategies 
 
The OIE is responsible for setting internationally agreed standards relating to animal 
health and conditions under which a country can be considered free of CSF. Due to the highly 
infectious nature of CSF, disease free countries have introduced trade barriers that prohibit 
importation of animals or animal products from countries that do not possess CSF free status 
with the ban continuing until the OIE recertifies that country as CSF free. 
 
Currently, there are two strategies utilized in the prevention and control of CSF. Usage of 
either strategy results in international trade restrictions of pork and pork products for a set period 
of time as outlined by the OIE. The first strategy is the use of traditional LAVs which are 
commonly employed in regions where CSF is endemic, such as, Asia and South and Central 
America.  Live attenuated CSFV vaccines have been in existence since the 1960s with the most 
widely used CSFV LAV being the Chinese (C) Strain. CSFV LAVs are avirulent strains of 
CSFV, which have been attenuated by adaptive mutations obtained through serial passage in 
either rabbits, as is the case for C strain, or passage in tissue cell culture. In general, modified 
live attenuated vaccines are easy and economical to produce. These vaccines replicate in the host 
without causing significant adverse clinical effects, and provide protection against challenge with 
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virulent virus of the same serotype typically after the administration of just one infectious dose. 
The major advantage that this type of vaccine has over others is that it is able to elicit both 
cellular and humoral immune responses, which are able to protect host animal against infection 
with wild type virus. Accordingly, CSFV LAVs have been proven both safe and efficient 
providing protection in animals as early as 7 days after vaccination (Terpstra et al., 1990). 
However, the drawback of using live attenuated CSFV vaccines is that vaccinated animals 
cannot be serologically differentiated from infected animals. As a result, once emergency 
vaccination is implemented in a region, that region is thereafter prohibited from international 
trade for a period of at least 2 years before the OIE will recertify that area with a CSF free status 
(van Oirschot et al., 2003). The resulting ban on pork and pork products could potentially result 
in huge economic losses for the affected region.      
The second strategy for CSF control is a non-immunization “stamping out” policy which 
has a more expedient time frame in the return to CSF free status. Due to the economic benefits of 
rapid return to disease-free status, the European Union (EU) and some parts of Eastern Europe 
have opted for this latter approach. The “stamping out” policy has been in effect in the EU since 
1980 and was instituted in an attempt to eradicate CSF as well as to ensure free trade of pigs 
within the EU member states. 
 
Under the stringent regulations of the “stamping out” policy, all animals on a farm where 
CSF is detected must be destroyed. In addition, all pigs on farms within a 3 km radius of a CSF 
infected farm must be pre-emptively slaughtered, with this area being referred to as the 
protection zone (Stegeman et al., 2000). Finally, farms 7 km beyond the protection zone would 
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be established as a surveillance zone and a movement ban would be enforced for these farms for 
a period of at least six months while the farms in this area are periodically tested for the presence 
of CSF (Stegeman et al., 2000). If no additional CSF cases are detected over this time the OIE 
will restore a CSF free status to the region.   
 
The large scale culling in the surveillance zone is very problematic in that many healthy 
animals eventually have to be destroyed over the 6 month surveillance period due to welfare 
reasons caused by the overcrowding of farms and the lack of income to feed animals on 
overcrowded farms (Stegeman et al., 2000). An outbreak of CSFV in the Netherlands 
exemplifies the serious economic ramifications that this large scale culling can cause. The 
Netherlands outbreak was the largest and most devastating of any outbreak that has occurred in 
Europe since the implementation of the “stamping out” policy. The outbreak began in February 
of 1997 and progressed into an uncontrollable epidemic that lasted until March of 1998.  During 
this period 429 CSF-infected herds (700,000 pigs) were destroyed and 1286 herds (1,125,000 
pigs) were pre-emptively slaughtered (Stegeman et al., 2000). Incredibly, an additional 
10,567,000 pigs not infected with CSF had to be killed for welfare reasons. (Stegeman et al., 
2000). The total economic loss that the Netherlands endured during this epidemic amounted to 
2.3 billion in U.S. currency. 
 
Due to the huge economical losses caused by the non-vaccination policy as well as 
ethical objections to the mass killing of healthy animals, modifications to the current policy are 
needed.  One option that has been given high priority is the development of a safe “marker” or 
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differentiating infected from vaccinated animal (DIVA) vaccine with an accompanying 
discriminatory antibody assay that would allow for the differentiation of infected animals from 
vaccinated animals (van Oirschot et al., 2003). The use of such a DIVA vaccine would be used 
for emergency vaccination in conjunction with the “stamping out” strategy during a CSFV 
outbreak to limit the duration and extent of the outbreak, as well as, minimize the economic 
losses caused by the outbreak by reducing the number of pigs that have to be destroyed. In 
addition, an efficient marker vaccine would also be useful in the implementation of control 
programs in countries where the disease is endemic.  
 
 
Live Viral Vector Vaccine Candidates  
 
Over the last two decades various strategies have been utilized to develope experimental 
vaccines in an attempt to satisfy the need for safe and efficient DIVA vaccines. Early efforts 
were focused on the use of recombinant live attenuated viral vectors such as vaccinia virus, 
pseudorabies virus, and porcine adenovirus. These live attenuated viruses, which are harmless to 
swine, are able to act as delivery vectors expressing its inserted foreign immunogenic antigen(s). 
The benefit of using live viral vectors as vaccines is that live vaccines are excellent inducers of 
the immune system because they are able to replicate in cells eliciting both humoral and cellular 
responses against the inserted antigen thereby mediating protection in pigs against CSFV. Since 
only a portion of the CSFV genome would be included in the viral vector the resulting antibody 
pattern in an immunized animal would substantially differ from that of a CSFV infected animal.  
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The first two CSFV viral vector vaccines to be developed were recombinant vaccinia 
viruses, with one vector expressing all four CSFV structural proteins; C, E0, E1 and E2 and the 
other vector similarly expressing the structural proteins but lacking most of the E2 glycoprotein 
(Rumenapf et al., 1991). Notably, both vaccine candidates were found to mediate protection in 
pigs against lethal CSFV challenge at 42 days post immunization. Subsequently, the next 
recombinant viral vector to be utilized as a CSFV vaccine was the Pseudorabies virus vector 
containing only the E2 glycoprotein. Immunization with this experimental vaccine was also able 
to confer protection in swine at 42 days (van Zijl et al., 1991).  Similar results were later reported 
for expression of E2 in the vaccinia virus vector (Konig et al., 1995) as well as in the porcine 
adenovirus vector (Hammond et al., 2000), although, in both of these cases protective immunity 
was established a full week earlier. In addition, vaccination with vaccinia virus expressing the E0 
glycoprotein of CSFV was also found to protect swine against virulent challenge at 35 days 
(Konig et al., 1995). 
 
Although animals immunized with these live recombinant virus vectors successfully 
acquired protective immunity against CSFV, a major deterrent in using these recombinant 
vaccine candidates is the pathogenic potential of the vector viruses to non-vaccinated humans as 
well as animals. As a result, the use of live viral vector recombinant vaccines is currently 
prohibited.    
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Non-replicating Subunit Vaccine Candidate 
 
The unsuitability of viral vectors for development of recombinant vaccine candidates 
spurred the necessity for further research into safer vaccine alternatives. To this end, one 
successful option considered was a protein based non-replicating subunit vaccine. Unlike 
inactivated vaccines, non-replicating subunit vaccines contain only the immunogenic antigen 
portion of a pathogen, which is necessary to elicit a protective immune response. Identifying 
which antigens best stimulates the immune system is a complicated and time-consuming process. 
Non-replicating subunit vaccines have a general safety advantage over live attenuated vaccines 
due to the fact that they are non-living, non-replicating molecules, as such, there is absolutely no 
risk of inducing disease. Furthermore, subunit vaccines have an excellent stability profile and are 
more stable than live attenuated viruses. However, in contrast to live vaccines where the immune 
response closely resembles natural infection, the immune response to a non- replicating subunit 
vaccine is mostly humoral with little to no cellular immunity raised. Due to this, the first dose of 
a non–replicating subunit vaccine does not usually produce protective immunity, but merely 
“primes” the immune system. It is the second or third dose, referred to as a booster shot which 
stimulates a protective immune response. Another disadvantage of the non-replicating subunit 
vaccine is that antibody titers against inactivated antigen(s) diminish with time. As a result, non-
replicating subunit vaccines may require intermittent immunization with booster shots to 
increase antibody titers to maintain active immunity to the desired antigen(s). 
  
The most immunogenic of both the structural and non-structural CSFV proteins is the E2 
envelope glycoprotein. Expression of the E2 protein alone has been established to be sufficient to 
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raise high levels of neutralizing antibodies and confer protective immunity in swine against 
CSFV. For these reasons, the E2 glycoprotein protein has been the target of CSFV non-
replicating subunit vaccine research. Notably, the successful non–replicating subunit vaccine 
candidate that has been developed contains E2 produced in insect cells by a baculovirus 
expression vector (Van Rijn et al., 1996). The advantage of using this expression system is that 
insect cells are able to glycosylate proteins, as such the resulting viral E2 glycoprotein is 
glycosylated and in so doing is thought to be expressed in a more ‘natural’ way. The E2 proteins 
produced in the baculovirus system are subsequently adjuvanted with a water–oil–water 
emulsion for final non-replicating subunit vaccine preparation (Moormann et al., 2000). 
 
When the E2 non-replicating subunit vaccine was tested in vaccination/challenge 
experiments in swine, it was found that a single dose of the non-replicating subunit vaccine was 
unable to produce protection at 7 days post lethal challenge nor 10 days post challenge (Bouma 
et al., 2000 and Uttenthal et al., 2001). In fact, complete protection was not observed until 14 
days post challenge with protection lasting up to 13 months (Bouma et al., 2000). However, 
marked improvement in immunity was observed when a second dose of non-replicating E2 
subunit was administered with clinical protection developing by 7 days post challenge (Dewulf 
et al., 2001). 
 
The E2 non-replicating subunit vaccine was the first to be considered a marker vaccine as 
discrimination between vaccinated and infected pigs can be based on the detection of antibodies 
against Erns and/or NS3 proteins (Moormann et al., 2000). Importantly, after infection with 
CSFV, antibodies are raised against two structural glycoproteins, E2 and Erns, and one non-
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structural protein NS3 (Terpstra et al., 1988; Paton et al., 1991; Kwang et al., 1992). As would 
be expected, vaccination with non-replicating subunit E2 vaccine only raises antibodies against 
E2. Therefore, the detection of specific antibodies by an ELISA assay would be able to provide a 
direct measure as to the immune status of animals and establish whether animals have been 
vaccinated or CSFV infected. Resultantly, the accompanying ELISA test for the E2 non- 
replicating subunit was based on the detection of Erns glycoprotein antibodies. Detection of NS3 
protein antibodies was not utilized due to the fact that the NS3 protein is conserved among 
pestiviruses (Moorman et al., 2000). Unfortunately, there are limitations with the anti-Erns 
ELISA also. First, antibodies against Erns do not develop until 3–6 weeks after CSFV infection 
which makes early detection unfeasible (de Smit et al., 2000). Second, only one of 3 different 
anti-Erns ELISAs developed was found to be specific for CSFV, the others two were found to 
cross-reactive with Erns antibodies from other pestiviruses. Consequently, it was concluded that 
the currently available anti-Erns ELISA assays are not sensitive or specific enough to detect 
CSFV infected animals reliably within vaccinated herds. Both the lack of CSF-specificity of 
Erns-ELISA assays combined with the need for several injections makes the E2 non-replicating 
subunit marker vaccine unsuitable for use as an emergency vaccination to control a CSFV 
outbreak. 
 
 
Recombinant Pestivirus Vaccine Candidates  
 
The advent of reverse genetics technology has enabled researchers to construct and 
genetically modify cDNA infectious clones (IC) of CSFV strains in order to produce live 
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attenuated pestivirus vaccines. Live attenuated vaccines are usually the most efficient of all the 
different types of vaccines in raising a protective immune response as they have the most similar 
mode of infection as the wild type virus. Several novel reverse genetic approaches have been 
employed over the last two decades to manipulate cDNA IC in an effort to identify virulence 
factors and produce live attenuated CSF viruses. Resultantly, a wide array of virulence factors 
have been identified in the CSFV genome. Importantly, various genetic mutations in the 
proceeding CSFV genes in the context of virulent CSFV IC have all been demonstrated to be 
effective mechanisms of attenuation: Npro, Core, Erns, E1, E2, p7, and NS4B. Moreover, virus 
mutants containing most of these mutations have also been shown to provide protection in pigs 
against lethal challenge. 
 
One approach that was utilized to generate a novel live attenuated CSF virus was by 
deleting the Npro gene from the CSFV genome. It had previously been demonstrated that the 
Npro gene was dispensable for CSF viral replication by replacing the coding sequence for Npro 
in the full length infectious clone of CSFV strain of Alfort/187 with nucleotide sequence for the 
murine ubiquitin gene (Tratschin et al., 1998). Subsequently, this group later tested their Npro 
deletion viruses in pigs for attenuation and potential to provide protection from CSF (Mayer, et 
al. 2004). They observed that removal of Npro in the moderately virulent Alfort and highly 
virulent Eystrup CSFV strains was able to attenuate the virulent phenotype of both parental 
strains as well as protect against challenge with a lethal dose of highly virulent CSFV at 21 days 
post immunization.  
 
  
61 
 
Another method researchers have employed to produce live attenuated vaccines is by 
producing chimeric viruses via substituting gene(s) of one virus with the corresponding gene(s) 
from a closely related virus or strain. Accordingly, two full length chimeric viruses were 
constructed in which either the E2 or the E0 antigenic regions of BVDV II strain 5250 were 
substituted for the homologous regions in full length infectious clones of CSFV C strain vaccine 
(van Gennip et al., 2001). Importantly, the use of the BVDV antigenic regions in these constructs 
would allow for the potential serological discrimination between vaccinated and naturally 
infected animals. When evaluated in animals both of the resulting chimeric viruses continued to 
exhibit the attenuated phenotype of the parental C strain as well as conferred protection against 
lethal CSFV challenge at 28 days post infection. Unfortunately, neither of these CSFV/BVDV 
chimeric viruses were able to fully prevent transmission of the challenge CSFV virus from 
vaccinated animals to sentinels (de Smit et al., 2001). Consequently, another potential chimeric 
virus with marker capabilities was constructed, this time however using an infectious cDNA 
clone of a BVDV vaccine strain, CP7, in which the E2 gene in the BVDV IC was replaced with 
the analogous region from CSFV strain Alfort/187 (Reimann et al., 2004). As expected this 
chimeric virus was found to be attenuated in animals as the BVDV backbone harboring CSFV 
E2 is apathogenic in pigs. Importantly, this chimeric virus provided complete protection in swine 
when challenged with virulent CSFV at 28 days after infection. The implications of the 
attenuation and protective immunity generated by this chimeric virus coupled with its DIVA 
capability will be discussed further in the next section.  
While these putative marker vaccine candidates were being developed, another research 
group was using the same chimera technology to detect CSFV virulence factors and host range 
determinants in an effort to use the knowledge gained in these areas to rationally design putative 
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attenuated marker vaccines. To accomplish this objective, a series of chimeric viruses were 
initially constructed where regions of CSFV genome were systematically replaced with the 
homologous regions of attenuated vaccine CSFV strain CS in the genetic backbone of highly 
virulent CSFV Brescia strain (Risatti, et al., 2005a). The resulting chimeric viruses were 
evaluated in swine for viral virulence. Interestingly, only chimeras harboring the CS E2 gene 
were attenuated suggesting that a significant virulence determinant absent in CS E2 was 
responsible for attenuation. As such, a separate chimeric virus was produced in which only the 
E2 genomic region of the pathogenic Brescia strain was replaced with analogous region from the 
CS vaccine strain (Risatti et al., 2005a). When this chimeric virus was tested in swine, a 
significant in vivo attenuation was observed. Importantly, animals immunized with this virus 
were also found to be protected from lethal challenge as early as 3 days post vaccination. Further 
research identified the exact amino acid residues in CS E2 producing the attenuation of Brescia 
virus (Risatti et al. 2006). In addition, it was found that attenuation of Brescia coincided with the 
elimination of reactivity associated with a specific epitope residing in CSFV E2 that is 
recognized by monoclonal antibody (mAb) WH303. Notably, mAb WH303 is routinely used for 
CSF diagnostics due to its inability to react with the E2 region from related pestiviruses, BVDV 
and BDV (Lin et al., 2000). The amino acids responsible for binding mAb WH303 were 
determined by progressive mutations introduced into an area of E2 between residues 829 and 
837. The corresponding amino acid sequence, TAVSPTTLR, of CSFV Brescia was 
progressively replaced with the corresponding amino acid residues of BVDV, TSFNMDTLR, 
producing 4 chimeric viruses. The resulting viruses were designated T1v – T4v and were 
evaluated in animals. T1v – T3v induced lethal disease, while T4v, containing BVDV residues 
TSFNMD, induced mild transient disease in pigs and culminated with the elimination of 
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reactivity with mAb WH303. Remarkably, animals infected with T4v were protected when 
challenged with virulent Brescia virus at 3 and 21 days post-vaccination implicating the 
homologous CSFV residues, TAVSPT, as a significant determinant of CSFV virulence.  
 
In addition, researchers have successfully generated several live attenuated viruses by 
targeting known protein functions associated with specific CSFV genes by mutating various 
amino acids in the virulent genomic sequences of different CSFV strains. As a result, a number 
of virulence factors in CSFV have been identified. For instance, in a study designed to abrogate 
the RNase activity of Erns in an effort to determine the function of this enzyme on CSFV 
pathogenesis and virulence, researchers constructed multiple mutants substituting either lysine or 
leucine at two specific residues, H297 and H346, in the E0 gene of CSFV strain Alfort/187 
(Meyers et al. 1999). Notably, these targeted residues were theorized to be involved in catalytic 
reaction of RNase activity (Meyers et al., 1999). Animal experiments with the resulting virus 
variants showed that all of the mutations inactivating the RNase had an attenuating effect in 
swine. Although the degree of attenuation varied among the variant viruses, all of the infected 
animals effectively developed protective immunity, as demonstrated by the challenge with highly 
pathogenic CSFV Eystrup 10 weeks after the immunization implicating RNase activity in Erns 
as one of many determinants of virulence in CSFV that will be discussed throughout this chapter.  
 
Similarly, glycosylation sites in all three CSFV glycoproteins have been found to 
influence viral virulence as mutations of several individual N-linked glycosylated sites residing 
in Erns, E1 and E2 of highly virulent Brescia resulted in attenuation of the parental virus in pigs 
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(Fernandez-Sainz, et al. 2008 ; Fernandez-Sainz et al., 2009; Risatti et al., 2007). To briefly sum 
up the findings from these studies, mutation of one glycosylation site, N269A, in Erns, 
substitutions in three glycosylation sites in E1, N594A and N500A/N314A and alanine 
exchanges in two N-linked glycosylation sites residing in E2, N116A and N185A, produced 
attenuated phenotypes in vivo. Notably, each of the corresponding nonglycosylated mutant 
viruses were also able to elicit protection against lethal CSFV challenge as earlier as 3 days post-
inoculation. 
 
CSFV intermolecular disulfide bonds have also been determined to be factors of 
virulence in the homodimerization and heterodimerization of glycoproteins Erns and E1, 
respectively (Tews et al., 2009; Fernandez-Sainz et al., 2011). Importantly, the formation of 
disulfide bridges is mediated between cysteine residues. It has been shown that eight of the nine 
conserved cysteines in glycoprotein Erns form intramolecular disulfide bonds while a ninth 
cysteine residue found near the carboxyl end at residue 171 of the Erns protein is responsible for 
formation of Erns homodimers (Langedijk et al., 2002). Deletion or replacement of amino acid 
C171 to either Phe or Ser results in loss of dimerization as revealed by immunoprecipitation and 
western blot (Tews et al. 2009). Furthermore, a mutant virus containing substitution, C171S, in 
infectious cDNA clone of CSFV Alfort/Tübingen was markedly attenuated in pigs. Likewise, the 
E1 envelope protein contains six cysteine residues. The role of these E1 cysteine residues in 
formation of E1-E2 heterodimers and resulting effect on CSFV replication and virulence in 
swine was determined by generating a panel of single and double recombinant mutant viruses 
substituting cysteine residues with serine in E1 glycoprotein (Fernandez-Sainz et al., 2011). Only 
one recombinant virus in the panel of mutants resulted in an attenuated phenotype in pigs with 
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that virus containing two amino acid substitutions, C24S and C94S, in E1 glycoprotein 
suggesting that these residues are critical in the proper formation of E1-E2 heterodimers and 
virulence in swine. In addition, the attenuated mutant displayed a partial disruption of E1-E2 
heterodimer formation in infected cells as well as decreased growth rate in primary swine 
macrophages. Despite its diminished growth in vitro, this mutant virus provided protection in 
swine challenged with virulent CSFV at 3 and 28 days post infection. These findings strongly 
suggest that Erns and E1-E2 dimerization are virulence determinants of CSFV and prevention of 
Erns and E1-E2 dimerization leads to attenuation of CSFV.  
 
Structural prediction analysis software has also been effectively utilized to identify 
specific domains in p7 and NS4B involved in viral virulence. Previously, the p7 protein of 
hepatitis C, HCV, has been characterized as a member of viroporin family and found to be 
crucial for the production and release of infectious HCV particles from infected cells (Griffin et 
al., 2003). Viroporins by definition are small, highly hydrophobic, virus-encoded proteins that 
able to oligomerize to form hydrophilic ion channels in host cell membranes (Scott, et al., 2015). 
Due to structural similarities between the p7 protein of HCV and CSFV it has been suggested 
that CSFV p7 may similarly function as a viroporin involved in pore formation and release of 
infectious particles across cell membranes. To test this premise, a series of p7 recombinant 
mutant viruses each containing either three to six consecutive alanine substitutions spanning the 
entire protein was created using a scanning mutagenesis approach (Gladue et al., 2012). These 
recombinant viruses resulted in the identification of regions within CSFV p7 that are critical for 
virus production in vitro and resultantly demonstrated that the C-terminal transmembrane helix 
of p7 does in deed possess pore-forming activity. While, some of the virus constructs where 
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unable to produce infectious progeny, other constructs produced viruses that were either partially 
or completely attenuated in animals, indicating that CSFV p7 plays a significant role in viral 
virulence.  
 
Similarly, a Toll/interleukin-1 receptor (TIR)-like domain has been determined to reside 
in NS4B protein. This domain is unique to both CSFV and BVDV and is not found in other 
pestiviruses or flaviviruses. TIR domains are known to participate in signal transduction of Toll-
like receptors (TLRs). In general, TLRs are a large family of proteins that play a crucial role in 
recognition of various microbial components, activate the innate immune system, and induce of 
cytokines needed for the adaptive immune response (Akira et al., 2004). Importantly, the TIR 
domain contains 3 conserved motifs, termed box 1, 2 and 3. It has been shown that alanine 
substitutions in box 1 and 2 of a TIR domain in a human interleukin receptor can inhibit its 
signaling, while signaling was unaffected by alanine substitutions in box3 of the TIR domain. 
Based on these observations, Fernandez-Sainz et al. (2010) selectively generated mutations in 
boxes 1 and 2 in order to elucidate the function of this TIR domain in CSFV NS4B. Mutations, 
V2566A, G2567A, and I2568A in the box 2 domain produced a virus (NS4B VGIv) with an 
attenuated phenotype in pigs. Infection with recombinant NS4B VGI was characterized by 
localized replication in the tonsils with limited viral dissemination during infection. Furthermore, 
animals inoculated with NS4B VGIv were completely protected against lethal CSFV challenge 
as early as 3 days post infection. Analysis of cellular gene expression of infected primary swine 
macrophage revealed cultures infected with NS4B VGIv showed increased activation of several 
genes, compared to those in cultures infected with the parental virus. Notably, most of the genes 
exhibiting increased transcriptional activation with NS4B VGIv infection are similarly induced 
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by activated TLR-7 (Lee et al., 2003). Furthermore, TLR-7 functional involvement was 
indirectly confirmed by the observation that transfection of macrophages with wild-type NS4B 
reduces the responsiveness of TLR-7 to a well characterized activator, imiquimod R837 (I-R837) 
while transfection with NS4B gene harboring box 2 domain mutations was less efficient at 
mediating this reduction. Fernandez-Sainz et al. (2010) speculated that these findings suggest 
that NS4B of wild-type CSFV blocks TLR-7 transcriptional activation during infection in 
animals.  
 
In addition, using proteomic computational analysis, a putative fusion protein (FP) was 
suggested to reside between amino acid residues 818CPIGWTGVIEC828 of CSFV E2 (Garry and 
Dash, 2003). To discover the role of this putative FP on in vitro and in vivo replication of CSFV 
as well as in the production of disease in swine, a series of recombinant CSF viruses containing 
amino acid substitutions in the FP area were designed using the cDNA infectious clone of the 
virulent CSFV Brescia strain (BICv) (Fernandez-Sainz et al., 2014). Resultantly, none of the 
mutations resulted in an attenuated phenotype in animals but double (C818S/C828S) and triple 
(P819S/I820S/W822S) residue substitutions were found to completely abrogate virus replication. 
Subsequently, synthetic peptides representing native, double and triple mutant FP variants were 
generated and assessed for their ability to penetrate into lipid bilayers. While no significant 
alterations to the secondary structure were observed among the three synthetic FP, the double 
and triple mutations did appear to affect the degree in which the peptide was able to insert itself 
into model membranes. These findings reveal that amino acid sequence, 818CPIGWTGVIEC828, 
is critical for membrane fusion and virus replication. 
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More recently, yeast two hybrid system has been employed to identify viral/host protein-
protein interactions for CSFV as another tool to investigate viral virulence. Yeast two hybrid 
screening revealed several swine proteins which specifically bind to CSFV Core protein; Sumo-
1, UCB-9, IQGAP-1 and OS9. Of these host proteins, SUMO-1 and UBC9 are both involved in 
the cellular SUMOylation pathway (Niedenthal, 2007). Importantly, several viruses are able to 
effectively evade the host immune response by inducing modifications to the host SUMOylation 
pathway (Sadanari et al., 2005; Huh et al., 2008; Shirai et al., 2008; Chiu et al., 2007; Yueh et 
al., 2006; Palacios et al., 2005). As such specific residues within CSFV Core protein mediating 
the interaction with SUMO-1 and UBC9 proteins were identified (Gladue et al., 2010). Amino 
acid substitutions of these residues to alanines in the viral genome resulted in recombinant 
viruses with attenuated phenotypes indicating that CSFV virulence is associated with the ability 
of Core protein to interact with host proteins in the cellular SUMOylation pathway. 
Subsequently, interaction of the cellular protein, IQGAP1 with CSFV core was examined to 
determine its significance (Gladue et al., 2011). IQGAP1 protein has been shown to play an 
important role as a regulator of the actin cytoskeleton (Fukata et al., 2002; Watanabe et al., 
2004). Notably, it has been reported that interaction of IQGAP1 with the Moloney murine 
leukemia virus (MMLV) matrix (M) protein plays an important role in the intracellular 
trafficking of MMLV, which is essential for virus replication (Leung et al., 2006). In this same 
study the critical residues within MMLV M protein that interact with IQGAP1 were mapped by 
mutagenesis experiments. Based upon these findings, four regions within CSFV Core, designated 
I – IV, were identified that potentially bind IQGAP1. (Gladue et al., 2011). Amino acid residues 
in these putative binding sites were replaced with alanines. Resulting mutations in areas I and III 
completely disrupted the Core–IQGAP1 protein–protein interaction while substitutions in areas 
  
69 
 
II and IV only partially affected protein binding. CSFV mutants harboring substitutions in these 
four areas were assessed in animals to determine importance of the Core–IQGAP1 protein 
interaction on virulence. Interestingly, substitutions in regions I and III of the Core, resulted in 
complete attenuation in swine. These results suggest that the ability of CSFV Core protein to 
bind cellular IQGAP1 protein during infection plays a critical role in virus virulence within the 
swine host. Lastly, osteosarcoma amplified 9 protein (OS9) a protein involved in the 
endoplasmic reticulum-associated degradation (ERAD) pathway, was identified by YTH system 
to interact with CSFV Core (Gladue et al., 2014a). OS9 has been shown to be involved in the 
degradation of misfolded glycoproteins (Huttner et al., 2012), which could be significant 
considering CSFV Erns, E1 and E2 are heavily glycosylated structural proteins. Therefore, it is 
possible that binding of OS9 by the Core protein could prevent degradation of viral 
glycoproteins. Utilizing alanine scanning mutagenesis, the OS9 binding site within the CSFV 
Core protein was mapped to the C-terminus of unprocessed Core, before its cleavage by signal 
peptide peptidase. A recombinant CSFV mutant lacking OS9 binding site in Core protein 
presented a significant decrease in its ability to replicate in primary swine macrophage cell 
cultures, the natural cell target of CSFV. However, no differences were observed in mutant 
infected swine and animals infected with parental CSFV. As a result, it was concluded that the 
OS9-Core interaction affects the efficiency of virus replication by an unclear mechanism. 
Overall, the YTH system and resulting identification of Core host proteins partners has provided 
interesting insight into the pathogenesis of CSFV by elucidating what appears to be multiple 
roles for Core in the CSFV replication cycle. 
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Lastly, a transposon linker insertion mutagenesis approach was also utilized to identify 
virulence and host range determinants of CSFV. Hence, Risatti et al. (2005b) used transposon 
linker insertion mutagenesis (TLIM) to mutate an infectious clone of the pathogenic strain 
Brescia, BIC (Risatti et al., 2005b). Significantly, one of the resulting viral mutants with an in-
frame transposon linker insertion of 57 nucleotides in the carboxyl terminal domain of E1, at 
genomic position 2429, four residues upstream of the cleavage site between E1 and E2, was 
found to attenuate the Brescia virus thus identifying a virulence determinant associated with the 
E1 glycoprotein of CSFV. Infected animals exhibited decreased replication in tonsils, limited 
generalization of infection, and significant reduction of viral shedding. Notably, these animals 
survived lethal challenge of CSFV presenting no signs of clinical disease. These results indicate 
that this mutation in E1 glycoprotein attenuates the virus and consequently has been identified as 
a virulent factor of CSFV. 
 
Importantly, the identification of these genetic determinants of virulence have been 
instrumental for providing researchers with a rational approach for designing an improved 
marker CSF LAV. Conceivably, the genetic introduction of mutations containing one or several 
of these determinants into a CSFV cDNA infectious clone may lead to the creation of a safer and 
more efficient vaccine with increased utility and ultimately producing a novel vaccine with 
DIVA capabilities which will be discussed in more detail in the next section.   
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CP7_E2alf Marker Vaccine Candidate 
 
In 2009 an international collaboration composed of 17 multidisciplinary scientific 
partners from 11 different countries was established to complete a project called 
CSFV_GODIVA. The project was initiated because despite extensive efforts made to eradicate 
CSFV from the European Union (EU), CSFV continues to be a problem in several countries 
where the wild boar population are endemically infected with CSFV. These wild boar serve as a 
continual threat for introduction of CSFV into the domestic pig population. Due to the high costs 
of the large scale culling and the ethical objections to vast killing of healthy pigs associated with 
the current “stamping out” control policy and restrictions on prophylactic vaccination usage, 
there has been an ongoing debate over the possible use of emergency vaccination upon 
development of an approved CSFV DIVA vaccine within the EU. Unfortunately, the C strain 
vaccine which has historically and effectively been used for vaccination against CSFV does not 
possess the ability for serologically differentiating vaccinated animals from animals infected 
with CSFV field isolates. As a result, in order to ease trade restrictions for domestic pigs, potent 
marker vaccines are required that allow for reliable differentiation of CSFV infected from 
vaccinated animals. Although the DIVA E2 subunit vaccines have the potential for 
differentiation they lack some critical properties that live vaccines offer such as fast and sound 
protection after single application, prevention of trans-placental infection, and suitability for use 
via the oral application route. Moreover, the CSF E2 subunit vaccines are no longer 
commercially available due to the overall lack of specificity exhibited by the current 
discriminatory ELISA assays based on detection of Erns in the marketplace. Resultantly, the 
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CSFV_GODIVA project was therefore dedicated to improving the tools and strategies for the 
prevention and control of CSF.  
 
The principal objective of CSFV_GODIVA project was to develop a marketable live CSF 
marker vaccine candidate that could be intramuscularly administered to domestic pigs and orally 
administered via baits to wild boar. Although several experimental CSFV marker vaccines have 
been developed, none of these candidates at the time of the project’s conception were close to 
market authorization. It was therefore of utmost importance to select candidates to bring them to 
the level of licensing.  To this end, two promising chimeric pestivirus marker vaccine candidates, 
“flc11” (van Gennip et al., 2000) and “CP7_E2alf” (Reimann et al., 2004) were selected for 
further development. The flc11 chimeric mutant virus contained the genetic backbone of CSFV 
C strain in which the CSFV ERNS was exchanged for the homologous gene of BVDV II 5250 
while the CP7_E2alf recombinant virus contained the E2 sequence of CSFV strain Alfort 187 in 
the genetic background of BVDV strain CP7. Comparative animal trials were conducted by two 
independent and separate research groups for both vaccine candidates via intramuscular and oral 
administration. The performance of the marker vaccine candidates in vaccination/challenge 
experiments were compared to efficacy of the C-strain vaccine in order to choose a final 
candidate for proceeding with registration and licensing. In addition, immunity induction to 
vaccination was assessed by intranasal challenge with highly virulent CSFV strain Koslov at 7, 
14, and 21 days post vaccination. Both vaccines proved to be safe and yielded full protection 
upon challenge 21 days post vaccination. In addition, the CP7_E2alf mutant virus was also able 
to mediate protection against lethal challenge at 14 days post vaccination. After reviewing the 
data collected from these independent comparison trials, it was determined that future efforts 
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would be directed towards improving mutant virus CP7_E2alf for acquiring licensure as a CSFV 
live marker vaccine. 
 
A Master Seed stock was produced for the CP7_E2alf vaccine candidate and evaluated in 
animals. The main objective of this study was to assure the scaled up Master Seed stock of 
CP7_E2alf vaccine retained its efficacy under laboratory and field conditions in naïve piglets 
(http://cordis.europa.eu/result/rcn/53691_en.html). CP7_E2alf vaccine candidate was tested in 6-
10 week old piglets by intramuscular and oral administration. All piglets were challenged with 
virulent CSFV Koslov strain 4 weeks after vaccination. Resultantly, the vaccine proved to be 
effective against lethal CSFV challenge with the exception of one orally vaccinated piglet (out of 
15) which succumbed at 7 days post-challenge. In addition, immunization and challenge trials 
showed that the antibody titers after a single intramuscular or oral vaccination were stable for a 
minimum of 6 month and fully protected from lethal CSFV challenge. Subsequently, the impact 
of maternal immunity and effect on pregnant animals was analyzed. CP7_E2alf vaccine provided 
protection against severe clinical signs and mortality in piglets with maternally derived 
antibodies (MDA) against CSF C-strain. The DIVA potential of the vaccine in these piglets was 
proven as well. However, when the experiment was repeated in piglets with MDA against CSF 
induced by CP7_E2alf vaccination in pregnant sows, orally vaccinated piglets displayed only 
partial protection. Lastly, the vaccine showed a reduction but not full prevention of 
transplacental infection. In all, the vaccine was deemed to be safe and efficacious after 
immunization of piglets and pregnant sows. 
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Notably, most of the CSF outbreaks in domestic pigs in Europe are a result of outbreaks 
in the wild boar population. For this reason, CP7_E2alf marker vaccine was tested for efficacy of 
oral vaccination in wild boar and shown to induce similar protection as the classical C-strain 
vaccine in wild boar (Koenig, 2007). The vaccine was subsequently evaluated as a bait vaccine 
for wild boar in field trials in France and Italy. Virus neutralizing antibodies were detected in 
36.3% of the wild boars tested after a single vaccination campaign. However, due to the absence 
of a positive marker in the CP7_E2alf vaccine formulated baits it was not possible to confirm 
whether analyzed animals had actually consumed the baits. The main obstacle for bait uptake 
appears to be the availability of other food sources. As such, several new baiting systems were 
tested, unfortunately, these systems failed to enhance the uptake by young boars. Overall, it was 
determined for effective control and eradication of CSF in the wild boar population to occur; 
three vaccination campaigns should be performed per year for a minimum of 6 consecutive years 
to effectively eradicate the disease.  
 
Importantly, DIVA vaccines are only useful when accompanying DIVA diagnostics are 
available. As such, two commercially available Erns-based discriminatory ELISAs were 
evaluated for use with CP7_E2alf vaccine. Both tests were found to be only suitable for 
application on a herd basis. In particular, the specificity of the tests was too low to reliably 
discriminate vaccinated from CSFV infected pigs. In successive studies it was further shown that 
one of the tests is not specific for CSFV, as pigs infected with other members of the pestivirus 
family also reacted positively for Erns antibodies (Schroeder et al., 2012). The PrioCHECK 
CSFV Erns ELISA proved to give the best results against the CP7_E2alf vaccine candidate. 
Despite several attempts to optimize the assay’s performance, the test still exhibited deficiencies 
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in both, sensitivity and specificity, as well as problems with robustness and reproducibility 
(Blome et al., 2012). Resultantly, improved DIVA ELISAs have been developed under CSFV 
GO_DIVA project to be used in conjunction with CP7_E2alf vaccine candidate and are pending 
validation for manufacturing at the present time.  
 
Lastly, the usefulness of an emergency vaccine largely depends on how early the vaccine 
is able to provide protection against lethal infection. To this end, several protection studies have 
been performed for Cp7_E2alf vaccine candidate. As stated previously, during the process of 
selecting a CSFV vaccine candidate CP7_E2alf mutant virus was shown to protect animals as 
early as 14 days post challenge.  In addition, CP7_E2alf vaccine stock was evaluated in naïve 
piglets in a set of vaccination/challenge experiments in which groups of animals were 
intramuscularly vaccinated with CP7_E2alf vaccine and challenged 1 week later with highly 
virulent CSFV strain Koslov or vaccinated oronasally and challenged 2 weeks after vaccination 
(Leifer, I. et al. 2009). In both cases all vaccinated animals were completely protected against 
lethal CSFV challenge. A subsequent study was performed in which CP7_E2alf vaccine 
candidate and C strain were compared for efficacy to induce protection at even earlier times post 
vaccination. Animals were intranasally vaccinated and challenged with moderately virulent 
CSFV isolate Bas-Rhin at 2 days post vaccination (Renson et al 2013). After challenge, both 
groups were only able to provide partial clinical protection against CSFV. Thus, to date the 
earliest CP7_E2alf recombinant virus is proven to be able provide complete protection against 
CSFV is 7 days post vaccination.   
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The CP7_E2alf vaccine has recently been submitted for registration and its usage will 
improve future efforts to eradicate CSF in Europe. From simulation models of EU CSF spread, it 
has been concluded that emergency vaccination with this type of DIVA vaccine is a better 
control alternative than the present policy of stamping out and will prevent mass-destruction of 
non-infected livestock when accompanied with rapid testing procedures. This method will allow 
for the demonstration of absence of virus and ultimately expedite the time frame in order to 
regain CSFV free status.  
 
Flag T4v Marker Vaccine Candidate 
 
Our research group has also successfully developed a putative CSFV marker vaccine 
called Flag T4v; however, our vaccine differs from the European CP7_E2alf vaccine candidate 
as it contains a negative and positive antigenic marker (Fig. 6) (Holinka et al. 2009). This marker 
vaccine was produced by introducing two separate genetic determinants of viral virulence into 
the backbone of CSFV strain Brescia (Risatti et al., 2005b; Risatti et al., 2006). The first of these 
determinants was previously discovered by the random insertion of a transposon into the 
carboxyl end of glycoprotein E1 at base pair 2422 in the virulent CSFV Brescia backbone. 
Disruption of this region produced an attenuated phenotype in animals. We further modified the 
19mer transposon by altering the insertion sequence to include the nucleotide sequence of a well 
characterized synthetic epitope, Flag® (Sigma, St. Louis, MO) (Fig. 4). This inserted Flag 
epitope was designed to serve as a positive antigenic marker. In addition, Flag T4v also contains 
a negative antigenic marker resulting from modifications in a region of E2 glycoprotein known 
to interact with monoclonal antibody WH303 (mAbWH303) which has a specificity for CSFV 
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(Edwards et al., 1991). This highly conserved CSFV epitope was mutated to contain the 
corresponding homologous amino acid sequence of BVDV (Risatti et al., 2006). Shown in Fig. 5 
are the progressive mutations which were introduced in this region to determine the minimum 
alterations required to eliminate total reactivity with mAbWH303. By plaque assay loss of 
reactivity with mAbWH303 began to be seen between T3v and T4v. As a result of these 
observations, all further studies were based on mutations required to produce T4v.  
 
Importantly, a critical aspect to be addressed in development of novel live attenuated 
vaccines for use during a CSFV outbreak in areas free of disease is the ability to produce early 
protection. Consequently, most CSFV experimental vaccines developed to date have only been 
tested for their potency against challenge between 2 to 4 weeks post-vaccination. As a result, 
data is lacking about how efficacious these vaccines are in shorter vaccination-to-exposure trials 
which would deem them suitable for emergency vaccination. Remarkably, Flag T4v is able to 
induce a solid protection status in swine from day 3 post-inoculation when administered 
intranasally, or from day 2 post-inoculation when delivered intramuscularly (Holinka et al., 
2009).  
 
A final essential feature required for a live attenuated CSFV vaccine is the ability to 
distinguish naturally infected animals from vaccinated animals which necessitates the need for an 
accompanying diagnostic test. We were able to successfully develop two proof of concept tests 
to complement Flag T4v. The first set of tests were designed to measure the serologic response 
against either the Flag epitope or the mAbWH303 epitope which would allow for discrimination 
between animals immunized with Flag T4v or animals infected with CSFV by enzyme-linked 
  
78 
 
immunosorbent assays (ELISA). The second set of tests were developed to genetically 
differentiate Flag T4v from wild-type CSFV based on the annealing of probes to both Flag and 
T4 sequences in real-time reverse transcriptase polymerase chain reaction (rtRT-PCR) assays 
from RNA extracted from infected and vaccinated animal samples (Holinka et al., 2009). 
Notably, the latter could prove to be instrumental in monitoring the epidemiological situation 
during an epidemic as it would provide the ability to test for virus presence even before an 
efficient antibody response is mounted in CSFV vaccinated or infected animals.  
 
Thesis Research  
 
In light of the DIVA capabilities demonstrated by Flag T4v as well as its remarkable 
ability to provide complete protection against lethal challenge as early as 3 days post infection, 
we partnered with a leading animal vaccine manufacturer that had expressed interest in licensing 
and producing the Flag T4v marker vaccine for commercial use in the field. In collaboration with 
this company a master seed stock of our virus was produced by the manufacturer at their facility 
and sent to us for further evaluation. Notably, the master seed stock of Flag T4v was generated 
by propagation of the virus in a proprietary cell line. This was done in order to yield a single 
uniform batch of Flag T4v for downstream large scale vaccine production. Consequently, the 
process to obtain a license for the commercial use of a vaccine is one that is long and rigorous. 
One of the initial steps in this procedure is the determination of the safety profile for the master 
seed stock. This entails the testing of the master seed stock in the host animal to determine the 
minimum protective dose of the vaccine as well as an overdose study to ascertain whether there 
are any deleterious side effects associated with the vaccine. In addition, it is required for master 
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seed stocks derived from live attenuated viruses to demonstrate that they are genetically stable. 
This requirement is due to concerns that the master seed stock virus may be transmitted from the 
host to contact animals potentially causing disease if the viral stock was to retain any residual 
virulence or if reversion to virulence was to occur. Resultantly, all live vaccines are tested for 
virulence by virus passage studies, in the host animal, using the most sensitive and usually the 
youngest animals for which the product is intended.  
 
During the vaccine evaluation process, the master seed stock of Flag T4v was shown to 
be immunologically potent as well as non-toxic, however, Flag T4v did not sufficiently display 
genetic stability in reversion to virulence testing when passaged in pigs. Sequence analysis of the 
revertant virus obtained from the spleen of infected animals showed specific deletions and 
mutations mainly in the areas encoding for glycoproteins, E1 and E2, when compared with the 
sequence of the parental Flag T4v. Interestingly, both genetic modifications reside in areas which 
were previously shown to individually provide the attenuation observed in Flag T4v. Complete 
deletion of the 18mer insertion at the carboxyl end of the E1 glycoprotein as well as a single 
amino acid substitution of  N850S in the E2 glycoprotein were discovered in the revertant virus, 
Flag T4SPv. Surprisingly, the virulent phenotype is only observed when the two mutations occur 
simultaneously; viruses harboring either mutation exclusively were completely attenuated in 
pigs. The majority of the non-synonymous mutations observed in Flag T4SPv were restricted 
mainly to the Flag and T4 regions of the genome. Only two additional non-synonymous 
mutations, A109V in Npro and A993E in E2, were detected in this virus. 
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It was hypothesized the genetic stability of Flag T4v could be optimized while still 
retaining its attenuated phenotype and double antigenic marker elements by altering the codon 
usage in the Flag and T4 regions. A new viral construct was produced by taking advantage of the 
redundancy of the genetic code and selecting nucleotide sequences for synonymous codons in 
these areas that resulted in a construct with a nucleotide sequence differing as much as possible 
from the initial genomic sequence while maintaining the original amino acid sequence. In 
addition, a N850G substitution within the T4 region was also introduced due to the observation 
that reversion of N850S contributes to viral virulence. The resulting virus was called Flag T4Gv 
and was shown to be stably attenuated when assessed in a reversion to virulence experiment 
using highly susceptible 5-6 week old piglets. Interestingly, FlagT4Gv could not be detected in 
tonsil extracts obtained from any of the five successive passage groups. As a result, it was not 
feasible to ascertain whether the new Flag T4Gv underwent any genomic adaptations as it was 
passaged in pigs. Consequently, it is not clear how the introduced mutations affecting the codon 
usage in the Flag and T4 regions increased the genetic stability of Flag T4Gv. Lastly, Flag T4Gv 
exhibited a similar efficacy to Flag T4v in terms of protecting swine at early and late times post 
vaccination. These results suggest that Flag T4Gv may be the best suited vaccine candidate 
developed thus far for emergency usage during a CSFV outbreak.   
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MATERIALS AND METHODS 
 
Viruses and cells.  
 
The porcine kidney cell line SK6 (Terpstra et al., 1990), free of Bovine Viral Diarrhea 
Virus (BVDV) was used throughout this study.  SK6 cells were cultured in Dulbecco's minimal 
essential medium (DMEM) (Gibco, Grand Island, NY) supplemented with 10% gamma-
irradiated fetal bovine serum (FBS) (HyClone Laboratories, Logan, UT) and 1% 1 X Antibiotic-
Antimycotic (Gibco). Virulent CSFV Brescia strain (obtained from the Animal and Plant Health 
Inspection Service, Plum Island Animal Disease Center) was propagated in SK6 cells.  
 
Minimum Protective Dosage of Flag T4v Master Seed Stock 
 
A master seed stock of Flag T4v was produced by an outside animal vaccine 
manufacturer and returned to our lab at Plum Island Animal Disease Center for assessment. For 
determination of minimal protective dose, forty (n=40) 5-6 week old commercial female pigs 
were used. All animals were acclimated for a period of seven days before being used. Pigs were 
randomly assigned into four groups of 10 pigs and inoculated intramuscularly in the neck with 
105, 104, or 103 TCID50 (50% tissue culture infective dose) of the master seed stock of Flag T4v. 
The remaining group of 10 pigs was mock vaccinated receiving sterile DMEM media. All 
animals were intranasally challenged 21 days post vaccination with a lethal dose of 105 TCID50 
of highly virulent CSFV Brescia strain, (BICv). Clinical symptoms were scored according to a 
semiquantitative system based on 10 CSF-relevant criteria described by Mittelhozer et al. (2000). 
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These 10 CSF parameters are liveliness, body tension, body shape, breathing, walking, skin, 
conjunctiva, appetite, defecation, and leftover food. Each parameter was judged on a scale of 0 to 
3. Accordingly, normal behavior was scored as 0, a slightly altered phenotype was scored as 1, 
distinct clinical signs were scored as 2, and severe CSF symptoms were scored as a 3. Scores 
from all 10 criteria were then added up and the total score for each animal was plotted daily. In 
addition, body temperatures were also recorded daily, with fever defined as values above 104° F.  
 
Blood and serum samples were collected from all animals at 0, 7, 14, and 21 days post 
vaccination. In addition, blood, serum and nasal swabs were collected from all animals 4, 7, 11, 
15 and 21 days post challenge. Lastly, palantine tonsils were removed at 21 days post challenge 
or at time of death for detection of challenge virus by immunofluorescent histochemistry with 
mAb 303 (Edwards et al., 1991) and mAb anti-Flag (Sigma-Aldrich, St. Louis, MO). 
 
This animal study as well as all the following studies described here were carried out in 
accordance with regulations as outlined in the USDA 9CFR-121 and animal welfare act under 
methodologies described in protocol 171-14-R approved and periodically revised by PIADC 
IACUC. 
 
 
Toxicity and Safety Assessment of Flag T4v Master Seed Stock 
 
The intrinsic safety and toxicity of the master seed stock of Flag T4v was evaluated in 
seven (n=7) 5-6 week old commercial female pigs. Five pigs were randomly selected to be 
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infected intramuscularly with 107.4 TCID50 of the Flag T4v master seed stock. Pigs were 
observed over a 21 day period. Rectal temperature as well general clinical symptoms were 
recorded daily. Presence of local lesions were analyzed by measuring the dimension of the area 
surrounding the injection site with a caliper daily and comparing with measurements of local 
reaction of injection site obtained from a group of 2 mock vaccinated animals. 
 
Reversion to Virulence Assessment of Flag T4v Master Seed Stock 
 
Reversion to virulence test was performed using twenty (n=20) 5-6 week old commercial 
female pigs. All animals were randomly assigned into 5 groups and acclimated for a period of 
seven days before being used. Reversion to virulence protocol was performed in accordance with 
OIE regulations with minor modifications. A group of five animals was intramuscularly 
inoculated with 106 TCID50 of master seed stock of Flag T4v. Animals were observed for 7 days 
and clinical signs and body temperature were recorded daily. At day 7 post infection animals 
were euthanized and palatine tonsils removed. Presence of virus was detected in tonsils by virus 
isolation evidenced by immunohistochemistry using mAb WH174 for virus detection. Tonsils 
were then macerated in a 10% w/v suspension and then clarified by centrifugation at 2,000 rpm 
for 20 minutes. The resulting tonsil tissue supernatants were pooled and used to inoculate a new 
group of 5 animals. This procedure was repeated for 4 more times for a total number of 5 viral 
passages in swine.  
 
  
84 
 
Viral RNA Extraction from Spleen Sample for Sequencing  
 
QIAGEN RNeasy kit (QIAGEN, Valencia, CA) was used to isolate revertant viral RNA 
(Flag T4SPv) from the spleen of one of the affected piglets in passage 5 of the reversion to 
virulence experiment (Flag T4SPv). The RNeasy protocol used, selectively combines silica-
based membrane binding properties with high speed microspin technology. The spleen samples 
were first lysed and homogenized in a highly denaturing buffer containing guanidine-
thiocyanate. Subsequently, 70% Ethanol (Sigma-Aldrich) was added to homogenized sample to 
provide appropriate binding conditions for RNA to silica membrane. The sample mixture was 
then applied to RNeasy Mini spin column and centrifuged. Following centrifugation, wash buffer 
was flowed over spin column to remove contaminants. The bound RNA was eluted off 
membrane in 20 μl of nuclease free water (Promega, Madison, WI). 
 
Reverse Transcription and PCR amplification of Flag T4SPv for sequencing  
 
The extracted Flag T4SPv RNA was reverse transcribed from RNA to cDNA as follows: 
a 20 ul reaction mixture [2 U of Moloney murine leukemia virus reverse transcriptase (MMLV) 
(Stratagene, Jolla, CA), MMLV 10x buffer, 4 mM deoxynucleosidetriphosphates,(dNTPs), 10 
pmol random primers (ThermoFisher Scientific, Waltham, MA), and 5 μl of Flag T4SPv RNA] 
was incubated 1 h at 37°C. Subsequently, the cDNA of Flag T4SPv was amplified by traditional 
PCR, producing 5 overlapping PCR amplicons spanning the entire viral genome. PCR 
amplification was performed in a 50 μl reaction using Advantage® 2 PCR kit (Clontech, Palo 
Alto, CA) [5 μl of 10× Advantage 2 buffer, 400 μM of dNTPs, 10 pmol of each of primer set 
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(Table 4), 1 μl of Advantage 2 Polymerase Mix and 2 μl of cDNA] and denatured at 95 °C for 1 
min followed by 25 cycles at 95 °C for 20 seconds, 52 °C for 20 seconds, and 68 °C for 30 
seconds, and a final 68 °C extension cycle for 1 minute on MJ Research Peltier Thermal Cycler 
(Bio-Rad). PCR products were resolved on 1% agarose gels stained with ethidium bromide and 
visualized using gel doc (Bio-Rad, Berkeley, CA). PCR products were purified using QIAGEN 
PCR purification kit and sequenced.  
 
DNA Sequencing  
 
Full-length infectious cDNA clones, in vitro rescued viruses, and in vivo rescued virus (Flag 
T4SPv) were completely sequenced with 96 CSFV specific primers (Table 2) by the 
dideoxynucleotide chain-termination method (Sanger et al., 1977). Sequencing reactions were 
prepared with the BigDye Terminator Cycle Sequencing Kit (Perkin-Elmer, Boston, MA). A 
10ul reaction containing BigDye™ Terminator Ready Reaction Mix, 100ng/ul cDNA template 
and 3.2 µM CSFV primers and cycled on MJ Research Peltier Thermal Cycler (Bio-Rad) as 
follows: incubate 96 °C for 1 minute, followed by 25 cycles of denaturation at 96 °C for 
10 seconds, annealing 50 °C for 5 seconds and extension at 60 °C for 4 minutes. DNA was 
precipitated and washed with 70% ethanol and resuspended in 10ul of Hi‑ Di™ Formamide. 
Reaction products were sequenced on a 3730 xl DNA Analyzer (Applied Biosystems, Foster 
City, CA). Resulting Sequence data was assembled and aligned using SequencherTM 5.2.4 
software program (Gene Codes Corporation, Ann Arbor, MI). The final DNA consensus 
sequences presented on average a five-fold redundancy at each base position. 
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Construction of CSFV chimeric plasmids representing mutations in Flag T4SPv 
 
Sequence analysis of the revertant virus, Flag T4SPv, isolated from the spleen of animals 
infected with the master seed stock of Flag T4v, revealed the presence of three nonsynomous 
amino acid substitutions and absence of the Flag epitope insertion residing in the glycoprotein E1 
when compared to the sequence of parental Flag T4v genome. The three nonsynomous amino 
acid mutations were specifically caused by random nucleotide replacements of C687T which 
resulted in the A109V substitution, nucleotide A2910G resulted in the N850S substitution, and 
nucleotide C3339A resulted in the A993E substitution (Table 1). To identify the contribution of 
these mutations on viral virulence observed in Flag T4SPv, a set of recombinant viruses were 
constructed containing these individual nonsynomous amino acid mutations in both the presence 
and absence of the Flag epitope insertion. As a result, three mutant plasmid constructs were 
developed using a full-length infectious cDNA clone (IC) of FlagT4 (Holinka, et al., 2009) as 
DNA template; plasmid Flag T4 699, exchanging nucleotide C at position 699 for T, plasmid 
Flag T4 2932, replacing base A at position 2932 for G, and plasmid Flag T4 3351, substituting 
nucleotide C at position 3351 for A. These same mutations were also introduced into the full-
length infectious cDNA clone of T4 (Risatti, et al., 2006), a DNA template containing the T4 
mutation but lacking the Flag insertion. The plasmids using the T4 template were designated T4 
699, T4 2932 and T4 3351 respectively. All 6 plasmids were generated using PCR-based 
QuikChange® XL Site-Directed Mutagenesis kit (Stratagene). In order to introduce these 
nucleotide changes into either the full length plasmid of FlagT4 or the plasmid of T4, a set of 
mutagenic oligonucleotide primers were designed in accordance with manufacturer’s guidelines 
(Table 3): primer length between 25 and 45 nucleotides, melting temperature of ≥78 °C and a 
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GC content of 40% with desired mutation centered within probe with ~ 10-15 nucleotides of 
correct sequence on either side (Table 4). Each mutagenic reaction contained ~100ng of dsDNA 
template and 125ng of the appropriate forward and reverse primer set. Reactions were thermal 
cycled according to manufacturer’s suggested cycling parameters in order to synthesize cDNA 
mutant strands. Following mutagenesis, the reactions were treated with 10 U of the endonuclease 
Dpn1 to eliminate methylated nonmutated parental DNA templates, and extended cDNA 
products were transformed into XL Gold ultra competent E. coli cells (Stratagene) pretreated 
with β-mercaptoethanol (Stratagene) for increased transformation efficiency and plated on 
terrific broth agar plates with 100ug/ml of Carbencillin (Teknova, Hollister, CA). Plates were 
incubated overnight at 37°C. The following day individual colonies were picked and again grown 
overnight in TEKgro terrific broth with 100ug/ml of Carbencillin at 37°C (Teknova). All plasmid 
DNAs were purified using QIAGEN highspeed maxi kit. The QIAGEN plasmid purification 
protocol is based on a modified alkaline lysis procedure. The bacteria were first lyzed under 
alkaline conditions and then the lysates were subsequently neutralized. Bacterial lysate were next 
cleared without centrifugation using QIAfilter cartridges. After lysate clearing, the samples were 
purified on QIAGEN-tips packed with QIAGEN proprietary anion-exchange resin. Plasmid 
DNAs bind to QIAGEN resin under the low-salt buffer conditions. Contaminants, such as, RNA, 
proteins, dyes, and low molecular weight impurities were removed with a medium-salt buffer 
wash. Plasmid DNAs were eluted in a high-salt buffer and then concentrated and desalted by 
isopropanol (Sigma-Aldrich) precipitation. Finally, the purified full-length cDNA plasmids were 
sequenced in their entirety to verify the presence of the desired mutations and absence of 
undesired random mutations as previously described.   
 
  
88 
 
Construction of CSFV Flag T4Gv 
The full-length DNA plasmid of Flag T4 was used as DNA template in which mutations 
were introduced to alter codon usage in order to produce a new plasmid called Flag T4G. 
Mutations were introduced by site-directed mutagenesis using QuikChange® XL Site-Directed 
Mutagenesis kit as described above.  In order to introduce the altered codon usage in Flag and T4 
regions (Fig. 8) a series of 4 mutagenic oligonucleotide primer sets were designed in accordance 
with manufacturer’s guidelines, as described above (Table 7). Notably, 3 sets of primers had to 
be designed to introduce alterations to the Flag insertion codon usage due to limitations of the 
site directed mutagenesis protocol in which the efficiency of the reaction significantly decreases 
after a maximum of 6 base pair substitutions (Fig. 8). Each primer set was individually used in 
the site directed mutagenesis protocol to introduce mutations progressively into Flag T4 plasmid 
DNA. After each site directed mutagenesis reaction, the resulting plasmid DNA was transformed 
into E. coli and then isolated from bacteria using the QIAGEN plasmid purification protocol. The 
new plasmid DNA from each reaction was then used as the template to add the next set of 
mutations through site directed mutagenesis. This process was repeated a total of four times in 
order to produce the Flag T4G cDNA construct. Lastly, the Flag T4G plasmid was sequenced in 
its entirety to verify the presence of the desired mutations and absence of any undesired random 
mutations as described previously.   
 
Rescue of CSFV chimeric viruses 
 
 Full-length genomic clones were linearized with SrfI and in vitro transcribed using the T7 
Megascript® system (Ambion, Austin, TX), and RNA precipitated with LiCl. RNA was 
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transfected into SK6 cells by electroporation at 500 volts, 720 ohms, 100 watts with a BTX 630 
electroporator (BTX, San Diego, CA).  Cells were plated in 6 well tissue culture plates (Corning 
Life Science, Corning, NY) and incubated for 4 days at 37C and 5% CO2. In order to detect 
viral infectivity, one well of each plate was fixed and stained by immunochemistry. Fixation was 
carried out using a 50% (vol/vol) ethanol-acetone (Fisher Scientific, Pittsburg, PA) solution and 
incubated for 30 minutes at room temperature and subsequently blocked with DMEM (Gibco) 
supplemented with 2 % normal horse serum (Vector Laboratories, Burlingames, CA) to prevent 
non-specific binding. Immunohistochemistry staining was performed using the CSFV E2 
specific monoclonal antibody (mAb) WH303 or mAb174 in combination with the Vectastain 
ABC® kit (Vector Laboratories) (Risatti et al., 2003). Cells and supernatant were harvested from 
remaining wells for stock virus using rubber cell scrapers (Corning Life Sciences, Corning, NY). 
Stocks of rescued viruses were stored at -70ºC.  
 
In Vitro and In Vivo Rescued Flag T4G Viral RNA and NGS Sequencing  
 
Viral RNA was isolated from in vitro produced viral stock of Flag T4Gv and tonsil 
tissues from Flag T4Gv infected pigs using TRIzol® LS Reagent method (Life Technologies, 
Grand Island, NY, USA). 3 Parts Trizol LS was added to 1 part tissue sample/virus stock for 
efficient lysis. Chloroform (J. T. Baker, Center Valley, PA) was added to sample and 
subsequently centrifuged. Centrifugation resulted in the reaction mixture separating into 3 
phases, with the upper aqueous phase containing the RNA.  Next, the upper layer was transferred 
to a clean nuclease-free polypropylene microcentrifuge tube and the RNA was precipitated from 
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solution with isopropanol (Sigma-Aldrich). The precipitated RNA was washed with 70% ethanol 
(Sigma-Aldrich) to remove impurities, and then resuspended in nuclease free water (Promega). 
 
 
The RNA concentration of in vitro rescued Flag T4Gv, and Flag T4Gv tonsil samples and 
were determined using the Qubit® RNA high-sensitivity (HS) assay kit (Life Technologies) and 
read on a Qubit 2 fluorometer (Life Technologies). One microgram of viral RNA was 
enzymatically fragmented to obtain blunt-end fragments in a length range of 100 to 300 bp using 
the enzyme RNase III (Life Technologies) and incubated at 37°C in a MJ Research Peltier 
Thermal Cycler (Bio-Rad). Ion adapters were hybridized to fragmented RNA, hybridized 
fragmented RNA was reverse transcribed to cDNA and cDNA was ligated to ion library 
barcodes and amplified using the Ion total RNA-seq v2 kit (Life Technologies). 1ul of amplified 
cDNA was loaded onto Agilent DNA 1000 chip (Agilent, Santa Clara, CA, USA) and quantified 
using 2100 bioanalyzer (Agilent). Using the 2100 expert software, a smear analysis was 
performed to quantify the molar concentration (nM) of the cDNA libraries in order to determine 
the library dilution required for template preparation. After dilution of cDNA library to a 
concentration of 20pM was performed, the cDNA library was clonally amplified onto Ion Sphere 
particles (ISPs), generating template-positive ISPs using the Ion PGM template OneTouch 2 200 
kit (Life Technologies) with the Ion OneTouch 2 instrument (Life Technologies). Before 
proceeding to enrichment, quality assessment of nonenriched template-positive ISPs was 
performed using the Ion Sphere quality control (QC) assay kit (Life Technologies) and a Qubit 2 
fluorometer. The template-positive ISPs were then enriched using the Ion PGM template 
OneTouch 2 200 kit (Life Technologies) and Ion OneTouch enrichment system (ES) instrument 
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(Life Technologies) to eliminate template-negative ISPs and to denature cDNA on template-
positive ISPs. Using the Ion PGM 200 sequencing v2 kit (Life Technologies), enriched template 
ISPs were prepared for sequencing, loaded onto either an Ion 316 chip v2 (Life Technologies), 
and run on the Ion PGM sequencer (Life Technologies). The sequences obtained were then 
trimmed using Galaxy (https://usegalaxy.org) NGS QC and manipulation tools. Sequences were 
aligned and analyzed using Sequencher 5.2.2 (Genecodes) and CLC Genomics Workbench 
(CLCBio) software.  
 
Protection of Flag T4Gv Animal Study 
 
Protection experiments were performed using commercial female pigs weighting 40-60 
lbs. Animals were randomly allocated in three groups harboring five (n=5) animals each. Two 
groups were intra muscularly immunized with 105 TCID50 of Flag T4Gv. The third group was 
mock vaccinated with sterile DMEM media. One Flag T4Gv vaccinated group of animals were 
intranasally challenged at 7 days post vaccination with 105 TCID50 BICv. The remaining two 
groups were challenged at 21 days post immunization with 105 TCID50 BICv. Clinical signs and 
body temperature were recorded daily throughout the experiment as previously described. 
Viremia was determined for samples collected at 4, 7, 11, 15, and 21 days post-challenge by 
virus titration in SK6 cells as described below.  
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Reversion to Virulence Assessment of Flag T4Gv  
 
Reversion to virulence assessment for Flag T4Gv was implemented using twenty (n=20) 
5-6 week old commercial female pigs. Animals were randomly assigned into 5 groups and 
acclimated for a period of seven days before beginning experiment. Reversion to virulence 
protocol was performed as described previously. The initial group of five animals were intra 
muscularly inoculated with 106 TCID50 Flag T4Gv produced in our lab. Clinical signs and body 
temperatures were recorded for a period of 7 days. Seven days post infection all five animals 
were euthanized and palatine tonsils collected. Virus isolation was performed to determine 
presence of virus in tonsils and confirmed by immunohistochemistry using mAb WH174 for 
virus detection. Tonsils were then macerated in a 10% w/v suspension and a pool of tonsil tissues 
suspension and used to inoculate a new group of 5 animals. This process was repeated a total of 
four intervals resulting in 5 passages of Flag T4Gv through animals. 
 
Early Protection of Flag T4Gv Animal Study 
 
To determine the earliest onset of FlagT4v protection swine were allotted into 6 groups of 
5 animals each. Five groups were intramuscularly (IM) inoculated with 105 TCID50 of Flag 
T4Gv, and one additional group was mock inoculated. All groups were then challenged 
intranasally with 105 TCID50 of virulent BICv at day 0, 1, 2, 3, 5 or 7 post Flag T4Gv 
inoculation. Clinical evaluation and sampling of animals was performed as described as earlier. 
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Virus Titrations 
 
 End point titrations for virus stocks and clinical samples were performed by preparing 
ten-fold dilutions in a diluent of DMEM with 1% antibiotics. The serial dilutions were 
transferred into six wells each of 96 well tissue culture plates (Corning Life Sciences, Corning, 
NY) seeded with 1.0 X 104 cells/ml of SK6 cells. After 4 days of incubation at 37C and 5% 
CO2, cells were fixed with a 50% (vol/vol) ethanol-acetone (Fisher Scientific, Pittsburgh, PA) 
solution for 30 min. at room temperature and subsequently blocked with DMEM supplemented 
with 2 % normal horse serum (Vector Laboratories, Burlingames, CA) to prevent non-specific 
binding. Immunohistochemistry staining was performed using either the CSFV E2 specific mAb 
WH303, (Edwards et al., 1991) in combination with the Vectastain ABC® kit (Vector 
Laboratories Burlingames, CA) (Risatti et al., 2003) in order to detect viral infectivity. The 
monolayers were read microscopically for stained cells (Wensvoort et al., 1986).  Titers were 
calculated using the method of Reed and Muench (Reed et al., 1938) and expressed as log 10 
TCID50/ml. As performed, test sensitivity was > 1.8 TCID50/ml.   
 
Virus replication kinetics 
 
  Characterization of the replication kinetics of the Flag T4Gv was compared to parental 
virus, Flag T4v and WT Bresciav by the performance of multistep growth curves.  Six well tissue 
culture plates seeded with 1.0 X 104 cells/ml of SK6 cells were infected at a multiplicity of 
infection (MOI) of 0.01 TCID per cell and allowed to adsorb for 1 hr at 37C and 5% CO2.  The 
virus inoculum was removed from the cells, and the cells were washed and incubated in freshly 
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prepared media of DMEM containing 10% уIR FBS and 1% antibiotics at 37C and 5% CO2.  At 
the following hours post infection; 2, 6, 24, 48 and 72 the respective tissue cultures plates were 
put at - 70° C to stop virus replication. Virus yield was determined by end point titration in SK6 
cells. 
  
Plaque Assays 
 
 Six well tissue culture were seeded with 1.0 X 104 cells/ml of SK6 cells and incubated at 
37°C and 5% CO2 for 24h.  After 24h, each well was independently infected with either Flag 
T4Gv or BICv (50 to100 TCID) and subsequently overlaid with 0.5% agarose and incubated for 
4 days at 37°C and 5% CO2.  Plates were fixed and stained by immunohistochemistry as 
previously described. 
 
Early Protection Animal Study for Assessment of Cytokine Expression  
 
In an effort to elucidate probable mechanisms mediating the early protective immune 
response observed in animals infected with Flag T4v and challenged at 3 days post infection with 
virulent BICv an early innate immune response study was conducted using 11 animals. Three 
groups of 3 pigs each were intramuscularly infected with either 105 TCID50 of FlagT4Gv and 
euthanized at 3 days post infection, or infected with 105 TCID50 BICv and euthanized 3 days later 
or infected with 105 TCID50 of FlagT4Gv and intranasally challenged 3 days post infection and 
euthanized 3 days post challenge. An additional two animals were used as naive controls. Tonsils 
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and draining lymph nodes were collected after euthanasia from all 11 swine. Blood samples were 
also collected at time of death. 
 
 
Quantification of Cytokine Expression in Serum 
 
Sixteen commercially available ELISA kits were used to measure presence and quantify 
cytokine expression following manufacturer protocols (MyBioSource, San Diego, CA), were 
used for detection and quantification of various cytokines in serum of animals euthanized 3 days 
after either being intramuscularly infected with either 105 TCID50 of FlagT4Gv, 10
5 TCID50 
BICv or 105 TCID50 of FlagT4Gv/challenge 3dpi with 10
5 TCID50 BICv  or mock infected  
animal. Concentrations of cytokines in serum were calculated by extrapolation in a standard 
curve simultaneously determined with recombinant porcine IFNα (PBL Assay Science). 
MyBioSource ELISA kits: Interleukin 8 (IL-8), Interleukin 1 alpha, Interleukin 1beta, Interleukin 
2 (IL-2), Interleukin 5 (IL-5), Interleukin 6 (IL6), Anti-Interleukin 10, Interleukin 12 p35, 
Interferon-induced GTP-binding protein Mx1 (MX1), Interferon beta, IFN-beta/IFNB, Monocyte 
Chemotactic Protein 2 (MCP2), Protein Kinase R (PKR), Transforming growth factor beta1 
(TGF-beta1), Total Tumor Necrosis Factor, VCAM-1/CD106, 2',5'-Oligoadenylate Synthetase 1. 
 
RNA extraction and cDNA synthesis for cytokine assay 
 
Total cellular RNA was extracted from tonsils of swine euthanized 3 days after either 
being intramuscularly infected with either 105 TCID50 of FlagT4Gv, 10
5 TCID50 BICv, 10
5 
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TCID50 FlagT4Gv/challenge 3dpi with 10
5 TCID50 BICv  or mock infected  animals. RNA was 
extracted using a RNeasy Mini Kit (Qiagen) following the manufacturer’s protocol. Contaminant 
DNA was removed by DNAse treatment using Turbo DNA-free (Ambion, Austin, TX). After 
DNAse treatment, genomic DNA contamination of RNA stocks was assessed by real-time PCR 
amplification targeting the porcine β-actin gene. Total RNA was quantified using a NanoDrop 
1000 (Thermo Scientific, Waltham, MA). cDNA was synthesized with a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA) using random hexamer primers 
(Invitrogen, Carlsbad, CA) in a 100 μl reaction containing 1500 ng of total RNA. 
 
Quantitative reverse transcription real-time polymerase chain reaction (qRT-PCR) 
 
For gene expression quantification, first-strand cDNA was amplified by real-time PCR 
using Power SYBR® Green PCR Master Mix (Applied Biosystems, Foster City, CA) with primer 
pair sets illustrated in Table 10. A 50 μl reaction contained 25 μl of Power SYBR® Green PCR 
Master Mix, 5 μL of cDNA, and 400 nmol/μl of each primer. Cycling conditions were as 
follows: activation of the AmpliTaq Gold® Polymerase at 95 °C for 10 min, followed by 40 
cycles of denaturation at 95 °C for 15 seconds, and annealing and extension at 60 °C for 
1 minute, with a melting curve analysis performed at the conclusion of the PCR assay. Real-time 
PCRs were run with an ABI 7900HT real-time PCR system (Applied Biosystems). 
Quantification of gene expression was performed by the 2−ΔΔCt method (described in ABI 
PRISM® 7700 Sequence Detection System User Bulletin #2 (PN 4303859)), and was analyzed 
with ABI software: RQ Manager 1.2. 
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RESULTS 
 
Minimum Protective Dosage of Flag T4v Master Seed Stock 
 
In collaboration with a major animal vaccine company a master seed stock of Flag T4v 
was produced by the manufacturer at their facility and sent to us for further evaluation. Notably, 
the master seed stock of Flag T4v was generated by propagation of the virus in a proprietary cell 
line. This was done in order to yield a single uniform batch of Flag T4v for downstream large 
scale vaccine production. Consequently, potential vaccines must undergo a rigorous licensing 
process to ensure the safety, efficacy, purity and potency before it can be approved for 
marketing. One of the initial steps in this procedure is the determination of the safety profile for 
the master seed stock. This entails the testing of the master seed stock in the host animal to 
determine the minimum protective dose of the vaccine as well as an overdose study to ascertain 
whether there are any deleterious side effects associated with the vaccine. The minimal 
protective dose is defined as the dosage that protects at least 80% of the animals in a given study. 
Furthermore, determination of the minimum protective dose demonstrates the potency of the 
vaccine candidate as an immunogen. Importantly, faulty dose selection can result in either 
selecting a dose that is too low to achieve the desired benefit or one that is too potent, resulting in 
unacceptable toxicity.  
 
Three groups of 5 animals each were inoculated with dose ranges of 105, 104 and 103 
TCID50 of Flag T4v master seed stock. A fourth group of 10 pigs were mock vaccinated. Fever 
responses and clinical signs were monitored daily following lethal CSFV challenge 21days post 
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infection. Unexpectedly, one animal in the group inoculated with 105 TCID50 of Flag T4v died at 
day 6 post infection. Importantly, necropsy of this animal showed no evidence of CSFV, ASFV, 
or FMDV related pathology indicating that death was not due to inoculation with Flag T4v or a 
result of unintentional introduction of another foreign animal disease used at our facility. All 
remaining nine animals in this group survived lethal challenge remaining clinically normal with 
a few pigs occasionally exhibiting body temperatures slightly above 104°F (Table 5 and Fig. 
7A). In contrast, two animals developed fever 6 days post challenge in the group inoculated with 
104 TCID50 Flag T4v (Table 5 and Fig. 7B). These two animals were euthanized at days 9 and 15 
post challenge. At necropsy, pathological findings indicative of CSFV were found in both 
animals. Similarly, two pigs in the group infected with 103 TCID50 Flag T4v developed fever at 
days 3 and 5 post challenge (Table 5 and Fig. 7C). These pigs were euthanized at days 8 and 13 
post challenge presenting CSFV related symptoms/lesions. The remaining animals in all 3 Flag 
T4v infected groups remained clinically normal. In contrast, all animals in the mock vaccinated 
group presented CSFV related symptoms after challenge and were euthanized at days 7 (two 
animals), 8 (one animal), 9 (two animals), 10 (two animals) and 11 (three animals) post 
challenge (Table 5 and Fig. 7D).  
 
Back-titrations of the Flag T4v inoculums revealed that each animal group received 
approximately one log less of Flag T4v than intended. These findings infer that the minimum 
protective dose of Flag T4v master seed stock is actually 102 TCID50 rather than 10
3 TCID50. 
Remarkably, these results indicate that Flag T4v is a potent immunogen. 
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In addition, immunohistochemistry and titrations were performed on collected tonsil 
tissues. For animals infected with a dose of 105 TCID50 of Flag T4v all animals were negative 
by virus titration and immunohisotchemisty using mAb 303 showing that multiplication and 
spread of challenge virus is very limited or not present. However, immunohistochemistry with 
mAb anti-Flag showed the presence of vaccine virus in two animals. These same animals were 
negative in virus titrations. Animals in the groups infected with 104 and 103 TCID50 of Flag T4v 
no virus was detected using mAb anti-Flag. As expected the two animals in each group that 
exhibited clinical CSFV symptoms after lethal CSFV challenge were both positive by 
immunohistochemistry and virus titrations using mAb 303. All mock infected animals were also 
positive by immunohistochemistry and virus titrations using mAb 303 but negative for presence 
of vaccine virus as shown by immunohistochemistry with mAb anti-Flag  
 
 
 
Flag T4v Safety Test 
 
The intrinsic safety of vaccines should be demonstrated early in the development stage 
and documented as part of the vaccine licensing process. Five 40-60 lb swine were 
intramuscularly inoculated with 107.4 TCID50 of the master seed stock of Flag T4v. Animals were 
observed over a 21 day period. Rectal temperatures, as well as general clinical symptoms were 
recorded daily. Notably, over the course of the first week post inoculation the injection site of 
animals vaccinated with Flag T4v was carefully monitored for appearance of local lesions and 
compared with reactions at inoculation site of the two mock vaccinated pigs. None of the five 
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animals developed CSFV related symptoms or exhibited adverse reactions at injection sites. The 
absence of clinical signs of infection or tissue reactions at the application site after vaccination 
with Flag T4v shows that the candidate vaccine is completely atoxic. 
 
Reversion to Virulence Test for Flag T4v Master Seed Stock. 
 
With live vaccines, there is always a concern that the live attenuated virus might be shed 
from the host and transmitted to contact animals, causing disease if the virus was to retain 
residual virulence or revert to virulence. Therefore, all live vaccines are required to be tested for 
virulence by means of passage studies, in the host animal, using the most sensitive, usually the 
youngest, animals for which the product is intended. Consequently, putative vaccines are 
propagated in vivo by inoculating a group of target animals with the master seed stock. 
Subsequently, the live attenuated virus is recovered from tissues of these infected animals one 
week after inoculation and then used to infect the next group of naïve animals. After not less than 
four virus passages in animals, with at least a total of five groups of animals, the live attenuated 
virus is isolated from tissue and then fully characterized, using the same procedures used to 
characterize the master seed stock. This process was used to assess the genetic stability of Flag 
T4v master seed stock. Accordingly, the conventional five passage reversion to virulence 
experiment was performed by intramuscular inoculation of piglets with 105 TCID50 of Flag T4v 
master seed stock with subsequent passage groups receiving supernatant macerates from pooled 
virus-positive tonsils obtained from the previous passage. The first three passages of inoculated 
piglets did not demonstrate clinical signs of CSF. However, during the fourth passage, all 
animals presented a transient rise in body temperatures, although none of them presented any 
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additional CSFV related clinical symptom. In addition, no CSFV related lesions were found at 
necropsy (data not shown). In the fifth passage two animals were euthanized after exhibiting 
severe CSFV clinical signs. Necropsy of these animals also revealed presence of CSF related 
lesions. The other three animals presented transient fever between days 4 and 5 accompanied by 
depression, with some minimal CSF related lesions found at necropsy (data not shown). These 
results indicate that Flag T4v was not able to maintain its attenuated phenotype when 
successively passed in its natural host. 
 
Genetic Modifications Introduced in Flag T4v During the Reversion to Virulence Protocol 
 
To elucidate the genetic changes in the Flag T4v genome that led to reversion to 
virulence, full genome sequencing of the virus isolated from the spleen of one of the affected 
piglets (Flag T4SPv) was performed. The obtained sequence was then compared to attenuated 
parental Flag T4v. Interestingly, nucleotide sequence comparisons revealed three amino acid 
substitutions, a deletion of a stretch of 18 amino acids, and one single nucleotide deletion (Table 
1). Of the three amino acid substitutions in Flag T4SPv, one mutation was found to affect the 
structural protein Core. At amino acid position 109, a non-polar hydrophilic alanine was replaced 
for another non polar amino acid valine. The other two mutations found in Flag T4SPv resided in 
the glycoprotein E2. The first of these mutations exchanged a polar uncharged hydrophilic amino 
acid asparagine for a similarly uncharged polar hydrophilic serine at amino acid position 850. 
Intriguingly, N850 is located in the center of the T4 mutated region that is associated with the 
lost of reactivity to mAb WH303 (constituting the negative antigenic marker of Flag T4v) and 
attenuation of T4v in swine (Risatti et al., 2006). The second amino acid mutation in 
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glycoprotein E2 was found at amino acid position 3351 and substitutes a non-polar hydrophilic 
alanine for a negatively charged glutamic acid. In conjunction with these three amino acid 
substitutions, Flag T4SPv was found to contain a large deletion of 18 amino acids between 
residues 688 to 706 in the carboxyl end of glycoprotein E1, which comprises the complete Flag 
epitope/transposon insertion. Finally, a deletion of a cytosine nucleotide was observed at position 
12342 within the 3’UTR of Flag T4SPv (Table 1). 
 
Identification of Flag T4v Mutations Leading  to Increased Virulence in Flag T4Sv  
 
In order to identify the individual contribution of each of the mutations found in Flag 
T4SPv on reversion to virulence, a set of recombinants viruses were constructed containing 
either the 3 amino acid substitutions either individually or in combination with deletion of the 
Flag insert. Importantly, the amino acid substitutions observed in Flag T4SPv were caused by 
single nucleotide mutations: nucleotide C699T resulting in the A109V substitution, nucleotide 
A2932G resulting in the N850S substitution, and nucleotide C3351A resulting in the A993E 
substitution (Table 1). Consequently, six different mutant viruses were developed: Flag T4v 
harboring the A109V mutation (Flag 699v), Flag T4v harboring the N850S mutation (Flag T4 
2932v), Flag T4v harboring the A993E mutation (Flag T4 3351v), T4v (lacking the Flag 
insertion) harboring the A109V mutation (T4 699v), T4v harboring the N850S mutation (T4 
2932v), and T4v harboring the A993E mutation (T4 3351v). Each of these recombinant viruses 
was assessed for virulence in swine. Groups of four 40-60lbs pigs were independently inoculated 
with 104 TCID50 of the six viruses. The presence of CSF related clinical signs and temperatures 
were recorded daily throughout the observation period of 21 days. Animals inoculated with these 
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recombinant viruses remained clinically normal with the exception of the group of pigs 
inoculated with T4 2932v which presented clinical disease indistinguishable from that observed 
in animals infected with virulent CSFV BICv (Table 6). These results suggest that deletion of the 
Flag insertion within the E1 glycoprotein, along with the amino acid substitution N850S in the 
E2 glycoprotein are responsible for the virulent phenotype observed in revertant Flag T4Sv.  
 
Development of Flag T4Gv 
 
After identifying the genetic changes within Flag T4v that caused the virulent phenotype, 
in revertant virus Flag T4SPv, the next step was to devise a method to modify the Flag T4v in 
order to improve its genetic stability while maintaining its attenuation as well as its double 
antigenic marker elements. In order to accomplish this task we decided to genetically modify the 
Flag and T4 areas by taking advantage of degeneracy of the genetic code. It is the degeneracy of 
the genetic code which accounts for overabundance in the number of codons that encode for the 
same amino acid, specifically there are a total of 64 codons, three of these codons encode for 
stop codons while the remaining 61 codons are translated into only 20 different amino acids. The 
term codon usage is used to describe this phenomenon. Consequently, the genome of Flag T4v 
was modified in the areas encoding for the Flag and T4 epitopes (amino acid residues at 
positions 688-706 and 848-852, respectively) by changing the codon usage. By using 
synonymous variant codons we were able to alter the nucleotide sequences as much as possible 
from the original Flag T4v nucleotide sequence without changing the protein sequence of Flag 
T4v (Fig. 8). In addition, a hydrophilic polar amino acid asparagine at position 850 in the T4 
region, was replaced with a non-polar glycine in an effort to help inhibit reversion from 
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asparagine to another hydrophilic uncharged polar amino acid, serine, the native residue at this 
position 850 in virulent CSFV strain Brescia (Fig. 8B). The resulting cDNA infectious clone, 
Flag T4G, was obtained by multiple rounds of sequential site directed mutations introduced into 
full-length infectious cDNA clone of the Flag T4, using primers presented in Table 7 (complete 
description of all substitutions introduced depicted in Fig.8A and B). 
 
Rescue of Flag T4Gv 
 
Infectious RNA was in vitro transcribed from full-length cDNA infectious clone of the 
Flag T4Gv (Fig. 8) and used to transfect SK6 cells. Virus was rescued from transfected cells by 
day 4 post-transfection. Full-length nucleotide sequence of the rescued virus genome was 
identical to parental DNA plasmid, confirming that only the predicted mutations were reflected 
in rescued virus. 
 
In vitro growth characteristics of Flag T4Gv were evaluated relative to wild type CSF 
BICv and parental Flag T4v in a multi-step growth curve. SK6 cell cultures were infected at a 
multiplicity of infection (MOI) of 0.1 TCID50 per cell. Virus was adsorbed for 1 hour (time 
zero), and samples were collected at 2, 6, 24, 48 and 72 hours post-infection (PI). Samples were 
titrated in SK6 cells, the presence of virus detected by immunoperoxidase with mAb WH174 
(which recognizes an E2 epitope different from that recognized by mAb WH303) and titers using 
calculated using the Reed and Muench methodology (Reed et al., 1938) and expressed as log 10 
TCID50/ml. The results (Fig. 9) showed that Flag T4Gv had an approximately 5-8 fold decrease 
in the final virus progeny yield relative to wild type CSF BICv and 5-8 times more progeny 
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relative to parental Flag T4v (reaching average titer values of 7.25, SD=0.09; 6.3, SD=0.17; and 
7.62, SD=0.09 TCID50/ml, for Flag T4Gv, Flag T4v, and BICv, respectively).  
 
The antigenic profile of Flag T4Gv was evaluated by assessing the reactivity of the virus 
against mAbs anti-Flag, WH303 and WH174 and comparing the antigenic profile with that of the 
control virus, BICv. Flag T4Gv strongly reacted with mAbs anti-Flag and WH174, but did not 
react with mAb WH303 (directed against the highly conserved epitope in the T4 region) (Fig. 
10). Wild-type CSFV BICv reacted with mAbs WH174 and WH303 but lacked reactivity against 
mAb anti-Flag. Thus, Flag T4Gv displayed the expected antigenic reactivity profile. 
 
Assessment of genetic stability of Flag T4Gv Using the Reversion to Virulence Protocol 
 
Flag T4Gv genetic stability was then assessed using the reversion to virulence protocol 
set by the OIE under the same conditions used to evaluate Flag T4v.  A group of five, 5-6 week 
old female piglets were intramuscularly inoculated with 106 TCID50 of Flag T4Gv and 
euthanized 7 days later. Palatine tonsils from each piglet were removed and macerated in DMEM 
to obtain a 10% weight/volume suspension which was then used to intramuscularly inoculate 
another group of naïve female piglets.  This process of inoculation-euthanasia-inoculation was 
repeated a total of five times. In all cases animals were kept under observation during a 7 day 
period and clinical signs and body temperature were recorded daily. At day 7 post infection 
animals were euthanized and their palatine tonsils removed. Detection for the presence of the 
Flag T4Gv was tested by infecting SK6 cell cultures with each passage of the tonsil extracts and 
evidence by immunohistochemistry using mAb WH174. None of the animals in any of the 
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passages exhibited CSFV related symptoms. Moreover, presence of Flag T4Gv was only 
detected at low titers (103.2 TCID50/ml) in tonsil extracts obtained from the initial group of 
animals inoculated. All subsequent tonsil extracts were negative by virus isolation. In contrast to 
Flag T4v, these results demonstrate that Flag T4Gv is genetically stable and able to maintain an 
attenuated phenotype under direct pressure for reversion to virulence. 
 
 
Flag T4Gv Protects Pigs Against Lethal CSFV Challenge  
 
The ability of Flag T4Gv to induce protection against virulent BICv was assessed in early 
and late vaccination-exposure experiments. Two groups of pigs (n=4) were intramuscularly 
inoculated with 105 TCID50 Flag T4Gv and challenged at either 7 or 28 days post infection with 
105 TCID50 of virulent CSF BICv. Mock-vaccinated control pigs receiving BICv only developed 
anorexia, depression, and fever by 4 days post-challenge and died or were euthanized in extremis 
9 to 10 days post challenge (Table 8). Notably, Flag T4Gv induced complete clinical protection 
at 7 days and 28 days after immunization. All pigs survived infection and remained clinically 
normal, without fever (Table 8). Viremia in vaccinated and challenged animals was examined at 
4, 6, 8, 11, 14 and 21 DPC. Detection was performed using mAb WH303, which reacts 
specifically with the challenge virus BICv. As expected, in mock-vaccinated control animals, 
viremia was observed within 4 days after challenge, with virus titers remaining high until the last 
time point tested before animals died or were euthanized (Fig. 11). Conversely, animals 
inoculated with Flag T4Gv and challenged with BICv at 7 or 28 DPI did not present any 
detectable viremia (Fig. 11). In addition, the presence of BICv could not be detected in blood 
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samples during the 21day observation period after challenge. These results indicate that 
protection induced by Flag T4Gv was complete, preventing both the presentation of CSF-related 
clinical signs and the replication of the challenge virus.  
 
 
Assessment of Early Protection Induced by Flag T4Gv 
 
To assess the efficacy of Flag T4Gv as an experimental vaccine in terms of inducing 
early protection against challenge with the virulent CSFV BICv. Five groups of animals (n=5) 
were intramuscularly inoculated with 105 TCID50 of Flag T4Gv and were challenged by the 
intranasal administration of 105 TCID50 of BICv 1, 2, 3, 5, and 7 days later. Clinical signs and 
body temperatures were recorded daily over the course of the 21 day observation period. Mock 
infected animals presented a typical evolution of the disease starting at 5 days post challenge and 
evolving to a severe form of the disease with all animals euthanized between days 8 and 10 post 
challenge. All animals challenged on the first day post Flag T4Gv infection presented disease 
kinetics similar to that of the mock treated animals with all pigs euthanized between 9 and 11 
days post challenge (Table 9). Animals challenged on the second day post Flag T4Gv inoculation 
presented a heterogeneous phenotypic behavior. Two of the swine developed a severe form of 
disease starting at 6 days post challenge with disease kinetics similar to mock treated animals 
with all pigs euthanized between 11 and 14 post challenge. A third animal presented a transient 
elevation in body temperature without of any additional clinical signs. While the last two pigs in 
the group remained completely asymptomatic during the 21 day observation period. Importantly, 
animals in groups challenged on day 3, 5 and 7 after infection with Flag T4Gv also remained 
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completely asymptomatic during this same time frame. These results demonstrate that Flag 
T4Gv efficiently provides complete protection against the development of CSF disease since 3 
days post infection. 
 
Viremia in Animals from Flag T4Gv Early Protection Study 
 
Viremic values in Flag T4Gv infected animals challenge with BICv at 1, 2, 3, 5, and 7 
closely followed the appearance of clinical signs and severity of the disease (Fig. 12). Mock 
treated animals presented typical high titer values at both 4 and 7 days post challenges. Animals 
challenged by the first day post Flag T4Gv infection also presented high viremia at 7 and 14 days 
post challenge. While, average viremia titers were significantly lower in the groups of animals 
challenged at day 2 after Flag T4Gv due to the fact that surviving animals did not present 
detectable viremia. Viremia in animals challenged at either 3, 5 or 7 days post Flag T4Gv 
infection were consistently undetectable during the observational time frame. These results 
indicate that Flag T4Gv can efficient protect animals is able to provide solid protection against 
lethal challenge in animals after 3 post infection animals became solidly protected against the 
challenge with the virulent parental virus in terms of both the appearance of clinical signs 
associated with the disease and replication of the challenge virus. 
 
Detection and Quantification of Cytokine Expression in Early Protection Animal Study 
 
In an effort to elucidate probable mechanisms mediating the early protective immune 
response observed in animals infected with Flag T4v and challenged at 3 days post infection with 
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virulent BICv an early innate immune response study was conducted using 11 animals. Three 
groups of 3 pigs each were intramuscularly infected with either 105 TCID50 of FlagT4Gv and 
euthanized at 3 days post infection, or infected with 105 TCID50 BICv and euthanized 3 days later 
or lastly infected with 105 TCID50 of FlagT4Gv and intranasally challenged 3 days post infection 
with 105 TCID50 BICv and euthanized 3 days post challenge. An additional two animals were 
used as naive controls. Tonsils and draining lymph nodes were collected after euthanasia from all 
11 swine. Blood samples were also collected at time of death. The levels of multiple cytokines 
present in serum were measured in each group of animals by ELISA and qRT PCR cytokine 
assay. Specifically, levels of MCP2, TGF-1, IFN-, IFN-, IFN-, IL1- IL1-, IL2, IL5, IL-6, 
IL-8, IL10, IL12-p35, IL12p40, OAS, PKR, TNF, MX-1, and VCAM were assessed using 
commercial ELISAs following manufacturer protocols (MyBioSource, San Diego, CA). The 
results of the ELISAs were used to try to establish a correlation between mediators of the innate 
host immune response and infection with either attenuated Flag T4Gv or virulent BICv. Notably, 
the levels of most of the detectable cytokines were quite homogeneous among each group (Fig. 
13). The average cytokine values did not significantly vary between the virus infected groups nor 
did those values significantly differ between virus infected pigs and naïve animals. Notably, only 
IFN- showed any significant differences between groups. At three days post FlagT4Gv 
infection, circulating IFN- was determined to have a concentration of 536.72 ng/ml 
(SD+36.26). This concentration was much higher than those found in animals infected BICv 
which was 174.12 ng/ml (SD+45.85) or for swine infected with FlagT4G/BICv challenged 
which was 14.4 ng/ml (SD+10.37). Similarly, naïve animals presented values of 8.19 ng/ml 
(SD+1.34) for IFN-. These results suggest that IFN- may play a significant role as a mediator 
of innate immune response against BICv challenge. 
  
110 
 
 
 
DISCUSSION 
 
The majority of CSF control programs in enzootic areas are based on prophylactic 
vaccination of domestic pigs. Vaccination with live attenuated vaccine (LAV) strains induce 
protective immunity in pigs within a few days after vaccination, even before neutralizing 
antibodies can be detected, providing lifelong immunity against disease (Biront and Leunen, 
1988; Terpstra, 1991). However, current LAVs lack DIVA capabilities that would allow 
differentiation between infected and vaccinated animals, limiting their use as an emergency 
control strategy in the event of an outbreak in CSFV-free regions. CSFV subunit marker 
vaccines with DIVA capabilities have been developed using recombinant E2 envelope protein 
expressed in baculovirus system (Hulst et al., 1993; van Rijn et al., 1996; 1999). These subunit 
vaccines were commercially available but have since been removed from the market place due to 
insufficient sensitivity and specificity of their accompanying ELISA assays. In addition, these 
subunit vaccines were not ideal for emergency vaccination against CSFV due to delayed onset of 
protective immunity which does not fully develop until nearly two weeks after initial vaccination 
(Bouma et al., 2000; Uttenthal et al., 2001). Resultantly, there is an increased need for 
developing LAVs against CSFV with DIVA capabilities (Beer et al., 2007; Deng and Chen, 
2007). These vaccines, while inducing a rapid and effective immunity, should harbor antigenic 
markers for serological distinction of infected from vaccinated animals.  In addition, a rapid 
molecular diagnostic test, such as real-time RT-PCR, should also be constructed for early 
detection and differentiation between vaccinated and wild-type infected field isolates. 
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This research project describes the development of a novel CSFV live attenuated vaccine 
candidate, Flag T4Gv, based on the genetic alteration of codon usage in a previously described 
double marker vaccine virus, Flag T4v (Holinka et al., 2009). Flag T4v was a rationally designed 
LAV that was developed via genetic modification of virulent BICv, a virus derived from a full-
length cDNA copy of CSFV Brescia strain (Risatti et al., 2005a). The double antigenic marker 
LAV Flag T4v was obtained by combining two genetic determinants of attenuation: a) insertion 
of 19 amino acid residues in the carboxyl end of E1 (Risatti et al., 2005b), and b) mutation of the 
mAb WH303 epitope in E2 glycoprotein (Risatti et al., 2006). The 19mer amino acid insertion 
was further modified to include a synthetic Flag® epitope (Holinka et al., 2009). Intranasal or 
intramuscular administration of Flag T4v protected swine against virulent CSFV Brescia strain at 
early (2 or 3 days) and late (28 days) times post-inoculation. Flag T4v induced antibody 
responses in pigs that reacted strongly against the Flag epitope but failed to inhibit binding of 
mAb WH303 to a synthetic peptide representing the WH303 epitope (Holinka et al., 2009).  
 
When evaluating the genetic stability of Flag T4v via serial passages in highly susceptible 
5-6 week old piglets, reversion to virulence was observed in animals in the 5th and final passage 
group. The revertant virulent virus was rescued from the spleen of one of the sick piglets. 
Nucleotide sequencing revealed three amino acid substitutions, a deletion of a stretch of 19 
amino acids, and one single nucleotide deletion. A further study aimed at determining the 
contribution of these mutations on reversion to virulence revealed that deletion of the 19mer Flag 
insertion in combination with a single amino acid substitution at position N850S were required 
for producing the virulent phenotype. Notably, viruses harboring either mutation individually 
were completely attenuated in pigs. Interestingly, the majority of the non-synonymous mutations 
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observed in Flag T4Sv were restricted exclusively to the Flag and T areas of the genome. Only 
two additional non-synonymous mutations, A109V in Npro and A993E in E2, were observed in 
this virus. Why these discrete areas of the viral genome are genetically modified after successive 
passages in piglets remains unclear. Similarly, the occurrence of reversion to virulence has been 
reported by Tamura et al. (2012) in which a live attenuated CSFV vaccine strain, GPE- virus, 
was readapted to swine by serial passages in pigs that resulted in reversion to virulent phenotype 
after the eleventh passage in vivo. The original GPE- strain was obtained through passages in 
cultured cells and was found to possess 225 nucleotide mutations and 46 amino acid differences 
compared to its virulent parental virus, ALD strain (Ishikawa et al., 1995). The GPE- reversion 
to virulence mapped to three substitutions at positions T830A in E2 glycoprotein and 
V2475A/A2563V in NS4B protein.  
 
Residue A830 (present in ALD strain, BICv, and homologous to position 848 in Flag T4v 
and Flag T4Gv) seems to be critical for CSFV virulence. Interestingly, this residue is one of the 
five amino acid residues in the T4 mutation of Flag T4v and Flag T4Gv (830AVSPT834 to 
830SFNMD834 and 830SFGMD834, respectively). The T830A substitution in E2 acquired during 
passaging in pigs was shown to reduce viral replication in guinea pig cells while enhancing 
spreading and replication in pig cells when compared with parental vGPE_ virus. These results 
suggest that the residue at position 830 in E2 is involved in host tropism and plays a role in cell-
to-cell spreading, probably at the level of viral attachment and entry, as it is well known that the 
glycoproteins E2 and Erns of pestiviruses mediate viral attachment and entry into host cells 
(Hulst et al. 1997, Ronecker et al. 2008 and Tscherne et al 2008). Unfortunately, there is only 
limited information available on the receptors and pathways involved in CSFV binding and 
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entry. Moreover, as E2 is exposed on the outer surface of the virus it is well characterized as the 
most immunodominant protein of CSFV and responsible for inducing neutralizing antibodies in 
infected pigs (Weiland et al. 1990). As such, amino acid at position 830 is located in the N-
terminal region of E2, and this region is the minimal domain required for binding to pig 
antibodies generated during CSFV infection (Lin et al. 2000 and Zhang et al. 2006). 
Consequently, the direct impact of the substitution of alanine for threonine at position 830 in E2 
gene on virus infection in swine cells remains unclear and needs to be further examined. 
 
Although mutations observed in NS4B in GPE- revertant were not observed in Flag T4SP 
revertant virus our lab has also previously demonstrated the importance of this gene in CSFV 
virulence (Fernandez-Sainz et al., 2010; Gladue et al., 2011). Nevertheless, the amino acid 
substitutions at positions 2475 and 2563 in NS4B have not yet been reported to be involved in 
virulence. On the basis of the predicted topology of CSFV NS4B, the residues at positions 2475 
and 2563 are located in the N-terminal and C-terminal transmembrane domains, respectively. 
The role of transmembrane domains of CSFV NS4B in the virus life cycle is not well 
understood, while these domains of hepatitis C virus (HCV) are reported to play a role in viral 
replication (Han et al., 2011). Importantly, we previously identified a putative Toll/interleukin-1 
receptor-like domain in the C-terminal region of CSFV NS4B immediately downstream of 
residue 2563 which resulted in an attenuated phenotype along with enhanced activation of Toll-
like receptor 7 (TLR-7)-induced genes (Fernandez-Sainz et al., 2010). We believe this domain is 
involved in enhanced transcriptional activation of TLR-7-induced genes in swine macrophages, 
including sustained accumulation of IL-6 mRNA, and is also involved with virus virulence, since 
amino acid substitutions within this area of the genome lead to complete attenuation of BICv 
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(Fernandez-Sainz et al., 2010). Although these residues in NS4B were not affected by back-
passing Flag T4Gv in piglets it can all be considered general virulence determinants of CSFV as 
such, it is apparent that virulence of CSFV is a complex multigenic trait involving different 
genes and functions evidenced by numerous studies in which mutations of different functional 
domains in CSFV proteins C, E0, E1, E2, p7 and NS4B reduce pathogenicity in pigs indicating 
that these genes may be involved in determining CSFV virulence (Fernández-Sainz et al. 2009, 
Fernández-Sainz et al. 2010, Fernández-Sainz et al. 2011, Gladue et al. 2010, Gladue et al. 
2011a, Gladue et al. 2011b, Gladue et al. 2012, Meyers et al. 1999, Risatti et al. 2007a, Risatti et 
al. 2007b, Sainz et al. 2008, and Tews et al. 2009) To our knowledge, this report along with the 
report from Tamura et al., (2012) are the only to have identified specific mutations that result in 
the reversion of live attenuated vaccine viruses, after successive passages in pigs, back to 
virulent phenotypes. Remarkably, in both instances the observed reversions partially map to a 
similar area within the E2 glycoprotein of GPE- and Flag T4v genomes. 
 
Notably, we have shown here that substitutions with synonymous codons in Flag T4Gv 
provided increased genetic stability of the vaccine virus as five serial passages of Flag T4Gv in 
naïve piglets did not revert to a virulent phenotype. However, because Flag T4Gv was not 
detected in tonsil extracts obtained after each of the five successive passages in animals 
consequently there was no virus available for sequencing. Therefore, it was not possible to 
determine the presence of any genetic changes in Flag T4Gv throughout the passages in swine. 
As a result, it is not clear how the introduced mutations that affect the codon usage in the Flag 
and T4 regions of the genome increase the genetic stability of this attenuated virus. 
 
  
115 
 
In addition to increased genetic stability, Flag T4Gv is also able to provide protection 
against lethal CSFV challenge as early as 3 day post vaccination. Although, the ability of the 
host׳s innate immune system to interact with CSFV replication has been studied in vitro by 
several groups (Bensaude et al., 2004, Choi et al., 2004, Dong et al., 2013 and Fernandez-Sainz 
et al., 2010) the innate response factors mediating early protection remains unknown. To begin 
to understand the possible mechanisms producing early protection in the absence of an acquired 
antibody and T cell immune response, the presence and quantification of different components of 
the innate immune response were assessed for 3 animals vaccinated with Flag T4Gv and 
euthanized 3 days post immunization, 3 animals infected with WT CSFV and euthanized 3 days 
post infection and 3 animals vaccinated with Flag T4Gv, challenged 3 days later and euthanized 
3 days post challenge using cytokine specific ELISAs and an in-house cytokine RT-qPCR assay. 
Interestingly, of all the cytokines tested only, IFN-, showed any significant differences in levels 
between vaccinated, vaccinated/challenged and WT infected animals. Notably, changes in the 
expression of this cytokines due to CSFV infection have been reported previously (Magkouras et 
al., 2008, Fernandez-Sainz et al., 2010). Accordingly, Magkouras et al. (2008) reported CSFV 
possesses mechanisms that hinder the induction and production of IFNs during CSFV infection. 
Furthermore, a direct correlation between the virulence of a CSFV strain and the amount of IFN 
produced during CSFV infection in swine has also been reported (Renson et al., 2010, 
Summerfield et al., 1998 and Tarradas et al., 2014).  Likewise, the findings from this study 
suggest that increased levels of IFN- after Flag T4Gv vaccination may play a protective role 
against BICv challenge. Definitely, establishment of a robust antiviral state, both systemically 
and localized to primary sites of virus replication, seems to be crucial to preventing virus 
replication and spread.  
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Recently a live attenuated chimeric BVDV/CSF vaccine, CP7_E2alf has been submitted 
for licensing for usage in the countries of EU. This vaccine is a BVDV CP7 strain based 
chimera, expressing CSFV E2 of CSFV Alfort 187. The chimeric virus was characterized in 
vitro, and the vaccine’s efficacy and marker properties were investigated in 
immunization/challenge experiments. We believe our Flag T4Gv vaccine will prove to be a 
better alternative for CSFV control and emergency vaccine usage in countries free of CSFV for 
two main reasons. First, for CSFV control in the wild boar population of Europe, CP7_E2alf  
lacks a positive marker which prohibits the possibility to confirm whether analyzed animals have 
consumed baits, as a result, the effectiveness of CP7_E2alf vaccine campaigns in wild boar 
cannot be feasibly established. In contrast, our vaccine contains a positive marker, the flag 
epitope, which makes testing possible by either an ELISA that detects Flag antibodies or by 
genetic real-time PCR test that recognize the Flag sequence. More importantly, the earliest 
CP7_E2alf has been shown to protect animals against lethal CSFV challenge is 7 days post after 
IM vaccination, whereas, we have demonstrated that our vaccine protects as early as 3 days post 
intramuscular vaccination. This is very important for emergency vaccination usage due to the 
fact that the sooner animals are completely protected from CSFV infection the more likely the 
virus will be able to be contained to a smaller region thereby limiting potential spreading during 
an outbreak.  
 
In summary, we have demonstrated that precise mapping and modification of genetic 
determinants of virulence responsible for reverting a live attenuated strain back to virulence 
(Flag T4v), can lead to a more genetically stable attenuated phenotype (Flag T4Gv). More 
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importantly, shown here is the development of a CSF DIVA vaccine that could potentially be 
used for CSFV control in an effort to eradicate CSFV in EU as well as be used for emergency 
vaccination in CSFV free countries.  
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Figure 7. Daily temperature of animal groups in minimum protective dose study  
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Figure 8. Depiction illustrating altered codon usage for Flag T4G (A). Nucleotide changes for 
Flag region in E1 glycoprotein (B). Nucleotide substitutions for T4 region in envelope protein 
E2. 
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Figure 9. Growth Curve of Flag T4Gv compared with Flag T4v and BICv 
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Figure 10. Antigenic profile of Flag T4Gv compared to parental BICv and stained by 
immunohistochemistry with mAbs WH174, WH303, or anti-Flag (A). Flag T4Gv and BICv 
plaques shown at 1× magnification (B). Flag T4Gv and BICv plaques shown at 100× 
microscopic magnification. 
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Figure 11. Viremia Flag T4Gv Protection Assessment Experiment. 
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Figure 12. Viremia of Flag T4GV Early Protection Study 
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Figure 13. Cytokine Quantification in Serum 
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Figure 14.  qRT-PCR Cytokine expression (A). (B).  
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Table 1. Amino Acid and Nucleotide Changes Observed in Revertant Flag T4SPv. 
 
 
Position Changed CSFV Genomic Area 
Substitution residue 109 (A to V), nucleotide 699 (C to T) NPro 
Deletion residues 688 – 706,  nucleotides 2436 – 2489  E1 
Substitution residue 850 (N to S), nucleotide 2932 (A to G) E2 
Silent mutation residue 861, nucleotide 2944 (A to G) E2 
Silent mutation residue 866, nucleotide 2960 (A to C) E2 
Substitution residue 993 (A to E), nucleotide 3351 (C to A) E2 
Silent mutation residue 1360, nucleotide 4507 (T to C) NS23 
Silent mutation residue, nucleotide 8170 (A to G) NS4B 
Silent mutation residue, nucleotide 10177 (A to G) NS5B 
Deletion nucleotide C-12342 3’UTR 
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Table 2. Nucleotide Sequence of Primers used for Sequencing cDNA Infectious Clones             
(F designates forward primer; R designates reverse primer).  
 
Primer Name Sequence (5' - 3') 
F18 GTA TAC GAG GTT AGT TCA 
F200 GTC GTC AGT AGT TCG ACG 
R245 GGT TAA GGT GTG TCT TGG 
R483 TGT GGG TGT ACC TCA CT 
F556 CAT CAA AAC AAC ACT GAA 
F808 CTG CTG AAG CTA GCC AA 
R945 ATC CTC TTT TGG GGC TAT 
F1024 GGA AGG AGT AAA ATA CCA 
R1114 CCA ATA GGG CTT TTT CTA 
F1270 CAG AAG CTT GCA TGG GAT 
R1282 GGA CTC CTT TGC ATA TTT 
F1414 TGA ATG GAA CAA ACA TGG 
F1645 AGA GGG CCC ATG TAA TTT 
F1843 AGA AGC AAA ACC TGG TT 
R1888 TGT ACC ATA TGT ACC CTA 
F2008 GAT TCT CCA TGA GAT GGG 
R2046 GGC GAA GTC AGA CAG AAC 
F2379 CCT CAT CTG CTT GAT AAA AG 
F2599 CTG CAT GGC AGG TTC CTT 
R2715 GTC ATC CCC CAT TTC CTC 
R2886 GGT CTT TAC CAC TTC TGT 
F3007 GGG GGG CAA TTG GAC ATG 
R3361 AGC TGT CCC TGG GCT CAT 
F3421 CGA GTA TCA GTA CTG GTT 
R3539 AGC GGC GAG TTG TTC TGT 
F3784 GGG TGG AAA GAT AGA TGG 
R3831 ACT ACT ATA ACT GTC AG 
F3997 GCT AAC CTG GAC CTA CAT 
F4198 GAA TCT GGA CAT AGC CGG 
R4408 ACC CCT TCA CCA GCT TG 
F4369 ACC AAC TTC AAG AGG GT 
R4567 CTC CTG CTA TTT CAT CTA 
F4600 AGG GAC CAA CTT CAT CTC 
R4707 CCT CAC TTT GTG TTT GAT 
F4801 TGG CTT AGT CAA GGC AGC 
F4984 GGA TCA ATC AGA AGG GCC 
R5069 ACC AGG AGC ATC TTG ACT 
F5234 TTC GGT GTT ATG CCA AGG 
R5337 AGT GAC ATG GTC CAC TGA 
F5464 AGT TAA AAC TGA CTC CGG 
F5662 TGA GGC ATC AAG TGG AAG 
R5720 ACT GTT TGT ATT CCA CTC 
F5875 GTC ATA GAA GAG ATA GG 
F6062 CAG ATG CCA CAA CCT AAG 
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Primer Name Sequence (5' - 3') 
F6268 AGC CCC AGA AGT GAT GAA 
R6310 CCT CTA CTG GTA TCT TTA 
F6451 GGA GGA TCC ATC TAA CCT 
F6601 AAG ATG CCC TTC ATA GT 
R6636 CCT TCT CTG GGC TTG TTC 
F6787 GAT AAA CAT CAC CAA ATC 
R6915 TTC TGG GTG GTC AGT CCT 
F7039 TAA CTA TAC CTT CCT CAA 
R7083 AAG TCC TCA TCC TCT GT 
F7177 TGG TAG AGC ACT AAA ACA 
R7302 GTG GTG TCT TCC AAC CT 
F7402 TCA GGG GGA TGT GCA GAG 
F7588 ATA TGG GTT GTG GGG GAC 
R7713 TAA ACG ACC AAG TCT GT 
F7762 CCT CAG TTC CCA GGA GA 
R7935 ATG ACA ACG CTC TCC AA 
F8017 AAG CGA TGG TTT GCT AGG 
F8210 GAT GAA TTA GTC AAG GAG 
R8237 GTG TGC ACT GCT TCA AAC 
F8463 TCC TGT ATA AGT TCC GTG 
R8538 CCC GAG TCT GTC ATC CGT 
F8605 AAA TGC CCC TGT GGT TA 
R8751 TTC CAT TCT TAT CAC TGG 
R8824 ACT GGA TTT CAA CAA CAG 
R8872 TCT TGA GCA CCC TGA CCA 
F8965 CTG ATA GAG AGG GAC TG 
R9063 TTC TTG TGT ACC AAT TC 
F9180 ACC AGC CTT CGG GGA GAA 
F9422 CTG CAC GAA GCC ATA CAA 
R9467 ACT CTA TTA GAG GTG GCT 
F9659 ACC CTA GAG GCA TTA AGT 
R9682 CTT CTG CCT TGG TTA TGT 
F9831 GGG ATA TAG CTA CTA TCA 
R9853 TTT GTG GAG TCT GTA GCC 
F10039 GGT CTC TGC TTA CCA ACT 
R10143 GTG TTC CTC TAC CAA CTC 
F10167 TAG AGG AAC ACA AGA TGA 
R10272 CAG TTG CTC TGC CAC CTT 
F10412 GAC ACA ACC AAC TTC CAC 
R10500 CTC TAA CTC GGG TCG TTT 
F10658 GAG ATT ATT GAC AAT CTG 
R10774 TTG CTT CAG GGT ATT GTA 
R10931 TCG AAG CTC ACT GCC ACT 
F11080 TAT GTG AGA AGT ACC CGT 
F11275 GAT GGT TTC CTG ATC AC 
F11416 GTT TTG CTC CCA TAC ACC 
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Primer Name Sequence (5' - 3') 
F11650 GAA ACC AGG GAA GTC AAC 
R11727 CAG CTT CTC GAA GCT TGT 
F11824 ACT ACA AGA CTG TGT CAA 
R12222 TGA GTG TAG TGT GGT AAC 
F12058 GAT GAT GAC CCT GAT AGG 
R12307 GAG CCA TGG CCC GGG CCG TTA GAA ATT A 
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Table 3. Nucleotide Sequence of Primers used for Evaluation of Revertant Flag T4SPV  
(F designates forward primer; R designates reverse primer).  
 
 
Primer Name Sequence (5' - 3') 
  F699     CTAGAGTTTTTTGACGAAGTACAGTTTTGTGAGGTGACC 
  R699     GGTCACCTCACAAAACTGTACTTCGTCAAAAAACTCTAG 
  F2932     GGTGTTATAGAGTGCACGTCATTTAGTATGGACACTCTG 
  R2932      CAGAGTGTCCATACTAAATGACGTGCACTCTATAACACC 
  F3551     TAAGGAGATCGTCTCTAGTGATGGACCTGTAAGGAAAACTTC 
  R3551      GAAGTTTTCCTTACAGGTCCATCACTAGAGACGATCTCCTTA 
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Table 4. Nucleotide sequence of primers for Flag T4SPv PCR amplification                                
(F designates forward primer; R designates reverse primer). 
 
Primer Name Sequence (5' - 3') 
  F18     GTA TAC GAG GTT AGT TCA 
  R3361     AGC TGT CCC TGG GCT CAT 
  F3007     GGG GGG CAA TTG GAC ATG 
  R6310     CCT CTA CTG GTA TCT TTA 
  F6062      CAG ATG CCA CAA CCT AAG 
  R9063      TTC TTG TGT ACC AAT TC 
  F8965      CTG ATA GAG AGG GAC TG 
  
R12307      GAG CCA TGG CCC GGG CCG TTA GAA ATT A 
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Table 5. Determination of Minimum Protective Dose Experiment - Swine Survival and Fever 
Response Following Dose Ranging Infections with Flag T4v and Lethal Challenge 21 dpi. 
 
  
 
(a) One animal dye at day 6 post FlagT4 inoculation. Necropsy showed no CSFV/ ASFV/FMDV 
related symptoms.  
(b) Two animals were euthanized at days 9 and 15 post challenge presenting CSFV related 
symptoms.  
(c) Two animals developed fever at day 6 post challenge.  
(d) Two animals were euthanized at days 8 and 13 post challenge presenting CSFV related 
symptoms.  
(e) Two animals developed fever at days 3 and 5 post challenge.  
(f) Values are calculated based only in data from the two affected animals. All other animals in 
the group were clinically normal.  
(g) Animals were euthanized at days 7 (two animals), 8 (one animal), 9 (two animals), 10 (two 
animals) and 11 (three animals) post challenge presenting CSFV related symptoms.  
(h) Challenge was performed by IN inoculation of 105.13 TCID50 of  BICv.  
(i) Back-titration indicate that each group received approximately one log less of FlagT4v than 
intended 
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Table 6. Survival and Fever Response in Pigs Infected with CSFV Chimeric Viruses 
Representing Mutations in Flag T4SPv   
 
 
 Fever 
Virus 
No. of 
survivors/total 
No. 
Mean time to 
death 
(days + SD ) 
No. of days to 
onset 
(days + SD) 
Duration  
(days + SD) 
BICv 0/4 9.76 (0.95) 4 (0.0) .75 (0.5) 
FlagT4 699v 4/4 - - - 
FlagT4 2932v 4/4 - - - 
FlagT4 3351v 4/4 - - - 
T4 699v 4/4 - - - 
T4 2932v 0/4 11.25 (0.96) 3.5 (0.5) 7.75 (2.1) 
T4 3351v 4/4 - - - 
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Table 7. Nucleotide Sequence of Primers used for the Production of Flag T4Gv                          
(F designates forward primer; R designates reverse primer). 
 
 
Primer Name Sequence (5' - 3') 
  F T4G    GACGGGTGTTATAGAGTGCAGCAGTTTCGGAATGGATACTCTGAGA 
  
R T4G  TCTCAGAGTATCCATTCCGAAACTGCTGCACTCTATAACACCCGTC 
  
F Flag1 GTTACTGGTAACTGGGGCACCAGTGAGTTGCACCCACCTTGGCAGATTACAAG  
  
R Flag1 CTTGTAATCTGCCAAGGTGGGTGCAACTCACTGGTGCCCCAGTTACCAGTAAC 
  
F Flag2 CACCATGTAGTTGCACCCACTTAGCCGCGGCCGACTATAAGGATGACGACGATAAGCA  
  
R Flag2 TGCTTATCGTCGTCATCCTTATAGTCGGCCGCGGCTAAGTGGGTGCAACTACATGGTG 
  
F Flag3 CCCACTTGACCGCGGCCGACTATAAAGACGATGATGACAAACAAGGCCGGCTAGC  
  R Flag3 GCTAGCCGGCCTTGTTTGTCATCATCGTCTTTATAGTCGGCCGCGGTCAAGTGGG 
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Table 8. Swine survival and fever response in Flag T4Gv infected animals after challenge with 
parental virulent BICv. 
 
 
   Fever 
Challenge Group 
No. of 
survivors/total 
Mean time 
to death 
(+ SD) 
No. of days 
to onset 
(+ SD) 
Duration 
No. of days 
(+ SD) 
Maximum 
daily temp, 
°F (+ SD) 
Mock 0/4 10.25 (0.96) 4.25 (0.96) 6 (1.41) 106.1 (0.31) 
Flag T4Gv 7 DPI 4/4 0 0 0  103.2 (0.38) 
Flag T4Gv 28 DPI 4/4 0  0 0 103.1 (0.78) 
 
 
  
162 
 
 
Table 9. Swine Survival and Fever Response in Flag T4Gv Infected Animals Challenged with 
BICv at Different Time Points Post Infection.   
 
 
   Fever 
Challenge Group 
No. of 
survivors/total 
Mean time 
to death 
(+ SD) 
No. of days 
to onset 
(+ SD) 
Duration 
No. of days 
(+ SD) 
Maximum 
daily temp, 
°F (+ SD) 
Mock 0/5 9 (2.45) 5 (0) 3.8 (2.17) 105.6 (0.42) 
FlagT4Gv 7 DPI 5/5 - - - 103.3 (0.31) 
FlagT4Gv 5 DPI 5/5 - - - 103.4 (0.65) 
FlagT4Gv 3 DPI 5/5 - - - 103.4 (0.58) 
FlagT4Gv 2 DPI 3/5 13 (1.41) (1) 6.8 (1.26) (1)  4.5 (2.36) (1)  105.5 (1.66)(1)  
FlagT4Gv 1 DPI 0/5 10 (2.82) 5 (0)  5 (2.82) 106.4 (1.22) 
 
 
 
(1) Data are based in 2 out 5 animals presenting severe disease symptoms and ultimately 
euthanized at days 12 ad 14 days post challenge, and 1 out 5 animals presenting transitory 
rise of body temperature without any other CSF-related symptom. The other two animals 
remained clinically normal with maximum average daily body temperature of 103.6. 
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Table 10.  Primer Sets for qRT-PCR Cytokine Gene Expression Assay. 
 
 
Genes Forward primer (5′ → 3′) Reverse primer (5′→ 3′) 
 
 
Cytokines 
   
 IL-1α GTGCTCAAAACGAAGACGAACC CATATTGCCATGCTTTTCCCAGAA 
 IL-1β AACGTGCAGTCTATGGAGT GAACACCACTTCTCTCTTCA 
 IL-2 TCAACTCCTGCCACAATGTATAAGA CTTGAAGTAGGTGCACCGTTTG 
 IL-4 GCCGGGCCTCGACTGT TCCGCTCAGGAGGCTCTTC 
 IL-5 CGTTAGTGCCATTGCTGTAGAAA CAAGTTCCCATCGCCTATCAG 
 IL-6 CTGGCAGAAAACAACCTGAACC TGATTCTCATCAAGCAGGTCTCC 
 IL-7 GAGTGACTATGGGCGGTGAGA GCGGGCGTGGTCATGA 
 IL-10 CGGCGCTGTCATCAATTTCTG CCCCTCTCTTGGAGCTTGCTA 
 IL-12p35 CGTGCCTCGGGCAATTATA CGCAGGTGAGGTCGCTAGTT 
 IL-12p40 AACTCTTCACGGACCAAATCTCA GGTCCCGGGCTTGCA 
 IL-13 CCTGGAATCCCTCATCAACATC AGGGCGCTCAGCATCCT 
 IL-15 GCTGTATCAGTGCAGGTCTTCCT TTTCAGTATACAATGTGGCATCCA 
 IL-16 CGAAGACCCAGGTGCAAATAGT CCGAAAGGTTGAGCGAGAAG 
 TNF-α AACCTCAGATAAGCCCGTCG ACCACCAGCTGGTTGTCTTT 
 TGF-β1 CCTGCAAGACCATCGACATG GCCGAAGCTTGGACAGAATC 
 TGF-β2 TGTGTGCTGAGCGCTTTTCT GAGCGTGCTGCAGGTAGACA 
 NCP-1 CGCCATCTCCTCCTGTACCA GCAGTGACAATGGCAGCAAT 
Chemokines 
   
 IL-8 AAGCTTGTCAATGGAAAAGAG CTGTTGTTGTTGCTTCTCAG 
 AMCF-1 GCTCGTGTCAACATGACTTCCA GCCTCACAGAGAGCTGCAGAA 
 AMCF-2 CCACACCCGGGATTCATC GGCTATCACTTCTGCCTTGGA 
 MCP-1 GCAGCAAGTGTCCTAAAGAAGCA GCTTGGGTTCTGCACAGATCT 
 MCP-2 AAGACCAAAGCCGACAAGGA TCATGGAATTCTGGACCCACTT 
 RANTES AGCATCAGCCTCCCCATATG TTGCTGCTGGTGTAGAAATATTCC 
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Genes Forward primer (5′ → 3′) Reverse primer (5′→ 3′) 
 
Toxicity response 
 
 iNOS GCGATGGGAAGCACGACTT CATCTGGTAGCCGGCATACC 
 
IL-1β converting enzyme 
 
 ICE GCCAAGAGGGAGCCTCAAG CTCTGCTGACTTTTCTTTCCATAGC 
Adhesion molecules 
   
 ICAM CACAGGCCGCCACTAACAA GGTTCCATTGATCCAGGTCTTG 
 VCAM GCTCCCAGGGATACGACCAT ACTAGAGCAGGTCATGTTCACAGAA 
Antiviral effect 
   
 PKR AAAGCGGACAAGTCGAAAGG TCCACTTCATTTCCATAGTCTTCTG 
 OAS GAGCTGCAGCGAGACTTCCT TGCTTGACAAGGCGGATGA 
 Mx1 GGCGTGGGAATCAGTCATG AGGAAGGTCTATGAGGGTCAGATCT 
Interferons and interferon regulatory factors 
   
 IFN-α TCTCATGCACCAGAGCCA CCTGGACCACAGAAGGGA 
 IFN-β AGTGCATCCTCCAAATCGCT GCTCATGGAAAGAGCTGTGGT 
 IFN-γ CGATCCTAAAGGACTATTTTAATG TTTTGTCACTCTCCTCTTTCCAAT 
 IRF-1 GCACCAGCGACCTGTACAACT TCCTCATCTGTTGCAGCTTCA 
 IRF-3 CGCTTCTTGCCCCAACCT TCCCACTCGTCGTCATTCG 
 IRF-6 GTGTACTGGTCTGGGCCATGT GACCTTCTTTTGCCTCTCAATCA 
 IRF-7 CGCCTCCTGGAAAACCAA CCCTGAGTTGTCCTGCAACA 
 IRF-9 GGCCCTGCCATCTGGAA CAGGAACCTCCTCAAACTCAGTACT 
 
Complement regulatory proteins 
   
 CD46 GTGTCGTTGGCCCTAGTGTTC GGCCGCATGCTTTCAAACT 
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Genes Forward primer (5′ → 3′) Reverse primer (5′→ 3′) 
Cytokine receptors 
   
 IL-1R TTGCTTTGCAGGTAATCATCAGA TGCTGAACAAGGACACCACAGT 
 IL-2R-α GTATGCGGGCTGGATGCT TGCCTAAGCTGTTGCTATTCCAA 
 IL-6R GGTACCATTGCCCACATTCC GAACCTTAAGATGATGCCAATGC 
 IL-8R CATCTTCCGTGAAGCCTACCA TTGTATTGGCGCCCAGATC 
 IL-12R CTGACTCAAAGCCGGGAAAC ATCCATGTTGGAGGGTAAGTAACC 
 TNF-R CCGCTGGTGATCTTCTTTGG CGTTGGTAGCGGCAAGCT 
 TGF-β3R TTCTCCACCGATTTTTCATGGT AGCAGAGCTCCGATCACAAAC 
 DAP-12 GAGCCCAAATCAGGACAGTCA GTATCCTGGTGGGAGCAGAAAG 
 NKG2D AATCACAAGCAAATGTGGAGAAAA AAACGGATCCCCATAGCTATAGC 
 
Toll-like receptors 
   
 TLR-1 TCCTGATCTTGCTGGATTCCA TCCTTGGGCCATTCCAAA 
 TLR-2 GGCAAGTGGATTATTGACAACATC ACCACTCGCTCTTCACAAAGTTC 
 TLR-3 CAAAACCAGCAACACGACTTTC AATCATTACCAATCACACTTAAGCT 
 TLR-4 CCTCGGAGGCTGCTCTGA GCGGATGCGAGGAATCAT 
 TLR-5 TGCTAGATGTTTCTGGCAATGG GGCGAGAACCAAGGAGGAA 
 TLR-6 TCTCACAATCAGTTGCAGACAATCT CATATGGGCAGGGCTTCAAA 
 TLR-7 CAAGCACTTGACAGCGATTCC GGAAGGAGGCTGGAGTGATG 
 TLR-8 AAGGGCTGCAAAATCTGACTAAAA AAACGCCCCATCTGTAATAGTCAT 
 TLR-9 TGTCCAGCCTACGAACTCTCAA GTTGGGCTCGATGGTCATGT 
 TLR-10 ACTGCATGGAGAAAAGCTCTAAGTC GAGGTGGTGGTGGCCAAAG 
 
IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor; NCP, 
neutrophil chemotactic protein; AMCF, alveolar macrophage chemotactic factor; MCP, 
monocyte chemotactic protein; ICAM, intercellular adhesion molecule; VCAM, vascular 
cell adhesion molecule; PKR, protein kinase R; OAS, 2′-5′-oligoadenylate synthetase; 
Mx, interferon-inducible GTPases; IFN, interferon; IRF, interferon regulatory factor; CD, 
cluster of differentiation; DAP, transmembrane adaptor protein; NKG, natural killer cell 
receptor; TLR, toll-like receptor. 
 
